ࡱ> [@ bjbj44 .>ViVi4444444H****D+Hcjd,L 5555555ccccccc$eRYgtBc495599Bc4455WcAAA94545cA9cAJAAl[44]5X, ?Kv*#?8\]$mc0cR\gA|g4]HH4444g4]$5z6A 7t~7555BcBcHH&,*}A HH,*Rheumatology 2002 Question 8 Answer (A) Clinical manifestations and diagnosis of Behcet's disease INTRODUCTION Behcet's disease is a chronic, relapsing, inflammatory disease characterized by recurrent oral aphthae and any of several systemic manifestations including genital aphthae, ocular disease, skin lesions, neurologic disease, vascular disease, or arthritis. It is considered to be a type of multisystem vasculitis. The disease may have been described by Hippocrates, but was brought to the attention of the modern medical community by Hulusi Behet in 1936 [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=1~2~3&title=1-3" \t "side" 1-3]. The clinical manifestations and diagnosis of Behcet's disease are presented here. The pathogenesis and treatment of this disorder are discussed separately. ( HYPERLINK "http://www.utdol.com/application/topic.asp?file=rheumati/43913" See "Pathogenesis of Behcet's disease" and  HYPERLINK "http://www.utdol.com/application/topic.asp?file=rheumati/35329" see "Treatment of Behcet's disease"). Patient-related information can be obtained from The American Behcet's Association: The American Behcet's Association PO Box 19952 Amarillo, Texas 79114. Telephone 1-800-7BEHCET HYPERLINK "http://www.Behcets.com" \t "side" www.Behcets.com CLINICAL MANIFESTATIONS The common clinical feature in patients with Behcet's disease is the presence of recurrent painful mucocutaneous ulcers. Other clinical manifestations of this disorder are more variable among different patients and populations. Men and women have different propensities to develop the disease, but this varies among populations. Behcet's is more common in men in the Middle East and in women in Japan and Korea [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=4&title=4" \t "side" 4]. Oral ulcerations Most but not all patients initially manifest oral aphthae which are grossly and histologically similar to common oral ulcers; however, they tend to be more extensive and often multiple ( HYPERLINK "http://www.utdol.com/application/image.asp?file=rheumpix/oral_aph.gif" \t "side" show picture 1). They are rounded and range in size from a few millimeters to two centimeters. Minor ulcers are defined as less than 1 cm, and major ulcers as more than 1 cm. Oral ulceration that recurs more than three times in one year is required to meet the diagnostic criteria for Behcet's disease (see below). Healing of oral ulcers is typically spontaneous within one to three weeks; with recurrent lesions, however, some patients will have ulcers present continuously. Oral ulcers are typically the first to come and last to leave in the course of the disease; they may become less common after about 20 years [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=5&title=5" \t "side" 5]. They may be a less frequent manifestation in cigarette smokers [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=38&title=38" \t "side" 38]. Genital ulcerations Genital lesions occur in about 75 percent of patients with Behcet's disease. They are similar in appearance to the oral aphthae. Genital ulcers are most commonly found on the scrotum in men and the vulva in women, although any mucous membrane may be involved ( HYPERLINK "http://www.utdol.com/application/image.asp?file=rheumpix/vasculit.gif" \t "side" show picture 2). Recurrence is typically less frequent than with oral ulcerations. However, scar formation may occur. Epididymitis, salpingitis, urethritis, and other genitourinary inflammatory conditions may also occur in patients with this disorder [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=6&title=6" \t "side" 6]. Cutaneous lesions Cutaneous lesions occur in over one-half of patients with Behcet's disease. The skin manifestations vary, and may include pustules, papules, vesicles, acneiform lesions, erythema nodosum (septal panniculitis), superficial thrombophlebitis, pyoderma gangrenosum-type lesions, and palpable purpura. Acneiform lesions may be more common in those with associated arthritis [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=39&title=39" \t "side" 39]. Pathergy refers to an erythematous papular or pustular response to local skin injury. It is defined as a greater than 5 mm lesion that appears 24 to 48 hours after skin prick by a needle. Pathergy is less common in North American and North European patients with Behcet's disease (10 to 20 percent), than in Eastern patients (50 to 75 percent). Dermatographism as a response to light scratching of the skin is also present in some patients [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=40&title=40" \t "side" 40]. Nailfold capillary abnormalities occurred in 75 percent of 33 patients with Behcet's disease in one study compared to 7 percent of normal controls [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=7&title=7" \t "side" 7]. The degree of abnormality correlated with the degree of skin disease and arthritis. Ocular disease Ocular disease occurs in 25 to 75 percent of patients with Behcet's disease, depending upon the population studied; many progress to blindness. Ocular disease typically is less severe in North American populations, resulting in a lower incidence of vision loss [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=8&title=8" \t "side" 8]. ( HYPERLINK "http://www.utdol.com/application/topic.asp?file=rheumati/16947" See "Uveitis: Etiology, diagnosis, and treatment"). Anterior uveitis is often the dominant feature of Behcet's disease. It is typically bilateral and episodic, although it may not resolve completely between episodes. Hypopyon is a severe anterior uveitis with purulent material in the anterior chamber that is characteristically seen in patients with Behcet's disease. Posterior uveitis, retinal vasculitis ( HYPERLINK "http://www.utdol.com/application/image.asp?file=rheumpix/behcets.gif~rheumpix/retina3.gif" \t "side" show picture 3A-3B), vascular occlusion, and optic neuritis may require systemic immunosuppressive treatment and may irreversibly impair vision, and even progress to blindness if untreated. Other changes that can be seen include neovascularization, secondary cataracts, glaucoma, and, in approximately 3 percent of patients, conjunctival ulceration [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=9&title=9" \t "side" 9]. Neurologic disease Neurologic disease occurs in less than one-third of patients with Behcet's disease [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=10~11&title=10,11" \t "side" 10,11]. It is observed more frequently in men than women. Abnormalities include aseptic meningitis or encephalitis, peripheral neuropathy, cranial nerve palsies, focal deficits such as paralysis or ataxia. Progressive personality change, psychiatric disorders, and dementia also may be seen. The focal deficits are due to lesions in the basal ganglia, corticospinal tract, brainstem, periventricular white matter, cerebellum, and spinal cord. These lesions are detectable with magnetic resonance imaging (MRI) [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=10~12&title=10,12" \t "side" 10,12]. Pathology reveals local perivenular lymphocytic cuffing, inflammatory cell infiltration, gliosis, necrosis, and neuronal loss. Although frank vasculitis is not always observed in parenchymal lesions, it is sometimes noted in larger cerebral vessels, including arteries or veins. Arteritis may lead to ischemic strokes, dissection, aneurysmal dilatation, and subarachnoid hemorrhage. Cerebral vasculitis is occasionally detected on angiography. Cerebral venous thrombosis can occur, and may present with headache, papilledema, and an elevated cerebrospinal fluid (CSF) pressure [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=5~10~13~14~15&title=5,10,13-15" \t "side" 5,10,13-15]. Thrombosis of the cerebral arteries may also be observed [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=10~15&title=10,15" \t "side" 10,15]. In the largest series to date, the clinical features and outcomes of 200 patients with Behcet's disease and neurologic involvement were reported [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=10&title=10" \t "side" 10]. On average, a period of approximately 5 to 6 years elapsed between the onset of the earliest non-neurologic symptoms of Behcet's disease and the appearance of neurologic symptoms or findings. Nevertheless, neurologic findings may also appear concurrently (7.5 percent) or precede non-neurologic features (3 percent). Twenty percent of those with neurologic findings were asymptomatic. The prognosis varies with the type of neurologic process. Those with dural venous thrombosis or other non-parenchymal process are less likely to have recurrent disease, disability, or premature death. By comparison, patients with aseptic meningoencephalitis have a worse outcome [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=10~16&title=10,16" \t "side" 10,16]. Findings with cerebrospinal fluid (CSF) analysis also help determine prognosis. As an example, roughly 90 percent of those with elevated CSF protein levels or CSF pleocytosis had additional neurologic events, progressive disability, or death during at least three years of follow up. Only 25 to 30 percent of those with normal CSF protein levels suffered one such event [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=10&title=10" \t "side" 10]. Vascular disease Vascular involvement occurs in approximately one-third of patients with Behcet's disease [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=17&title=17" \t "side" 17]. Manifestations may include small to large vessel vasculitis, aneurysm formation, arterial or venous thrombosis, and varices. Arterial vasculitis with aneurysm formation may affect the aorta or other large vessels (including the pulmonary artery) and may be life-threatening. Hemoptysis may be the result of pulmonary artery-bronchus fistulae and may coexist with venous obstruction elsewhere [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=18&title=18" \t "side" 18]. This combination may result in a misdiagnosis of pulmonary embolism with a potentially poor outcome if anticoagulation is initiated. Ventilation-perfusion scans can be misleading; pulmonary arteriography, however, is diagnostic. Pulmonary infarction does not commonly occur. Acute myocardial infarction and a Takayasu's-like pulseless disease can occur due to vasculitis. Superior and inferior vena cava occlusion, Budd-Chiari syndrome, and other venous obstructive lesions can occur in addition to superficial and deep vein thrombosis. In one study of 493 cases of Behcet's disease, 53 were found to one or more large vessel thrombosis [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=19&title=19" \t "side" 19]. Fourteen of these 53 patients had hepatic vein thrombosis, eight also had inferior vena cava thrombosis and two had both inferior vena cava and portal vein thrombosis. A case-control study of 73 Behcet's patients found a 14-fold increased risk of venous thrombosis compared to controls [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=20&title=20" \t "side" 20]. Venous thrombosis, thrombophlebitis, folliculitis and retinal vasculitis were more common in men than in women. Central nervous system manifestations may result via arterial or venous thrombosis [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=15&title=15" \t "side" 15]. A vascular pathergy-like response may be evident after vascular procedures, resulting in phlebitis or aneurysms [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=21~22&title=21,22" \t "side" 21,22]. One review of the literature on vascular involvement in Behcet's disease found that it occurs more frequently in men and in those with a positive pathergy test or eye lesions. Venous disease was more common than arterial disease ( HYPERLINK "http://www.utdol.com/application/image.asp?file=rheumpix/vascular.gif" \t "side" show table 1). Arthritis A nonerosive, asymmetric, usually nondeforming oligoarthritis occurs in about one-half of patients with Behcet's disease, particularly during exacerbations of illness. The arthritis most commonly affects the medium and large joints, including the knee, ankle, and wrist; inflammation is evident on synovial fluid and biopsy specimens [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=23&title=23" \t "side" 23]. Pseudopodagra has also been described in these patients. Sacroiliitis may occur, particularly in patients with HLA-B27 [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=24&title=24" \t "side" 24]. Renal disease Renal involvement in Behcet's disease is less frequent than in other types of vasculitis. When present kidney disease is often mild. Patients with renal disease may have proteinuria, hematuria, or mild renal insufficiency, but rarely progress to renal failure [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=25&title=25" \t "side" 25]. Some studies have shown evidence of immune deposits in the glomeruli in those with active disease. More severe renal disease may occur in Behcet's disease [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=26~27~42&title=26,27,42" \t "side" 26,27,42]. Focal proliferative glomerulonephritis, diffuse proliferative glomerulonephritis, and membranous glomerulonephritis have all been reported. Histologic findings include mesangial and/or glomerular proliferation, and crescent formation. Glomerular deposits of immunoglobulin and complement may be present. Amyloidosis and renal vein thrombosis can occur . Cardiac disease Symptomatic cardiac disease is uncommon in Behcet's disease. Abnormalities that can occur include pericarditis, myocarditis, coronary arteritis, atrial septal aneurysm, conduction system disturbances, ventricular arrhythmias, endocarditis, endomyocardial fibrosis, mitral valve prolapse, and valvular insufficiency [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=28~29~41&title=28,29,41" \t "side" 28,29,41]. Gastrointestinal ulcerations Gastrointestinal ulcerations occur in some patients with Behcet's disease. Discrete ulcerations are most often seen in the terminal ileum, cecum, and ascending colon. Oral ulcers frequently occur in patients with inflammatory bowel disease that are indistinguishable from the oral aphthae of Behcet's disease; thus, inflammatory bowel disease needs to be considered before making the diagnosis of Behcet's disease. ( HYPERLINK "http://www.utdol.com/application/topic.asp?file=rheumati/46057" See "Gastrointestinal manifestations of vasculitis"). Lung disease In addition to pulmonary vascular lesions, already discussed ( see Vascular disease section, above), radiographic abnormalities including loss of lung volume, well defined opacities, and indistinct nodular or reticular shadows have been noted, but only rarely has histopathologic correlation been available. Among the various pathologic findings are: pulmonary infarction, hemorrhage, and both organizing and eosinophilic pneumonias [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=30&title=30" \t "side" 30]. Other Patients with Behcet's disease may suffer from constitutional symptoms including fever and malaise. Problems with urinary and erectile function may be due to neural or vascular disease [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=31&title=31" \t "side" 31]. Amyloidosis may occur [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=26&title=26" \t "side" 26]. A factitious "pseudo-Behcet's" syndrome has also been described, with predominant mucocutaneous involvement. DIAGNOSIS There are no pathognomonic laboratory tests in Behcet's disease; as a result, the diagnosis is made on the basis of the clinical findings. Serum levels of circulating immune complexes and C-reactive protein and the erythrocyte sedimentation rate may be elevated in patients with active disease; however, these findings are nonspecific. Increased serum intracellular adhesion molecule-1 (ICAM-1) has been described in patients with Behcet's disease, and the levels appear to correlate with disease activity [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=32&title=32" \t "side" 32]. The predictive value of this finding needs to be confirmed. Several clinical criteria have been developed to assist in the diagnosis. The older O'Duffy criteria required oral aphthae, plus as least two of the following: genital aphthae; synovitis; posterior uveitis; pathergy; or meningoencephalitis, in the absence of inflammatory bowel disease or other collagen vascular disease [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=33&title=33" \t "side" 33]. New international criteria were published in 1990 [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=34&title=34" \t "side" 34]. They require the presence of recurrent oral aphthae (three times in one year) plus two of the following in the absence of other systemic diseases ( HYPERLINK "http://www.utdol.com/application/image.asp?file=rheumpix/diagno46.gif" \t "side" show table 2): Recurrent genital aphthae Eye lesions (including anterior or posterior uveitis, cells in vitreous on slit lamp examination, or retinal vasculitis, observed by an ophthalmologist) Skin lesions (including erythema nodosum, pseudovasculitis, papulopustular lesions, or acneiform nodules consistent with Behcet's) A positive pathergy test (a papule 2 mm or more in size developing 24 to 48 hours after oblique insertion of a 20 to 25 gauge needle into the skin) These criteria appear to be both very sensitive and specific [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=35~36&title=35,36" \t "side" 35,36]. As an example, in one report of 32 clinically diagnosed patients with Behcet's disease and 56 controls with other rheumatic diseases, the sensitivity and specificity were 95 and 100 percent, respectively [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=35&title=35" \t "side" 35]. Crohn's disease, ulcerative colitis, and familial Mediterranean fever share some clinical manifestations with Behcet's disease. Including patients with these disorders among controls did not lead to substantially different sensitivity of specificity of the criteria [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=37&title=37" \t "side" 37]. Pathergy is less common in Northern European and North American patients. Thus, it has been suggested that other features might be substituted for pathergy in these populations, including aseptic meningoencephalitis, cerebral vasculitis, recurrent phlebitis, arteritis, synovitis, or focal bowel ulceration [ HYPERLINK "http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=35&title=35" \t "side" 35]. DIFFERENTIAL DIAGNOSIS The differential diagnosis varies with each patient's clinical features. Oral aphthae are present in almost all patients with Behcet's, and the differential diagnosis of recurrent oral ulcers includes herpes simplex, benign aphthous ulcers, inflammatory bowel disease, and other systemic rheumatic diseases such as systemic lupus erythematosus. Herpes can be ruled out with culture or Tzanck preparation. Dental prosthetics and oral hygiene products can cause oral irritation and ulceration. Medications such as  HYPERLINK "http://www.utdol.com/application/topic.asp?file=drug_l_z/162031&drug=true" \t "side" methotrexate can cause oral ulcers. Other causes of oral ulcers or stomatitis include pemphigoid, pemphigus vulgaris, cicatricial pemphigoid, lichen planus, and linear iga disease. Rheumatology 2002 Question 9 Answer (c) Polymyositis, Dermatomyositis, and Inclusion Body Myositis The inflammatory myopathies represent the largest group of acquired and potentially treatable causes of skeletal weakness. On the basis of well defined clinical, demographic, histologic and immunopathological criteria, the inflammatory myopathies can be classified into three major groups: polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM). General Clinical Features The incidence of  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "PM','contents',350,250,'yes')" PM,  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "DM','contents',350,250,'yes')" DM, and  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "IBM','contents',350,250,'yes')" IBM is approximately 1 in 100,000. PM is predominantly a disease of adults. DM affects both children and adults, and women more often than men. IBM is three times more frequent in men than in women, more common in Caucasians than African Americans, and is most likely to affect persons >50. These disorders present as progressive and often symmetric muscle weakness. Patients usually report increasing difficulty with everyday tasks requiring the use of proximal muscles, such as getting up from a chair, climbing steps, stepping onto a curb, lifting objects, or combing hair. Fine-motor movements that depend on the strength of distal muscles, such as buttoning a shirt, sewing, knitting, or writing, are affected only late in the course of  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "PM','contents',350,250,'yes')" PM and  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "DM','contents',350,250,'yes')" DM, but fairly early in  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "IBM','contents',350,250,'yes')" IBM. Falling is common in IBM because of early involvement of the quadriceps muscle with buckling of the knees. Ocular muscles are spared, even in advanced, untreated cases; if these muscles are affected, the diagnosis of inflammatory myopathy should be in doubt. Facial muscles are unaffected in PM and DM, but mild facial muscle weakness occurs in up to 60% of patients with IBM. In all forms of inflammatory myopathy, pharyngeal and neck-flexor muscles are often involved, causing dysphagia or difficulty in holding up the head (neck drop). In advanced and rarely in acute cases, respiratory muscles may also be affected. Severe weakness, if untreated, is almost always associated with muscle wasting. Sensation remains normal. The tendon reflexes are preserved but may be absent in severely weakened or atrophied muscles, especially in IBM where atrophy of the quadriceps and the distal muscles is common. Myalgia and muscle tenderness may occur in a small number of patients, usually early in the diseaese and more often in DM than in PM. Weakness in PM and DM progresses subacutely over a period of weeks or months and rarely acutely; by contrast, IBM progresses very slowly, over years, and its course may simulate late-life muscular dystrophies ( HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch383/ch383_p01.html" Chap. 383) or slowly progressive motor neuron disorders ( HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch365/ch365_p01.html" Chap. 365). Inclusion Body Myositis In patients  INCLUDEPICTURE "http://harrisons.accessmedicine.com/home/ent/glyphs/00/22/65/glyph_0x002265_arialuni_12_ffffff_000000.gif" \* MERGEFORMATINET 50,  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "IBM','contents',350,250,'yes')" IBM is the most common of the inflammatory myopathies. It is often misdiagnosed as  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "PM','contents',350,250,'yes')" PM and suspected only retrospectively when a patient with presumed PM does not respond to therapy. Weakness and atrophy of distal muscles, especially foot extensors and deep finger flexors, occur in almost all cases of IBM and may be a clue to early diagnosis. Some patients present with falls because their knees collapse due to early quadriceps weakness. Others present with weakness in the small muscles of the hands, especially finger flexors, and complain of inability to hold certain objects, such as golf clubs, or perform certain tasks, such as turning keys or tying knots. On occasion, the weakness and accompanying atrophy can be asymmetric and selectively involve the quadriceps, iliopsoas, triceps, biceps, and finger flexors, resembling a lower motor neuron disease. Dysphagia is common, occurring in up to 60% of IBM patients, and may lead to episodes of choking. Sensory examination is generally normal; some patients have mildly diminished vibratory sensation at the ankles that presumably is age-related. The distal weakness does not represent motor neuron or peripheral nerve involvement but results from the myopathic process affecting distal muscles. The diagnosis is always made by the characteristic findings on the muscle biopsy, as discussed below. Disease progression is slow but steady, and most patients require an assistive device such as cane, walker, or wheelchair within several years of onset. In at least 20% of cases,  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "IBM','contents',350,250,'yes')" IBM is associated with systemic autoimmune or connective tissue diseases. Familial aggregation has also been noted in coaffected siblings with typical IBM; such cases have been designated as familial inflammatory IBM. This disorder is distinct from hereditary inclusion body myopathy (h-IBM), which describes a heterogeneous group of recessive and less frequently dominant, inherited syndromes. The h-IBMs are noninflammatory myopathies with clinical profiles distinct from sporadic IBM. A subset of h-IBM that spares the quadriceps muscle has emerged as a distinct entity. This disorder, originally described in Iranian Jews and now seen in many ethnic groups, is linked to chromosome 9p1. Extramuscular Manifestations In addition to the primary myopathy, a number of extramuscular manifestations may be present to a varying degree in patients with  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "PM','contents',350,250,'yes')" PM or  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "DM','contents',350,250,'yes')" DM: Systemic symptoms, such as fever, malaise, weight loss, arthralgia, and Raynaud's phenomenon especially when inflammatory myopathy is associated with a connective tissue disorder. Joint contractures, mostly in DM and especially in children. Dysphagia and gastrointestinal symptoms due to involvement of the oropharyngeal striated muscles and upper esophagus. Dysphagia may be prominent in the active stages of DM and is frequent in  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "IBM','contents',350,250,'yes')" IBM. Gastrointestinal ulcerations due to vasculitis and infection were common in children with DM before the use of immunosuppressive drugs. Cardiac disturbances, including atrioventricular conduction defects, tachyarrythmias, dilated cardiomyopathy, and low ejection fraction. Congestive heart failure and myocarditis may also occur, either from the disease itself or from hypertension associated with long-term use of glucocorticoids. Pulmonary dysfunction, due to primary weakness of the thoracic muscles, drug-induced pneumonitis (e.g., from methotrexate), or interstitial lung disease may cause dyspnea, nonproductive cough, and aspiration pneumonia. Interstitial lung disease may precede myopathy or occur early in the disease, and develops in up to 10% of patients with PM or DM. Subcutaneous calcifications, sometimes extruding on the skin and causing ulcerations and infections, are seen in DM, primarily in children. Table 382-1: Features Associated with Inflammatory Myopathies  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET  Characteristic Polymyositis Dermatomyositis Inclusion Body Myositis  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET  Age at onset >18 yr Adulthood and childhood >50 yr  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET  Familial association No No Yes, in some cases  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET  Associated conditions  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET   INCLUDEPICTURE "http://harrisons.accessmedicine.com/home/ent/glyphs/00/20/03/glyph_0x002003_arialuni_12_FFFFFF_000000.gif" \* MERGEFORMATINET Connective tissue diseases Yes HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/" \l "notea" a Scleroderma and mixed connective tissue disease (overlap syndromes) Yes, in up to 20% of cases HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/" \l "notea" a  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET   INCLUDEPICTURE "http://harrisons.accessmedicine.com/home/ent/glyphs/00/20/03/glyph_0x002003_arialuni_12_FFFFFF_000000.gif" \* MERGEFORMATINET Other autoimmune diseases HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/" \l "noteb" b Frequent Infrequent Rare, but more frequently recognized  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET   INCLUDEPICTURE "http://harrisons.accessmedicine.com/home/ent/glyphs/00/20/03/glyph_0x002003_arialuni_12_FFFFFF_000000.gif" \* MERGEFORMATINET Malignancy No Yes, in up to 15% of cases No  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET   INCLUDEPICTURE "http://harrisons.accessmedicine.com/home/ent/glyphs/00/20/03/glyph_0x002003_arialuni_12_FFFFFF_000000.gif" \* MERGEFORMATINET Viruses Yes, with HIV, HTLV-I; HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/" \l "notec" c other viruses are uncertain Unproven Unproven (rare cases with HIV, HTLV-1)  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET   INCLUDEPICTURE "http://harrisons.accessmedicine.com/home/ent/glyphs/00/20/03/glyph_0x002003_arialuni_12_FFFFFF_000000.gif" \* MERGEFORMATINET Drugs HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/" \l "noted" d Yes Yes, rarely No  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET   INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET  aSystemic lupus erythematosus, rheumatoid arthritis, Sjgren's syndrome, systemic sclerosis, mixed connective tissue disease. bCrohn's disease, vasculitis, sarcoidosis, primary biliary cirrhosis, adult celiac disease, chronic graft-versus-host disease, discoid lupus, ankylosing spondylitis, Behet's syndrome, myasthenia gravis, acne fulminans, dermatitis herpetiformis, psoriasis, Hashimoto's disease, granulomatous diseases, agammaglobulinemia, monoclonal gammopathy, hypereosinophilic syndrome, Lyme disease, Kawasaki disease, autoimmune thrombocytopenia, hypergammaglobulinemic purpura, hereditary complement deficiency, IgA deficiency. cHTLV-I, human T cell lymphotropic virus type I. dDrugs include penicillamine (dermatomyositis and polymyositis), zidovudine (polymyositis), and contaminated tryptophan (dermatomyositis-like illness). Other myotoxic drugs may cause myopathy but not an inflammatory myopathy (see text for details).  Table 382-2: Criteria for Definite Diagnosis of Inflammatory Myopathies  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET  Criterion Polymyositis Dermatomyositis Inclusion Body Myositis  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET  Muscle strength Myopathic muscle weakness HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/" \l "notea" a Myopathic muscle weakness HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/" \l "notea,b" a,b Myopathic muscle weakness with early involvement of distal muscles HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/" \l "notea" a  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET  Electromyographic findings Myopathic Myopathic Myopathic with mixed potentials  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET  Muscle enzymes Elevated (up to 50-fold) Elevated (up to 50-fold) or normal Elevated (up to 10-fold) or normal  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET  Muscle biopsy findings HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/" \l "notec" c Diagnostic HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/" \l "noted,e" d,e Diagnostic or nonspecific Diagnostic HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/" \l "noted,f" d,f  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET  Rash or calcinosis Absent Present and diagnostic HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/" \l "noted,g" d,g Absent  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET   INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/all_images/space.gif" \* MERGEFORMATINET  aMyopathic muscle weakness, affecting proximal muscles more than distal ones and sparing eye and facial muscles, is characterized by a subacute onset (weeks to months) and rapid progression in patients who have no family history of neuromuscular disease, no endocrinopathy, no exposure to myotoxic drugs or toxins, and no biochemical muscle disease (excluded on the basis of muscle-biopsy findings). bIn some cases with the typical rash, the muscle strength is seemingly normal (dermatomyositis sine myositis); these patients often have new onset of easy fatigue and reduced endurance. Careful muscle testing may reveal mild muscle weakness. cSee text for details. dAn adequate trial of prednisone or other immunosuppressive drugs is warranted in probable cases. If, in retrospect, the disease is unresponsive to therapy, another muscle biopsy should be considered to exclude other diseases or possible evolution in inclusion body myositis. eProbable polymyositis is present if muscle biopsy shows nonspecific myopathy without inflammation. fProbable inclusion body myositis is present if muscle biopsy shows chronic nonspecific myopathy with inflammation but no vacuoles. gIf rash is absent but muscle biopsy findings are characteristic of dermatomyositis, diagnosis is definite. Differential Diagnosis The clinical picture of skin rash and proximal or diffuse muscle weakness has few causes other than  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "DM','contents',350,250,'yes')" DM. However, proximal muscle weakness without skin involvement can be due to many conditions other than  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "PM','contents',350,250,'yes')" PM. Subacute or Chronic Progressive Muscle Weakness This may be due to denervating conditions such as the spinal muscular atrophies or amyotrophic lateral sclerosis ( HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch365/ch365_p01.html" Chap. 365). In addition to the muscle weakness, upper motor neuron signs in the latter aid in the diagnosis. The muscular dystrophies, such as those of Duchenne and Becker and the limb-girdle and facioscapulohumeral types, may be additional considerations ( HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch383/ch383_p01.html" Chap. 383). However, the muscular dystrophies usually develop more slowly (over years rather than weeks or months) and rarely present after the age of 30. In rare patients it may be difficult, even with a muscle biopsy, to distinguish chronic  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "PM','contents',350,250,'yes')" PM from a rapidly advancing muscular dystrophy. This is particularly true of facioscapulohumeral muscular dystrophy, where interstitial inflammatory cell infiltration is commonly found early in the disease. Such doubtful cases should always be given an adequate trial of glucocorticoid therapy. Some metabolic myopathies, including glycogen storage disease due to myophosphorylase or acid maltase deficiency, lipid storage myopathies due to carnitine deficiency, and mitochondrial diseases produce muscle weakness, which is often associated with other characteristic clinical signs ( HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch383/ch383_p01.html" Chap. 383); diagnosis rests upon histochemical and biochemical studies of the muscle biopsy. The endocrine myopathies such as those due to hypercorticosteroidism, hyper- and hypothyroidism, and hyper- and hypoparathyroidism require the appropriate laboratory investigations for diagnosis. Muscle wasting in patients with an underlying neoplasm may be due to disuse, cachexia, or rarely to a paraneoplastic neuromyopathy ( HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch101/ch101_p01.html" Chap. 101). Diseases of the neuromuscular junction, including myasthenia gravis or the Lambert-Eaton myasthenic syndrome, cause fatiguing weakness that also affects the eye and cranial muscles ( HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch380/ch380_p01.html" Chap. 380). Repetitive nerve stimulation and single-fiber electromyography (EMG) studies aid in diagnosis. Acute Muscle Weakness This may be caused by an acute neuropathy such as Guillain-Barr syndrome ( HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch378/ch378_p01.html" Chap. 378) or a neurotoxin. When combined with painful muscle cramps, rhabdomyolysis, and myoglobinuria, it may be due to metabolic disorders including some of the glycogen storage diseases, such as myophosphorylase deficiency (McArdle's disease), carnitine palmityltransferase deficiency, and myoadenylate deaminase deficiency ( HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch383/ch383_p01.html" Chap. 383). Acute viral infections may cause a similar syndrome. Several animal parasites, such as protozoa (toxoplasma, trypanosoma), cestodes (cysticerci), and nematodes (trichinae), may produce a focal or diffuse inflammatory myopathy known as parasitic polymyositis. Staphylococcus aureus, Yersinia, Streptococcus, or other anaerobic bacteria may produce a suppurative myositis, known as tropical polymyositis, or pyomyositis. Pyomyositis, previously rare in the west, is now seen in occasional AIDS patients. Other bacteria, such as Borrelia burgdorferi (Lyme disease) and Legionella pneumophila (Legionnaire's disease) may infrequently cause myositis. Chronic alcoholics may develop a painful myopathy with myoglobinuria after a bout of heavy drinking; present with a painless acute hypokalemic myopathy, which is completely reversible; or show an asymptomatic elevation of serum  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "CK','contents',350,250,'yes')" CK and myoglobin. Acute muscle weakness with myoglobinuria may occur with prolonged severe hypokalemia or with hypophosphatemia and hypomagnesemia, often seen in chronic alcoholics and in patients on nasogastric suction receiving parenteral hyperalimentation. Macrophagic Myofasciitis This distinctive inflammatory muscle disorder, recently described in France, presents as diffuse myalgias, fatigue, and mild muscle weakness. Muscle biopsy reveals pronounced infiltration of the connective tissue around the muscle (epimysium, perimysium, and perifascicular endomysium) by sheets of periodic acid-Schiff-positive macrophages and occasional CD8+ T cells. The  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "CK','contents',350,250,'yes')" CK or erythrocyte sedimentation rate is variably elevated. Most patients respond to glucocorticoid therapy, and the overall prognosis is favorable. Histologic involvement is focal and limited to sites of previous vaccinations, which may have been administered months or years earlier. This disorder, which to date has not been observed outside of France, has been linked to an aluminum-containing substrate used in vaccine preparation. Drug-Induced Myopathies Penicillamine and procainamide may produce a true myositis resembling  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "PM','contents',350,250,'yes')" PM, and a  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "DM','contents',350,250,'yes')" DM-like illness has been associated with contaminated preparations of L-tryptophan. As noted above, zidovudine causes a mitochondrial myopathy. Other drugs may elicit a toxic noninflammatory myopathy that is histologically different from DM, PM, or  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "IBM','contents',350,250,'yes')" IBM. The most common drugs are the cholesterol-lowering agents such as clofibrate, lovastatin, simvastatin, or provastatin, especially when combined with cyclosporine or gemfibrozil. Rhabdomyolysis and myoglobinuria have been associated with amphotericin B,  INCLUDEPICTURE "http://harrisons.accessmedicine.com/home/ent/glyphs/00/03/b5/glyph_0x0003b5_arial_12_ffffff_000000.gif" \* MERGEFORMATINET -aminocaproic acid, fenfluramine, heroin, and phencyclidine. The use of amiodarone, chloroquine, colchicine, carbimazole, emetine, etretinate, ipecac syrup, chronic laxative use resulting in hypocalcemia, licorice, glucocorticoids, and growth hormone has also been associated with myopathy. Some neuromuscular blocking agents such as pancuronium, in combination with glucocorticoids, may cause the acute critical illness myopathy. A careful drug history is essential for diagnosis of these drug-induced myopathies, which do not require immunosuppressive therapy. Pain on Movement and Muscle Tenderness A number of conditions including polymyalgia rheumatica and arthritic disorders of adjacent joints may enter into the differential diagnosis of inflammatory myopathy, even though they do not cause myositis ( HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch317/ch317_p01.html" Chap. 317). The muscle biopsy is either normal or discloses type II fiber atrophy. Patients with fibrositis and fibromyalgia complain of focal or diffuse muscle tenderness, fatigue, and aching, which is sometimes poorly differentiated from joint pain. In other patients there may be minor signs of a collagen vascular disorder, such as an increased erythrocyte sedimentation rate, antinuclear antibody, or rheumatoid factor. Occasionally there is slight but transient elevation of the serum  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "CK','contents',350,250,'yes')" CK. The muscle biopsy is usually normal and the prognosis favorable. Many such patients show some response to nonsteroidal anti-inflammatory agents, though most continue to have indolent complaints. Chronic fatigue syndrome, which may follow a viral infection, can present with debilitating fatigue, fever, sore throat, painful lymphadenopathy, myalgia, arthralgia, sleep disorder, and headache ( HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch384/ch384_p01.html" Chap. 384). These patients do not have muscle weakness, and the muscle biopsy is usually normal. Rheumatology 2002 Question 10 Answer (C) See also the extra attached file that states that the recollection of the paper, that we have does not include anti synthetase syndrome, whereas the copplesons lecturer said it did. Thus the answer would be Anti synthetase syndrome. Dermatomyositis  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "DM','contents',350,250,'yes')" DM is a distinctive entity identified by a characteristic rash accompanying, or more often preceding, muscle weakness. The rash may consist of a heliotrope rash (blue-purple discoloration) on the upper eyelids with edema, a flat red rash on the face and upper trunk, and erythema of the knuckles with a raised violaceous scaly eruption (Gottron rash) that later results in scaling of the skin (see  HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_atlas/atlas_iie_figure_63.html" 63 and  HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_atlas/atlas_iie_figure_65.html" 65). The erythematous rash can also occur on other body surfaces, including the knees, elbows, malleoli, neck and anterior chest (often in a V sign), or back and shoulders (shawl sign), and may worsen after sun exposure. In some patients the rash is pruritic, especially on the scalp, chest, and back. Dilated capillary loops at the base of the fingernails are also characteristic. The cuticles may be irregular, thickened, and distorted, and the lateral and palmar areas of the fingers may become rough and cracked, with irregular, "dirty" horizontal lines, resembling mechanic's hands. The weakness can be mild, moderate, or severe enough to lead to quadraparesis. At times, the muscle strength appears normal, hence the term dermatomyositis sine myositis. When muscle biopsy is performed in such cases, however, significant perivascular and perimysial inflammation is seen. In children, DM resembles the adult disease, except for more frequent extramuscular manifestations, as discussed later. A common early abnormality in children is "misery," defined as an irritable child who appears uncomfortable, has a red flush on the face, is fatigued, does not wish to socialize, and has a varying degree of proximal muscle weakness. A tiptoe gait due to flexion contracture of the ankles is also common.  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/co_figures/ch382/figure382-1.gif" \* MERGEFORMATINET  Figure 382-1: Dermatomyositis Heliotrope (reddish purple) erythema of upper eyelids and edema OJ'the lower lids. This 55-year-old female had experienced severe muscle weakness of the shoulder girdle and presented with a lump in the breast that proved to be carcinoma.  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/co_figures/ch382/figure382-2.gif" \* MERGEFORMATINET  Figure 382-2: Dermatomyositis Violaceous erythema on the upper chest, neck, and face; periorbital heliotrope (violet color) with edema. The patient could barely lift his anns alld couldn't climb stairs.  INCLUDEPICTURE "http://harrisons.accessmedicine.com/harrisons/public/co_figures/ch382/figure382-3.gif" \* MERGEFORMATINET  Figure 382-3: Dermatomyositis Violaceous erythema and Gottron's papules on the dorsum of the Hands and fingers. especially over the metacarpophalangeal and interphalangeal joints; the light-protected areas of the forearms are not involved. Periungual erythema and telangiectasis.  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "DM','contents',350,250,'yes')" DM usually occurs alone but may overlap with scleroderma and mixed connective tissue disease. Fasciitis and thickening of the skin similar to that seen in chronic cases of DM have occurred in patients with the eosinophilia-myalgia syndrome associated with the ingestion of contaminated L-tryptophan. Autoantibodies and Immunogenetics Various autoantibodies against nuclear antigens (antinuclear antibodies) and cytoplasmic antigens are found in up to 20% of patients with inflammatory myopathies. The antibodies to cytoplasmic antigens, present in <10% of PM and DM patients, are directed against cytoplasmic ribonucleoproteins, which are involved in translation and protein synthesis. They include antibodies against various synthetases, translation factors, and proteins of the signal-recognition particles. The antibody directed against the histidyl-transfer RNA synthetase, called anti-Jo-1, accounts for 75% of all the anti-synthetases and is clinically useful because up to 80% of patients with anti-Jo-1 antibodies have interstitial lung disease. Some patients with the anti-Jo-1 antibody may also have Raynaud's phenomenon, nonerosive arthritis, and the HLA antigens DR3 and DRw52. In both  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "PM','contents',350,250,'yes')" PM and  HYPERLINK "javascript:popup('ch382_acronyms.html" \l "IBM','contents',350,250,'yes')" IBM, there is an increased frequency (up to 75%) of haplotypes of DR3 (molecular designation DRB1*0301, DQB1*0201), suggesting that these alleles may be risk factors for the development of these disorders ( HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch306/ch306_p01.html" Chap. 306). Polymyositis and Dermatomyositis (PM/DM)  HYPERLINK "http://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/ch382_p01.html" (See also Chap. 382)  HYPERLINK "javascript:popup('ch259_acronyms.html" \l "ILD','contents',350,250,'yes')" ILD occurs in ~10% of patients with polymyositis and dermatomyositis, and the clinical features are similar to those of  HYPERLINK "javascript:popup('ch259_acronyms.html" \l "IPF','contents',350,250,'yes')" IPF. Diffuse reticular or nodular opacities with or without an alveolar component occur radiographically, with a predilection for the lung bases. ILD occurs more commonly in the subgroup of patients with an anti-Jo-1 antibody that is directed to histidyl tRNA synthetase. Weakness of respiratory muscles contributing to aspiration pneumonia may be present. A rapidly progressive illness characterized by diffuse alveolar damage may cause respiratory failure. ,egs= > R S   = > # $ 3 4 5 L UVWX[klm()b\]^_(/0¸޸hs5>*\aJ hsaJhs0JCJaJjhsCJUaJhsCJaJhs5CJ\aJhs5CJ\aJhsH+,f 5 [7 x(!)"*$' & Fdd[$\$ & Fdd[$\$ & Fdd[$\$$a$   !xMNY Z l m !!#"$"%"&")";"""## # #%%w%x%}%~%''׼׼hs0J5CJ\aJjhs5CJU\aJhs5>*CJ\aJhs5CJ\aJhs0JCJaJjhsCJUaJhsCJaJE'B(C(M(N((((())))*** *,,----..//////t/u/////p1q11111a4b4444455_6`6b6c6*7+77777888888p9q9999999:;;;;;;;%<&<<<<hs5CJ\aJhs0JCJaJjhsCJUaJhsCJaJU')+!-/d02W3|56789;<>@vBDFIKM & Fdd[$\$ & Fdd[$\$ & Fdd[$\$ & Fdd[$\$ & Fdd[$\$<<<<==>>>>>>4?5?=?>?@@AAiBjBrBsBvBB5D6DDDDDDD{F|FFFFFFFGGHHH H:H;HHHHHI#I!K"KKKKKMM~MMMMMMM$N%N'NǺhs0J5CJ\aJjhs5CJU\aJhs0JCJaJhs5CJ\aJhsCJaJjhsCJUaJI'N(NNNOO)O*OP8Q9QQQQQRRRRRRSTkTlTnToTUUVVVVV/V{V2X3XXXXXIYKYYY$[>[O[ĺĺĺĺбؤhsOJQJhshsCJaJ hs5\ hsCJjhs5CJU\hs5CJ\hs0JCJaJjhsCJUaJhsCJaJhs0J5CJ\aJhs5CJ\aJjhs5CJU\aJ0M-OHOOfPPrTV{VKYLYMYNY`YkYlYwYxYyYY$[>[]ffffm & F dd[$\$O[P[[[[[[[\\\\ \\e\f\i\j\^M_N_______``````v`w`z`{`aabbbScd^e_eeeeeffffffffffIgLgPgQgggggggThUhWhXh hs0J>*hsOJQJhs56\]hs0J5\jhs5U\ hs5\ hs0JhsjhsUIXhhjnnZn[n^n_no4oUowoqqq.qqqrr r rrrfrgrirjrlr}r s2s]ssttttutxtytuu+v@vwwxSxUxVxxxxxxxxxxhs5CJ\aJhsCJaJjhsCJUaJhsCJaJjhsCJUaJ hs6]hs5OJQJ\hsOJQJ hs0JjhsU hs5\hs;mqq.qlr s]su+vwxxUxxxx$IfK$Ikd4$IfK$L$!  f634ap f d$IfK$ & F xxxxxyyyJ? d$IfK$skd $IfK$L$-\+"eee634-a$IfK$:kd$IfK$L$-"634-axxxxxxyyyyyyyyyyyyyyy,z-z.z/z0z1z2z3zazbzczzzzzzzzzzzzc{d{e{f{g{h{i{j{k{{{{ٹ٭١jhsCJUaJjhsCJUaJj hsCJUaJj hsCJUaJjOhsCJUaJjhsCJUaJhsCJaJjhsCJUaJhsCJaJhs5CJ\aJhsCJaJ6yyyyyyyys:kdo$IfK$L$-"634-a$IfK$Ikd$IfK$L$!  f634ap fyy0z1z2z7/$IfK$Ikd$IfK$L$!  f634ap f d$IfK$skd$IfK$L$-\+"634-a2z3zHzKzNzazbzzJ? d$IfK$skd $IfK$L$-\+"634-a$IfK$:kd# $IfK$L$-"634-azzzzzzzzs:kd $IfK$L$-"634-a$IfK$Ikd^ $IfK$L$!  f634ap fzzg{h{i{7/$IfK$Ikd$IfK$L$!  f634ap f d$IfK$skd5 $IfK$L$-\+"634-ai{j{|||g}h}}J? d$IfK$skd$IfK$L$-\+"634-a$IfK$:kd$IfK$L$-"634-a{{||||||||c}d}e}f}g}h}i}}}}}}}}}}o~p~q~r~~~~~;<=CDEFrst̸̠jhsCJUaJjqhsCJUaJjFhsCJUaJjhsCJUaJhsCJaJjhsCJUaJhsCJaJhs0JCJH*aJhsCJaJjhsCJUaJ8}}}} ;s:kd$IfK$L$-"634-a$IfK$Ikdo$IfK$L$!  f634ap f;<7/$IfK$Ikd$IfK$L$!  f634ap f d$IfK$skd$IfK$L$-\+"634-aQTorsJ? d$IfK$skdL$IfK$L$-\+"634-a$IfK$:kdE$IfK$L$-"634-az{|}^_`ςЂт҂ӂԂՂւׂfghinoijklmnopq˷ˬ˔ˬj"hsCJUaJj] hsCJUaJj+hsCJUaJhs0JCJH*aJjhsCJUaJhsCJaJjhsCJUaJhsCJaJhsCJaJjhsCJUaJjhsCJUaJ5.7^s:kd$IfK$L$-"634-a$IfK$Ikd)$IfK$L$!  f634ap f^_ӂԂՂ7/$IfK$Ikd$IfK$L$!  f634ap f d$IfK$skd$IfK$L$-\+"634-aՂւmJ? d$IfK$skd"$IfK$L$-\+"634-a$IfK$:kd$IfK$L$-"634-amnopskk$IfK$:kd\$$IfK$L$-"634-a$IfK$Ikd#$IfK$L$!  f634ap fdeij`abcdefgpq}~ξƟΈ߈߈߈ΟƟ|jH*hsCJUaJhs5CJ\aJj'hsCJUaJjhsCJUaJhs5OJQJ\hkOJQJhsOJQJhsCJaJhsCJaJhsCJH*aJhsCJaJjhsCJUaJj$hsCJUaJ0rj0:kd&$IfK$L$-"634-a$IfK$8kd&$IfK$L$!634a$IfK$Mkd&$IfK$L$-0"f!"634-ad d$IfK$8kd1'$$IfG"634a$Ifdefgq~s:kd`)$IfK$L$-"634-a$IfK$Ikd($IfK$L$!  f634ap f7/$IfK$Ikd+$IfK$L$!  f634ap f d$IfK$skd)$IfK$L$-\Y 0"eee634-a.R J? d$IfK$skdz,$IfK$L$-\Y 0"634-a$IfK$:kd,$IfK$L$-"634-aGH׊؊LMPQ |}~ҌӌԌCDEFGHIJ)*+,-./0FGǎȎ<=@͹ͭ͡jR2hsCJUaJj/hsCJUaJj,hsCJUaJhsCJaJjhsCJUaJhs0JCJH*aJjhsCJUaJhsCJaJhsCJaJ?Ҍs:kd.$IfK$L$-"634-a$IfK$IkdQ.$IfK$L$!  f634ap fҌӌGHI7/$IfK$Ikd0$IfK$L$!  f634ap f d$IfK$skd(/$IfK$L$-\Y 0"634-aIJYr-J? d$IfK$skd1$IfK$L$-\Y 0"634-a$IfK$:kdx1$IfK$L$-"634-a-./0B\s:kd&4$IfK$L$-"634-a$IfK$Ikd3$IfK$L$!  f634ap f@Afgۏ܏ߏRSTUVWXY |}~ؓ|}̸̬hs6CJ]aJhsCJH*aJj9hsCJUaJj7hsCJUaJj5hsCJUaJhsCJaJjhsCJUaJhsCJaJhs0JCJH*aJhsCJaJjhsCJUaJ7VWX7/$IfK$Ikd[6$IfK$L$!  f634ap f d$IfK$skd4$IfK$L$-\Y 0"634-aXYls J? d$IfK$skd27$IfK$L$-\Y 0"634-a$IfK$:kd6$IfK$L$-"634-askk$IfK$:kd9$IfK$L$-"634-a$IfK$Ikd 9$IfK$L$!  f634ap fؗٗۗܗBCϘAB™$01:;˛%&|}Şƞ;<EFXYbc`Ҽhs0J5\jhs5>*U\hs5>*\ hs0JjhsUhshsOJQJhsCJaJhsCJaJhsCJaJhsCJH*aJArj0:kd;$IfK$L$-"634-a$IfK$8kd;$IfK$L$!634a$IfK$Mkd;;$IfK$L$-0"f!"634-aϘf+l :aQRSTUV8kdW<$$IfG"634a$If`a֣ף!"Ǧɦ֦!6;FǧۧfgijlRSUV fgɮʮ !#$histwxwx:a0j<hsUhsCJaJhsOJQJ hs5\ hs6] hs0JhsjhsUN01 $˸xy]^qٻڻܻݻ,8ij`acd:Wwyzj[,hsU hs6]jy>hsUhsCJOJQJaJhs5>*\hk hs5\ hs0JhsjhsUHVWXYZ[\]^_q}qwyRTqrgdkRTUCDFG4cdr5pcKLNOTU|}*+jhsCJUhs0JCJOJQJjhsCJOJQJUhsCJOJQJhsOJQJhsCJaJ hs0Jj-hsUjhsUhsCJOJQJaJ hs6] hs5\hs7hshs0JCJjhsCJU hsCJ ,1h. A!4"4#n$n% Ddi  S ARglyph_0x002265_arialuni_12_ffffff_0000000x002265b-ⱈҗŇa;D^ n-ⱈҗŇa;PNG  IHDR tbKGD#2 cmPPJCmp0712`CIDATWc?0q4HS35>gd;A23 * '&3IENDB`[DdP  S ,A spaceb{J[ ^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-$IfK$L$-!vh5+55 57#v+#v#v #v7:V -6,5e534-[DdP  S ,A spaceb{J[ ^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-$IfK$L$-!vh5+55 57#v+#v#v #v7:V -6534-[DdP  S ,A spaceb{J[ ^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-$IfK$L$-!vh5+55 57#v+#v#v #v7:V -6534-[DdP  S ,A spaceb{J[ G ^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-$IfK$L$-!vh5+55 57#v+#v#v #v7:V -6534-[DdP  S ,A spaceb{J[  ^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-Dd  S ARglyph_0x002003_arialuni_12_FFFFFF_0000000x002003b_z^vL!-^ n_z^vL!PNG  IHDR:#r bKGD#2 cmPPJCmp0712`IDATWcπ Px C }NIENDB`$IfK$L$-!vh5+55 57#v+#v#v #v7:V -6534-[DdP  S ,A spaceb{J[ X^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-Dd   S ARglyph_0x002003_arialuni_12_FFFFFF_0000000x002003b_z^vL!^ n_z^vL!PNG  IHDR:#r bKGD#2 cmPPJCmp0712`IDATWcπ Px C }NIENDB`$IfK$L$-!vh5+55 57#v+#v#v #v7:V -6534-[DdP   S ,A space b{J[ ^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-Dd   S ARglyph_0x002003_arialuni_12_FFFFFF_0000000x002003 b_z^vL!^ n_z^vL!PNG  IHDR:#r bKGD#2 cmPPJCmp0712`IDATWcπ Px C }NIENDB`$IfK$L$-!vh5+55 57#v+#v#v #v7:V -6534-[DdP   S ,A space b{J[ ^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-Dd   S ARglyph_0x002003_arialuni_12_FFFFFF_0000000x002003 b_z^vL!D^ n_z^vL!PNG  IHDR:#r bKGD#2 cmPPJCmp0712`IDATWcπ Px C }NIENDB`$IfK$L$-!vh5+55 57#v+#v#v #v7:V -6534-[DdP  S ,A space b{J[ o^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-Dd  S ARglyph_0x002003_arialuni_12_FFFFFF_0000000x002003b_z^vL! ^ n_z^vL!PNG  IHDR:#r bKGD#2 cmPPJCmp0712`IDATWcπ Px C }NIENDB`$IfK$L$-!vh5+55 57#v+#v#v #v7:V -6534-[DdP  S ,A spaceb{J[ "^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-[DdpP  S ,A spaceb{J[ $^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`l$IfK$L$-!vh55"#v#v":V -"655f!34-N$IfK$L$!vh5!#v!:V 6534 \$IfK$L$-!vh5"#v":V -6,534-Y$$If!vh5t"#vt":V 6,534[DdP  S ,A spaceb{J[ '^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-$IfK$L$-!vh5Y5Y5~5 #vY#v~#v :V -6,5e534-[DdP  S ,A spaceb{J[ *^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-z$IfK$L$-!vh5Y5Y5~5 #vY#v~#v :V -6534-[DdP  S ,A spaceb{J[ :-^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-z$IfK$L$-!vh5Y5Y5~5 #vY#v~#v :V -6534-[DdP  S ,A spaceb{J[ /^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-z$IfK$L$-!vh5Y5Y5~5 #vY#v~#v :V -6534-[DdP  S ,A spaceb{J[ 2^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-z$IfK$L$-!vh5Y5Y5~5 #vY#v~#v :V -6534-[DdP  S ,A spaceb{J[ D5^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-z$IfK$L$-!vh5Y5Y5~5 #vY#v~#v :V -6534-[DdP  S ,A spaceb{J[ 7^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`w$IfK$L$!vh5!#v!:V   f6,534 p f\$IfK$L$-!vh5"#v":V -6,534-[DdpP  S ,A spaceb{J[ $:^ n{J[ PNG  IHDR%VPLTE+סtRNS@f cmPPJCmp0712Om IDATc`clIENDB`l$IfK$L$-!vh55"#v#v":V -"655f!34-N$IfK$L$!vh5!#v!:V 6534 \$IfK$L$-!vh5"#v":V -6,534-Y$$If!vh5t"#vt":V 6,534DdKx  S |ALglyph_0x0003b5_arial_12_ffffff_0000000x0003b5bc/~$5<^ nc/~$5PNG  IHDRjbKGD#2 cmPPJCmp0712`7IDATWcأjtAjg$~Ig6`ј4&!2iIIENDB`Dd/ t  S PAfigure382-1Figure 382-1bnzt!+lȵI3P>^ nnzt!+lȵI3PPNG  IHDRWK PLTE^,-XZܢ˵ҽPUinܣc\]Yf䫵䴽{|jzՋ챽ԩjxyԡתȉΙI,4ܲU˗rj{}fVشhVJĬwìӼ̼uiܺiզWE;ܽxYlXF5,xgxĤ̬ԴĴ̼wXJ˴Ĺ̤Ĵi[UԽ\K֦ݴqd_ylgW7,mXxhxȘi`{v̢`Mˌ{丬XJFSCJ{{9qG rsp/$DZ $)&aaИd=RDH@=ޱh/.|TwVUT*3Q]fGtQ1O=:΢3Fш&niմ]Դ=~նϟ6~ǫ^M͕c5WƬVuw3njcauoֹٍgVkX5l3^3\+)7\m2X7Vkn,\XT/ 5¢BCfK]T"/*,˔'vv&&{K uuZ%y|}}}gեUZUU^kUZ>]_PWWT*j[ZjG+&xܜx˗/?$z{}˯_x.wUwAggn4G–=|Qgn6t#/ {elmM[dw}~(z:_="v{6ޮ8gm5ZF,}1w{V,=>a5bOc9øj5Z#VX+WyƮ555Vk~MyyccX~j17j4嗋ԍjM "_'WUחՕɴTMWU/g}=֭燶>uRv{`ib0xf{Sx] ~㉯)].MZcSX{:]SkUc}m7ӵ1EF6|mwzz[[ڞEjc{جEֶp$lk>aiguӘx}mSq7gǞhl6G5^kʷcc/4~ihƮ͍E%,]~kDE_k 5]6r"m=Syꫴ҄mBABTQw}^o}UB_żuJeABQZ[Y.+(xQ\\|nV8Uᮯ/]eu|ʜ<6)R.kzz"iG=jX4h4ۭW5_mm_=}woo臨_ڮ `ox}]"tPsz}QǜeXk ~M,xn>6o󄈈lm5^k/w4]o<1Z5lq47⫚ƒ+qY-:KŌg]^PWx?=X:OgUg}QUBj J JJRQ9:WL7OLfx~gBk6{bKu;;`YY[;nĹDg^b? BqUQTW']Z{uYROMdz=jSGyƳ~e/lota(cjKDp.Xw#m??߭!W2>N.ªxyҍxٽ}k|5ƚfZsyYX) G9y.]{z4]BUީ.4 -Y_O)*wb ['SO ~$DuY]2A3F3ql1 9j#f?{F6ZQgh{NE|,5÷o}K~zvbXZ9F6[ KkrKHҬSUwV׮*%yg}HFB묫\Sjw˞ĄD.aVc]J0lYYG(Na/>y'/EO/+Hk䧞`5iJ8J$'JMyI"Auo]GzjZpHm),j,vKȤ YB}͎rHHD﮷爲W)ծ=cϬOJݱZu4|M5:&2+T8msI kL%?4Ք."MaIP]Q8AI[SһS_OP' (Vx'$bw*+ 0kY@@m@D̹3'q"_D ɜgC4\tXj8pԢ_itvbCd?`Ph,XCK4s^A:Q{"ϩ(vw`}cϞ񁖠uNط5cZ[OZP†0Bl`BPNT@`q'^*[b}tvR *%Q;&Taτ:Q_չݘ|]ZCm@YED>MW1VQX|0yiD:{A:1h&hhd_$xi#MBNСQ{՝.yQXԪ`oD)VkT 9 wt{ 81i% 1cf뷴j5EojV>U[%FQh܀jK(1 <Un%9Wت5*Ug',OU*WcS"9D-. iڬ4j&gIv {@vA_B%{!﷍}K|{ׯ5>֢֔4m7RZfMc03ɢ%{Vh?38:@GqEe֝Wun@ +%o T  fD|YWMrt<<=DaK3.;1QX6Cֻ]^,~5= ժ"rqUrmRi=*CVPm2{]mY4âl.,yj3`|h0γN#J KՊyyEplєh JtvWy禰$T1;U^kA)X@9B%nt E*Ctw2eA.XVWaT_ Ğj3 ؔyuCrc77TeUSacQ3^[;08½tfqI(ā@"A#96}=j ђ#3tc(\)Υ" 0e LYp%Rي U_YG*GjWVFGW{csT@ *@_̓/̪LcD3N*{bgI\dā`OkbWQ$]鎓ϩU/`БF EAaXW0`zmRO/[ W{ ~Xu{ ./3O k=-D`7#~Y`ڶv׽a( fZ eնuPRh2V54ENxUgaI0EJtwv;ň (?/^l^)Øe#c!~5@`HE Ã8#Gba_㯱FwLhfZ@x?lͲEZ&@7֖nXšWJ  K,ƶl;B=*["6u0;y( +jfI?LHDD:: t㱼pY1ϾQ@A ؉f ?{*3$g?1>^'bfcŝ2R%-ǼTҫ ^\t&+Uu-rGV XuB%wp fxv4ms32%f$+{{Dxf>;!+ ^z*Iƾ  D/~̦H1T.1'2Ty y .mQ' T;artedA K+~1b+8e {~Xߚ2}DTZ빳fqOSK`@̾tg'VgU⍥&Lvx`]n80]{C18A1%*F;:aD%VJ%ӆ.eܨKp{"{%S:'Q>y!i;ԃ$lcg+BM ёM QMg1IzHO*Ys;GFUn'1m'޹^=Tps'd CPVs$YSV8M/1mnm \m%ru C1i4G-5ⷩ%E(G^e*wQ VV/&/xq:r"f9~A5q/fϜ=wf͋͜Gb>E y?{.+f+`Γɏ*˴U;˼yMe<+G+;jK!Je*ڑ+)İh)YiQN#yv:6zwɹ4l4 c"̣aJSc@`ws s".$1{)ac|@c6Y]^b8oDPQK4"6ivbP4D>'-Ƭ/*/B.+b 3g|'ggg/ 1]pcz(Z.JsaH,DԽa>20\XTBLe# [#=1n$ۏF¦h`;,ɦ6{,pޞgnA)c=1e5pYi޷Dci)yyNM +#&}B |0ǧ_P4OX9b,}CęO?}SF/O,as?WoUK UN )j]Ku˃;NJg;ZZ:z+V v()Zn07qgiC!)rs+yZ:E43ePFPۣIR9.#ڶH5[Yusc巍bh .ZY@D-+QMTe/`.1'S%KH03ZG4 5TAw `W/^ ş`>pŹ>ٳӗ/?|K/ϼOzK }pӟ07Q2QVj*U *gKeQʊ\JiL[[9vl{f{&v)䴴#6^<}) ̓as<]{P,< ssඍ@\1fk1?wBkzT ]MIIZHv@MKJ2EB]-DG| ua6GD g홗esm4! B a8f`pbbtr+jWv2srݮ%즑ijHq.%7=ތ/((bOD,W#0lv8(enEl``ۭmxid3ECL#`Q 16ܝÃeT,WGvU $V ,sgُ }1OއMpV\eK!|T(݄{ǝ%o6V#T(] VTT%dN,c\K\]y{$Wwz9 7r'h̶Px?hI–g[s [jfoA],öXxƮbp'i9E2I8 _)vW++vVNlqS':O^'Q~t_>=C:S||.y.`{VXXE gϟ^|)i # :z th;+ʂ# reiittJeċ# `^`ERF;U{Jކggŕ pg<}dX /Ôr4Z?&.3R@`6~+17-s woL{B$.sv UUt\9vrdee'oy9p=͗t=e+f(֏>:鿼du̓YXDRJ':ADa_Ʀ\v eid~nMvR^YYs1\V,-ȯ[Y8M<_T[/t /rѕ3^ RLԎ8=yK^WD'jPSu--cA8<;oY)b[FyB;of]Tjra(h<C ;{zW&;K ; N>yQۍ*K)Ϳ 2u]{N \McD*-}V4=[ ^IX94|x^byy{Oϟ3O\x)z $:si2٫Oϼ'6 ^O 7*B>Q*q4W ΄V;lub؄JU^IXr >׏wSId++/+Zܜ $'oq_Z?4-9(sm!o׼&^ g/1:]m=?Z *ROx V05kT*:jk c,OUԝ:]`pGfi>9wO^zu+O}'||×O(`9駯^[^?e@*HKLj+*:Gz@BɃ](:sv8Lt|. F\82Py;yKiZK_嬔x2*E-9 v%2ZvmeڞoBlZB' 1*\ YdhK1] ]*}]eiN: Bk!}+VN\>r‹gΞ!^K_~ᇯW~Yο;|=?{EE8O/yA?3_?S z/僟0_ć/}&F\MNGWto[Y;ǕQAq*zd `^kGswdKe+K2Y^sy$/!wp4apCE*wK:H|>&;P]R{f-?Zga8mc`aW:5_1Lks/55ž 4 Q +;;VVN, zyvNG|L@Gg ~̧_L;6#O凸46(q-k} "ѲU+U.Oݒ;q;=2Hnudnr(2X^^;3nwB2HK g-TgBP:aĻ$]*}$b(w:.ƈe44Ym} mؕ+l̕ÎrC3D,F ԪĮ,RU(ѕnƩǺksd 2*ܑ}PLz>xEuW }-9Ys_̇GyOaVoabvU 5L_W% Sha(`]iܗqB^έ;\\ubܕ<+/!>!qį tW./]w!`@^?Ͽk]صNXDRXsUPG;+u+.@܆:ݙ#sl(S;Dz;+bߣ'ީpQeY,O5snǜ:e;nOۥiԖ+m  ,pмiK΢zs[Z$,EivNAT Jy)tr %y%0bgsn-}|駟|<#>~ =}H7*>z3΃^]/E\~`/_z\2PW22!@XvOY 26AZu^_?L8@5&G~*0[Z9=2W0bTV {rK4˛48TAUa4$1]xLVȲ`ZU,xPc7[pZ11i 7V}5QKuK&v|=""r0rB#gO8Sp=sԑ@gṗq9  Z_?/."D? o.3ݲJgr UU^(}\[vwԉ+;n/Vzмwh˱3!=Jph9<2LgʉuwYr>ipBgC?[&T?80kC&d ; NxnLv cAζa^$tnnetaeә[3 V10⊊3>Mp˟;;xF,fj/῜W?zE?w6D 8``QAKr: +PtVBSU'*n_p'>YP&VNbG s rkkM wQ]؇ic7AgZr EBq1W#Fү'%k ya½^Z&:ܪ/ggf|Bp@`ȅy?>}#V>w_ K?SV6~IJpT`LE< Xg^^ʤ u2ُ:+,W|+'Ҩ'Lu `'CV{| sHwʢ +*}=Q(\yܔXd;[ f-FLyte .!K1nL.{jWغ9̭`nrGsveiy '/(e͞xd W/.092p칏}ɹ G{P<_| }rӏhΞy? Փ_~S?^WWnQ@Mu6m+ Ꝼ#&x]R,U9Y|Ե$;i ^[bN0G^!S'K.SnFsdDvf`;tlg$*`hH]c{Z4CuKt;*1-oheZsytLDxbk>ӟ_!/"t`6Q|̿˃W/βUC`F>̅?e2zh~l°1RK-pg^EٱBdԳ,-(HHPW1|VTjsFLt ,6 \+yQz],X*%3GO:W\Y~tXXY:|NR2V8|N=pvB&5$ ~~3L5t2)PrWՙ V72(W؄ ӕ"VN\iYn${4'Befn8mDw(m3vٛ>n5A4u@H_%[Th:U" "/ ug_/m1®(\i=N|WBFcTE>AB㲊& ݣ6(feb^}c;+uXuap#ˇ/t0eh(^g7;ܤ#?ŋ3/)̾Y#(aꜬ4zfvңui Uzed]Ngej:1bP4ʒet 0[^crͬ^O{-ryV[VZvetJep[ʚ./Nɩc)[:ȝw iOy>TlȲ#+Ո=aVsMZi*L':k,BlQ0'pA HEBjmz*G 9<;!ƇPV-DE9B).,k'Xaf3ح,5*^Ao )S--m胐rGյR y-Wzu n&o>vE˫QD14t^R}e:;f`)Z:Z`/pjK{;Dk1wJLOEu4)k!;0c.VBX𩕏NL^.< Z0Sk;lձFKF@FwaZKJRf%~xKgȔֻ^7Rhn8,kvS75'E6y5^IٮM64J̛fuC>h%MJSlob]uP׃o/,҃8Ju}FKޑPaeꆚTAڅD3-3AΪ/m-"Ir%:`y !Nt>1_RΝJf'yKM?J*U+cVaP&UbYq<fRiQćDBACƬTU@W'U!ݔdInwMv-ꕛ ]67z^Y¾.[#V@KUM:28 DOU[8]\TZcF]k9WA00ZUxolނӍB W ~2 -@H(ٓ\\!loV.':ux ACFSaQv4ڴhY~-`_fZ25 .}IctMӂ}3SMONO_NJjnEŗ!̫(`j\G9*/tE/z/{uϣ+<]RB-JBEuΣ bmзe1Sށ&!g]gEG /;AАl(Bs id ~hzAN? Re#aWJWiAv=;{4!eDc3͚/+]8h\rQigrlM]lwLLv?O-L7#oi2u:v[ &6&P4.?fAXKQc {WuVbJD)Ĕ+;:i\>mP/ɡW}YP6V<+΅?ZkrEl\A΢%Z9e-\6M!cs1E)(-+Ϥ-ORT2Ce{]j3v `0wHb"?c ѷ,O$&Gk)Ӧi\n0ꮾ~d[5}][IՆUWsE̵b\7U0췴\(Njthh hr%v11]qR7YN67@g.W_|PթBm@[XZ笯hX L7IaW`R_[(v\f`%V!yg -g>ֵw UԦ!vǃʕQ'J‘?݌^D+ d p1#1m965&_#-Ȇp6m#h,Gj3M:U"oښ|zz aE)𝨳jUQIAJsy= j4|e"7_hZ[B~I]Tkw.i@&vuǭB.-R6@"BԥV˱oy N- ޏrSZIdÈ0vuyfsVŗ@SPda=;B: oHƏbFe07u4;OeegИo=N._X0Kj҄~K(nk+8,ȍF5~+hKRSX*o~RsUˈ g!DH(c}HB[TPu26ECZwS}Gt*ACG]ԥfBBL4{+.@ a%+b1i_B})P+l;f 'p~@vԚ㳛CosTׅȉ{1ibn[Lϼcϴ9nJJa߱p-(w\rh]PԷZ-6)lu0)))GʎA|+h60wBn:.N萞B]2/'I<ؕ!h4^KlDS/WWGQOʝ=_UjC5oV[D.TU*Uu&7(WG+[XEad  ^itJe( )Z>[ZN  ڐtB^vt94]A<ْ0މ0rَ81d ݖHL%ݒ5SavkA;Rب |#Z3]غ~u}46źWXzجK]MG,FPRr|oih5-nb}Wv$UsB@m1{:@cstc I|-Z%/ի;1 @܈򪘆eXL&끍 +S{@'Uكi(/dQ}x|f]T0~"ji`62QQ[MS㍦>厅ƯfZQtZ~!4^hͭ[M!(J5/ˁ_|K5+b'd] ooG\UCR\Vo|fܴx^Vh'<6[FE A+îr(F e 3s\L@ 7!CFTQ6?- I1$=I+|.T,q#d ܎[4ᅎ)2T_?>S FR^5ƚQHLZ͍f#Z[xW̿ǸӀdmKd,r +mWk._ѡ ѭK7[(Ux,B'Wiu.|XXFF}Sz^SP-2:ox z4GD Qgyb^Uh"pQd+\cg,`n4kgːIQPr\I#~#A"* f.ݥH0fZnoM[>Z }SSq_73i|9+`-,,mTd,LnZ 4~M8go_fDy\YЈY>,ύaۘ^5d0kJ'dRzyV^-£*BE*kΣrܾ-Ը!|]+`8 ~]9>*MOjËJWKBBv@\>r ~?0^k}TWFͣrkmb@lJ1#ha d:uNwbVhl_l   )׷з7uݾ k%r}~Z[-"+5B~Zk̰?#?"WگƋ8$ "_+BEN9$ ;zj]O$@{l(bPͰ>t'@׸dm\5}_ |!-Siwr9XP-gl˵BJիg' >WL[C (mge[-] ^G5v9#z5rt :Pk k|qc:m:h55asWhUd-RXۊ]ݗf嫯jp ;s`҂RH%PxEAe}BcyA\2mY֐ f ,Q11m v7L ^GT^}nt6\#!2=-Tĩ^>}C5m̦>7Ϗ?#R}PJ-/-Ӷ6CP$֡ξe[2}Kd{d Y( _ %8p16WX,| 6x5٭z" h:.YpA,3V.w%&*B {pn l}IIMCfV*}oàwgpj;7ÏL6PB=vg Yeص^aQ7͌(j,Ưtj}ۙ))qqm˂>Z$m}=wr݀]O_2s{gNzaח "m!܎)v{+$jE+[#n(})[e3[0,q [#lol v9 X"9jb'qa/gByjm㵅[7.54[@pU&]ibOocaas 1YN]Fv!ehr'_kmbx߳n8RC쇟oo-om[<6}h;6}~KR7 hښ)ఄt [[_`ssj`Ru~`0<<|tkXqK aWD){Et}"z8 .^q вNDHfM!-RKJ({>D+ն+j6eE+m{EJ.CC^Мiwc;p,9 ͈Ðz"f3='M' Wӥ[-C wAW.*7AZ@ۈX*uglx龠$)fؤI=dRpՂ lI%m78fT,T VؚJ3M&P+GL>Zl0hn]ayx X0),".q]e{/4TNPD~s(õvS8 H$OmmeG$r_t͑zwS*qS(nRWOfd>zf?eeq o +Z0H__i!+B>۷[5-U߷3ۺS43)s < 9%} L[mIqڮY>7 ʮ%@HaoE9&T^+K1t1 "m#/*lprQK*+ɨ't08D<{4ܕ x_ns66]4 >GxZJceC̰'c טvLvdҸ.vc[eO31P\-QZ2IutZLMYx+S$YtIi\͜uz5_H k64muu/.G1⏽8;%qutsh]nX5i׷K=JMٻ$| eÕ"vl9HV0.,IB㻦Lo?N"&%ƧlҒM}[q]dm}fGN-WbM 1> p vW/E6q҂;)6Z= KN?i&1K* f&3dIIt@K'nfFBTڤ)ōCz<~ם;W̏NOcD܎.v?|ܕ@LG;)O|>Mkqpu{fv`ۑ,=zTE;G oNqwSNaͩk̂Hb߾\tirɓRiTOfKNNg}[wW ތաGCCCzA^}o?Ǐ:~ѣoqgdNGŻWܿ4.ob÷_}v %=×*MN&nX_OLʗnZsHF" DV H˖5J#tnoeA, @fe8s@&JkSwWӒ' "-?G-Ea*BY)~ % ̀@,ޕ+XêJrqL]LpKEW薗d!7M&e8YJJLH )i%66Ex:5}Iz@͙w)-@S][wIM*~TEO$5lG(FIÿe:5㭀}䗤 |q:Kjz [ $`iZI=o>v= 8rM}te駱IGM7mvc |aTWCb_ΫT?2R :wKÌK=7zs#9AKI'OMRS3s2Vfg7af\ IaHlǔMNq-9q26MQ $\{c3um}= V]F 㸅U\2m}[19?ĝ(( Kc"/m*b^m:9UH.W 9.釡E9Cz,g?(4If㫾uT_r*>7)dP)֩a%0 6M43`MÒͮ.Mȭd,E*%cmR}'''?ĤTRy2ţf(m3g lhx6w,b_)Զqb׎( B+bmz^0v%9Yoы:2i 6{DՇO'e5E@멶ջo$rQJF7z{${w]8,&8G=x4G@Ls .f;7ml~Y0J]אMԱI[qk˚NEO 9UJ&%I 5޷.j72q*w JR }qY sssBWOoY56bkq3%}.s(0irag7YM^*U7~8xg慠HIypUL#eIViOnǾZ-.>?)XKKv~a {(׿d,NM43[ǗorbT~]I٬Z]\ tw|5.5 zյ>s(ma#΢]ݲ82M5$]Nz8ynIR33(l͵L +y]MX;~*hoooP0ܠd2 AP0moq yq'^6+kr)4kd΍\ҨLB Ϫ?'HY`XUzJ:i Ż~<7X]İoܙUx&|p{ċc̹<\o07ps9(MODTZH3G6KJJMRDLQ? Eڧn=OJNLMOLI62RMw%k s [G9l;ߞZnEh kQs#,&h.Vur 8@ڥ^7xw\.հ^>A26ZX<·CoJ]~%Di2W&?'KAn&M_'OIxscu8t7kb;Q`vw8!Fw  !g]䪾NӅj5n r+˾jpL37fo㫡͵L3F¬41T44jje88v_+/tn:pQ~f "PӂHp? |vrpU)Ԕ4¾ 5+Wx.nn0"AW#Mag>?iRė&#f?Kd) oj )oR q#wLW;?r杉w;;aTS(j1j¦B=!4ƯIMf/0nJ%L) 3z?d\_$SoW¨JslQ=,j< ź0*+ H3#޾ sK^gSFZt?W* 6ZWn8hW?fHEi!ofJ4~i&kP)bYijJ 7LII9񔍍{4|3?Mun"v?B ^Zfu8L7UsWI.n3F"1YqYCu,K"%ҊX2五:9)=9-H›&f븰{8qw '&aYKtv"],qڦA{x?]visTʑ;e >$'1(-wPoHYdx}ӂ~id_?3M!X/}5# > h ƺכw'HZFzwN(e-j):D0imvڨ+Y`[nY.J촴[~mV̴R LЧnMݤHYz>NM_{|t#$vDFvkbp8گdjO֢`(7Bg(wY:=}Y!of %4+`Kr'S%$Io?LYF纺:xhcCcf~w;߭Z;133F ?䶉I}ƪAr# :ik;) ,6rV9-=i'\֒IY髏\&d 珼w8+nþ}2ŒoL\O m5:c lb~`01>tř&&2PWy9s>-CN0׷ HOF63+ɠ?'GJM̐mҔUhD^/M#zG7i xU {v=pBK@8;}_8z$)zjZ5E{/ݖk8 `ދca{o{7LOLLon1Z_A+cfE:II@KK14rMHK":4V\ySYii' ikL*k'SKO}WD"Iؐb('K%DXo9:*yk{HOXհE6׺ xf1}qʶ^S=%sq M3`zcf3CCR7s4?)YffHNϔ0gp=Efoʻq qu]޻߾n7xM6 n>t,KH}vݖ`?{`uxXA3*>4 .B׮"נMH-A ;in0&J_o?z _=J/Rl®Ń)ynG\`["D83IIo==ʳ/*.Ixn.,>A޲>#1R8WK }ᶸ(0a|ߙ_qC1jj~5u_񥭧=xD3|7|o'qp1o$ZwmfWy3<°?x#UO A J10xqUo 3I, ,۫SN/|}!'0.g"cMiJVweFywe Y^Q.6.>,0T#H w|Bl2*XJ5{p,1O-Ix|!zNt]OHKI uog m#@mlFwFĻ3 nª?Դ ʰ.o9TZZHnyڇޡ[Ve|)9 ZU_VԣO'­3I&oӽ))n|J=ο{P;|F1wf" 6]I/_7 $i5#Z=ݠ-XF\ͤ5%pKR]_=pUؕ m~ddHY`qw'mFn%etTL GQCzt4|֖oQq9pWA0{jui/XrCRK#y{kC)Cߪ JoX bjc'C͔3|s8@"H=jwg&;Tݧ =ÚkG{_^6"t^ϧذ%&%>"ğO'䬓'%'GWWt)'1C@®t;?.*)뾴,ǛBlN ٙ'ŋ=} Q8&wNuz3tXj%?"1MڍR?WSV$BTϑf&3dphc[i=Zzt|l-%w&=rȻ䬙?XqɌ8#nJ>y1u#ÕAJ!p?~ݖnr2)ʤ\MQb&yҤ1Mo.fѦÖȰwpJSl9B !+˙ٻwo͒oO1+}Jh0*۱93zYXL6$6DUH69 ;BCrrrQ#xܖ\=yo-? {i֗IK͌MNzIf~RĭGG)ë^F?0!.r>F]iŊ:_xDNjݾt/^ Azn'Lڢ#D"H(p/XRH7yˏ;dnݺ3{ay=Ļj''cm '?^$G uŁ_ð[z=a[1<c,˪']mB)hcxa;KJF) 4,~ݝ;im9d֑a8g<:N:H뢥quP˝]h&nqsV0xp[{ӈ.]'t]0p\]zZC Ê)>| 84$=}iHT4nGo0FzoW?]+ْݷQ {X򔧞@! ۘ2mkڱ=R"ֽTýw8SxYb[ɑ%Gmvz\$-a0DȾ6Z2&ͪZDf.O^;-n*#֫`Э{[\#NgȽ_R(Ot6`NG?L}?@N硖7 .th_zR:BĜ aTW9|j΍Rrv,'7op`@@n>JI8~]oѲ{`?vsbpt}fZcDmrEq#]bW_1WP435^+zuHv)i29ҷWS<' oju}{d覊|CCzo/ PY ]Hx|t,)2v=Ryqn`UڎӱʇN.OO=^X -Lƅ]¬Li 9⁀\S0W@.C/=K=|{g. YeQ[hǎ\ᖄ:Т;cxqdiq~7LbLLSًOkr[uªM_'h b'd.⦉i>taW&^4 FnntaL8zyRLI9f`.zdJFA`>ocUox[wEz㌔ TDx,\,6rmzSd; C~`1bLi+9$,+1`q8 Sg9Zq&;o09\-X-c`<1~\Rf_V3dE^cig=W ЄuWݳi65yy/^ ɿv`^y!X` ꈲD>ܻqc\/G:i{\} 3<>r^&+z[F9yn)P;a8*A#- b 1_(ÚXL#7-7֡B#°~\=(C^j Po 6(Kqh{3O_WQ TpmNnSx4({qXTFI̹F&'2a vF5ΟVf=Ϝ 4[qSRg 5Mi}HCҏIP[Bw,HRQY#ciqS  2f:&r `{bԅkAj !dJ-qrA8כ:Uuoܸy[?ʐ{.DnQYU뙉ޑ3ޛe4g gb+_K(c8Վn>WyX]B!Oi-H`KK#4\wI/\|2SA(+.FF]48gA$ZBv4w/kɖl 3$ݽlB_ыz%.@d /tC!k &\/'tT E\H1\:tkV!wq C?r7yaH9ҭhV*opVNtL ppŃ^X!maى _yS y@D)PQ6PVQqI 'D`2>\\(fsБ|Y|ފE>tL>'Q* l;6^BnRtl}ďݿ6pRe;nܴ@õF^6khm+rp 2kqsXEe1XA{Ϳ$6-!W\B3dXcKE]`0G-L/OL,3ay/ϯ]:=wĵ6lfPsJc\hZ}X Gr!Nl>lOnFf婄DI-ej |ێ]:;&f Vn(E㰽\8^#ZyCCA:B9hN R\` +GҚ7>[C߅VV㩷JJOO2cG;͢my[?iCcAa.Fbס[M]c\7'Q}G ?d.Cƃ*\iWVl:lF c07;nGܑJηsMMLX}X̋n",18@Ê R-jv YOcBT]6[zǺK}u]`&S5:?WJx3Zi.u4ᚨ<#[q[\/W˜bezS-V=dqέlo ~X: 4!TD,`1{A͞= vpLEAIp=P}v>k[h?ȆO¦ᵹV m9Z{ڙhyr"1w{aL"Aלf]3.15p9ITqW1vrH?|xg[֥tOB[owkK5~rVvT)Ķ}K ˚?3A,@LGYG;Hk`טVa1<``"b$+KEYT3 x(Bļ~.=h#ghA[q @+ ڮIoIXbqv(])]15!o8ߘUEX]tyiRo9,!7H r4E;9:PTj9;`NxEZ#V9̧*= gǮ.M8;bc{Q="v;F 9-߸..Fu4طq>>8/ӭ ϶)YAwP:m,nlZ6ve/j<!V@M3Y=o}Q6߁"wwBnӥ*Z&@n \i6`BfKy EDhP/f^:44\Y2h*(O+fڲ]8$I-Y".\4jS묹/j-#WFLrv(-ADB`EێXt'zOk]qts4@cx;4տ4S*4HXo܈[ocPSW X0:[k3E 6ܧ*6ha×u@|]*zHp>]Cp@76RNfW_'UVh}RC/mM$I|*.+ڂ N$! ܵ⤼Hj>%64!?l){b2>&2gl[uwtVKHbUlşO/!a,Ӎ)^Q.6k5.t[` "/ +;ym X-@zaEE"k/MxMt)XT+LL DP4UA)u*0N%F,d!d'@nyXe]BQ}cȊd1CR1lVhmsMP[GgM؀3M=GX)[klwrAFl (_-Hbb},X`ۨE _=.,ЗI'@\ a֒8UZU$JK5\V1T:5  +0nm|y/lRS#sTw +v{8Y*X)]Pp)F-"ZmG|HFo,?27E)˦H=> 4Eaf?얧AcSdOC1X@]BC ZiE{]aNN2kD: jrߘ=vq.Z2(aêb⹉Y+XW ONLМfN|J~dIC(@@GԎ^r# 5#tѵTJo%= UK3"KSfu^8  z1 i䷁@D򺃎&n~όL>ua2c5%]`MH7}v}%%G=˸F=" )#݃X!+@o]/ٻSr>o.%0c$Ma1w8>z]HKނD/U $f4ta)Jxs(H=y)/qہ6$4Ka`M5ovlm'aͻ.n=%<)xmU.:-bVLƾ q(hlO@Wuq.p)D-z7BX>x)CnI\@7(N.>geA-KuǮЖuܹ U.I-"0-J@~`_O )v3  HU\#[(ר ݎ(EoRIB,)+S*3? H` WPmݸq[W-sh[Q-3MؕE>.a w]G`}@@BUuTp@,<.R4i <6A%ӂGLJW q7XYxMqGPI~Kp_CxȒ8+%/O5{vhl6kk>wbk&A2 5-thL~j ז/s@8*?FŬ6I`}( 5V!<7"|o{lS1xΟb`J &ZQ %܊?UmVT.5Pl"4C#ڮTb Fþ !zX7T!X䪞"_ aQ=5yw+!f4UHb@EaıEjĮ|K.]V gzTO(So?CFZb7`P i}soAGZUlٽ n8 7?Bh-5j\{޸uq+>^bKzfcRnku` ]&{wjm퐠 Znj~pH;ވPGJj F^E+q3hƮֹgډD`g'~Zӕ(\q*\d0>+zUucV {='WBѸ c) &*s O<ɡuָ,Q_07W--eJza0p YAHX VD~3. k !6X3YgtyWTS%`d[3y/kk" tOBfH6U R:)!N߱M+Cܿ񺯋bJTă\y'._?kE.v"fPwYipਲePS?n|ո+f`p(^9Ƚq/PUMK_ T!5-,ۗltST֌ m=ic!GE:u؇X7/>þ#u@з6=.1xjuL^YSx7T3G8gsoq\gϾ6wM׿e@c(8p*bgAd(>e#V E-WP*c-/o.\bu"kan 'r"95bUp4@SQd/ Ue@݀y13>yTv1$2$ > *ľ{}<1vYg Y;/$)>b^VN:cbW9/>UūR|'UYǂLTԧtaw&JzFLxwy )?X2ěd?|R ^z%RyXk| 5A+ڌrVAP;jS ;w},egY7}v)yn`PSI}cG^cfݾETе0DDG UDxTg0fL< beG)m1軝>˲K3E78sA>u{ :p0Y@8WPf,\TGO`3C7 7^ FSU%Pm_- SrR@>j_5*3\7})|qhbY"bwnغruW^[\̍]Kkk鍴(!,8C\5bV@ 6<=cq`x!fE(݇/8 _%岒z 8YUUd.'ȸ!(TVn$s!87jjBrEZsr52.8-,P2qA͜ࠚ8;ccV5"ҿ2;`$FC(~Xv˿u_?q%܀i8}:'&͙S3q2^TjceLVU$xHgh:ht^M`Ao/v_gIlDo3WL^e|X >8nHmSZ- I7Az(x ",e'δD*D_}D< 貚!!Eo)kC%hrrFX o :@=d^%ydžM#y /&  I&d33K]pi$uW Pn1`ZUJ}فb,AYZ->gǟvS+1U-g@P:Vhg S* !#Y1 YkE8p& P*$#O1 ](skpU_ pģȋ3/qK_rk1'k.FӁPޢr d,WUӷ_}b+fՌ3X^,Qo xJo. 6k({Uդ0[ư_䴕 ˞.8/j ^UlUVY,[7)o;NN7Hx%j2nT[c)H\r>V)[_T|x1Ĕ0Ȃ 6>+"]z3T!* 1 2-D .D?cW1sgfcrؕԅ17g֖HV0OgfWZ&'eWZՕu~po5U@ު,Wi(5/ׯ3h$ (_(P<@ģ9W;EYKVN.aul$I碻% :t;^&ؕpĵD[CW(5f ³CNf(E2 }v;b;pq wo.`?F.=]$ 8CYߠt7$6` s\ppMRqu\;bA:ו٩[ərXT#s/Wt |4Ő`H1.W)V e2nݒWSJCM4EŗnuMx-]A}eV] .|u&fyBE<spwr;|<mŀv,oƈPmvLI3 .:ԯ!er&]<# nu5MnhMHo=Y4Y5C"PYgz< yUU}RNZB )mX@aҧtfKRo%L]U=X-V'^[6A^|'ŚTú0\:\h Bj"ύUǀ][Sv0̢߼:ξɪJ]\ Gn n hf?-;l;3ͮɇ!u9dJGOIM{㌸nȲuk`U᳴F8-5$C:LD&zgraHD98FMǾB&zyeYC7U6ѓs}b*|U-_j$1 1}(X,r[lcVvu8]l{\7: ϩ 2@apweS3+zחgj7Ə243"sqk%w$,s,dhpاs߀46|0`M񤻽Hd]FO{mi Qo]Y-'b9j)i=(7df) R_&oU=PZk}fsU}u ׌[Jfm참db!OS+ FBK$Jwс#|201zQ*IA1=^0!CxƟ:@_rҩOHx9?=383Zy;IL%c :8хӇ6TZJYT;)NR WP;4-w˧Ya W_)BNUkKͺWqU]z TƩ|Tn論B1vN h!C)T v`V [ xI bWu?hǼ=UTRƲ~k"cAՇc9=80{*2ljam+E=GUZ4\1'C^(zswU4E㿰@AEJ>mP_Wy Ќe rèeauQz1jnڰz`OKeBlZ*luCMl*77cJa֏?`) dVI_'| gO`@IW#;AN(mX]Y]}8UviX~e|Qv=64\ؕqf[V| ?Uv/dW` w wހ fHpINg[!y9vSeBwZh#cv!UCPY+|KЁlPUdq/Ĉ%|Y!3r@:&*VbI^p0;C0j7t{'U90Ya]2cP0[ ڲ_\^{甫)=p:>yVfȮt*eXkk0^70- |@$>v"k:)ԿbXg*ca|JÙѸ7dSv,*hvqKC^_mZ'^oJpc:_]M% X 0X(ThJ5ۡETV.rP*KXpt| ۾x"/uL0-UE_]䡒O/ JhvI@Սե 8_(a*[5f<;>,.Q9sEJ'YUa;hD F8,^ [xŔt@!Yiwj 3Ʈo $l'C fM`Dfmg_fM|f&'l3D>[cHY ].2tۀ^h _ :ٱWEyX'H95(cN 3K`il+ l_UM` u[_ƇD@4nàM!T~ /a̠A N=`gv88F ?Fjq/[iT (zjAѼ +Yȑ-AŤpOACwZ-ˌ4ō\B?i &=xRôYχѭ(@ubڙ84T aadXsC-[Eɸ2,x~+s1׶}ے"* !SZs, &/٨TplE-x6 @-3s 9nƈ\ؕ$̚8PqWc~x7Dڬ8dp#'!F32%:LHZiU?B`=1؋}Z~ ]g]^MĶ$N BGySJMJSV%>+NR|`%juAC lP](l1p ;` c@jA+KV60!_=O֚vd EXE nIvj۟Y[ZTAbܥZևKK(O\SG4)Pzztp@ 仇95T)C{%+\WJ0S /Hs .alX&Tr Fx>ǭ(0P#p>)Xfo]=511X+mWl2,@mGW4˸Εa<)!O*_a`/6#fXBo߿laB|Ue>˜`AHG0:FL- !F+{JQ2qQ1 V0`#`r1LgR,nxVUsA%İAw⊋c[cc\K; `Ow[WqVC` tpn θbo㍑)WǞ=:ˮkwՂ%%@AaC / IT>)w1"q=le >T JJl: ߯&H9ew3t7$t,k6YU~mXK=_Him u5g7-g4J<8`6Mp?RJ^c@Xw aF~aEpiCt~|ԕ[/oDM5#gjkg\'a\…tFDH +j'g5 $T(Qpirdc ^rkdv:ڶF98N5T}k1Aښ4cIk];2 0.,c sNs,67M.MXUfpNn`+o]ކE`|\V _=9-azznM+gMpujp#V",m#Jwy6>S^"bRaGM5^ n< N,{-ߠ>YAU4J*\ChyΆAܜbHVmP9Z`( }n/Ŗ9cḠ؄(T4쵹pNAîǴ_9HTi,0 ,SwU oi^~J}vcN\.cQ3XzCLp cTފ)9&E67ކ7߻ sy|f/5~B?! KMHTaA^3(|뱻EwЄ!s.ԕh L43Bu{ӑ@c㱕e"aLX{Zl&AtnUղ!wŲw걎eU x~#KW> a!AO9>4/1/2BCn}$*2 ;rXw08"O݅7q 8;Ezӧcy΀K! "KJyNp\DU1Ͼ-@>YW:HSc6"5`Kߦ{uN>6`ݿzABHY.m:c* M&{ zU v7th¼r}tÊ.t#/IS3Ű5ICq"s~4)]lk^b-LtlzԚdk?ԙv5N :3c3(НxlծڬyRba q|`u6-; =x:*B Ag3m'B%{1/e8H&r\y','7r4k%AW0Xb"Ud⨌7PGt_P.Ƅ GżpZgGן0B {;#$|SO]&NWq!@ގtnF;Oӝ+J.F20jZp7b&EP\Q҆lo{{|-#z*^N[ln_H+K¹\}^ !’b2E׋Ѝؑ]i]/;RԐ?&: "7$hø6U\Zq0 cHٷtCVE|Ew{kem"ilM:&'w~C܇u:0!=캰5,‰WUՃl__c̐ P@t2w=fc{y%pxτj~*Wb-j4)@ԕ]u.^Y XN/b6K|4;3Mɩt$GH[ կ7dXv3aM Wf2{z0?b+WOGhd4XFAgg\w.m܉i:3Gu.そ6D(*vjZ"ʮA,YHU]p_2@ RǧReqAfwpCM {½؀]Wjd< xrQY@%Eۈ㠐g5ʶN5\PreG9kG␾.\aA2N,cf/1t\~Շ+;( PoJO/ OreCt-Jʩ]c$X1j\pعUNfOY#k#MO[=/ˤmAǝXƲ4aPì: ,,xtw ?]K\4I4UQJΚ_ #Y2J=|d"}E{{{yKHPl%){@rQj߁"ge3xz֕;5%B jmd7BF][W0,<Ar 0O_V3MO;s@JTfh /ҦopCsi-x*C/x3>3*g\QU7[U8FBv:t̤d%y.V*U入+v}Nh*ݹ4cU,Ƭ?j+Fs|k֒nSfQD^FVTük^h],H;a1[%21577ªé hj>uFGJ$:^:WS(iw$!>GXQdJvwux$s%rc{f:>JJb7,1*WbY)ʃA^ir*Q/({[V"叙પ[В |_NQ]ݰBo:iL(t5D;ݼ+|vڠ|gr貋J4RQEOI$+S/~T+l64F`Jh2I Vʤ,,JӮ+ pr/(͛S_T+똻]bήMgHO6ckSrGA௦a0jd{_+NP֧{"7<Xtؘ:/ged6YF':ʯɂ*V=g3 ~eBl$*o l64 KMaճWxubV@i:lϞ^O0~;v]twqoV V$4P†D̃sU]a8c|Fzx V;NْUU녃vaϿJ༥@(Gx'R ho#/o5C|ezvƮ\)FCR-AS/ޘ+%g$V@th;_;0xC."6KKSWnG,l|jwر[òIIL`;5kytyb~LN}ι>0'P`t==bo/RQs@:B3^f`wT6.]X]+,^-@ZYlsw#d+fwюMr TYʇK*}eRPвX?&Ou "іYH*RәJm3F)[ۣ)NNku~}6 ܳCjL*mIU[ ӊ:mL;.6hiTv:(+ȮL>܃B L&z+qoq~<E5t&DPbWV%#jo"$ RhG$-d+vߦX#F n\0iDbG%ʽmN,vjgw}^tn{睡F:ۘ/G;W6x{[4ڈ[;|..pc]0Phm m5m܆VK^[ȓ{Ŀ汅+!V$p/4RV EKgf쪲e3lƫ`exzvapP{A-W끽R?qܑN{!#~ꐣyjݘWxӧQ(@8S447qumj2-܃r>׏_v&]ke4gsc}[b)ߩ^ "APJO:c/-'ZOa\z zFz{*!l u 8J4e SDC )]ll_brn:Mpuh:t?9ĒQF+Cc7޾Hğ)*vvy#zƺĪH[nq?`r.\`WfMipI!, lQR`%l!H` {Ar'G!3Pnr'e^:>+4\Мb |ӒHefYE&fOQK P ,hRBHq mV=˾0'@Kɦ*~!g,UQ21a= rE Z|orRUE,HiDUy j ~%LȔ]vƯ" :| :dNcUZLEEe|]y _ރX+n 'D m1O81oM Uq `/qkHVx^QA+7tzʂb|ԿiLKlˣ+B\zWuܰ+Z18U*Ҿ>-${S~鈗wt9<sv6JN}tktkcKu}#cTLzk5o$KUU-W1}@uS!{*>ا*\t.g@ =wH8aN78ܛf+Ъ%>H%$~Ue*';h'g|Aei  U0XѕuSy]TF.!>U"}0tɅwvc͑_s =l*vAtD xQj1|=O|B QjVE8_䈟}a`.@0LCjp-uжOXj੸k+$&vpWwf0dm@􈛑,&w b@MĀ> n$400j[5U`ol7 Z)ZALNSz$Z2/\Slpã2P!7C~fFXLâLkc-ȋ/A bcm{:>CO>'΢5:pD4 Ƿ-޶@Qd`Oiw+_+DJv5j-d(o冲XQZ0cWŔk-C01<ܢ{6B/S F]yѣw2-V6h bRj/!6X2zerErؕ%d) 4׮bxXhrLY)T>mi8U{yJm '9[5;5&'5MLPVJ^ѵePDq=:{5]Ť55 yKkF{A(K(A5N JC \]LDpd׿}he(Ol%N|Ib,t^ #w{]I6}.`3q E߫爮l˫in5IENDB`qDdr~t  S PAfigure382-2Figure 382-2b qRW`[j:Cp,^ npRW`[j:CPNG  IHDRnVrPLTEك䜤4P $$ $$$,,,4 $$$,,364  $$,$,4, $$ݼݲԹʷũöy»|yj.,$̚ɫhpz߫rͫĿiô伹ĿҽxܴĪ[UGҽԴܼ̆x_̤ԫʸՕ`ĜҾ94,KF>Ücʤlڴ|ncRԼ?;5ڵŚ̢̬ܽԴܻԞ[֥kÜlʦyħ̜d{hٵĔb̜lקt䷊Ԭ伔ӴܼĤ̴̬Լ̹Xب|˨ѻΔbĔllRܬfxĢȪuKՙkԬܴ伜ӴĬ̴ԹwKLJY̔lgəwԤܬ䴔̼wXܴ⼤ĬɪlȊgܤxhIyWԤƛ䴜켤Ĵ̼zXؘy䧊uhHՉi\GԜܤ䬔촜ک㼬ĴͣjVzeܜZA|L<Ȋv۫䴤켬ԔO_lފ÷wvowxſV>qϼa7_y9^.ߗ%02+IG?|;/=/g߼^a/wş]{wĮ >>SfcCٵꉷ]ng6]??ے8Dޕ_ p@:pl~o !/<{-y[%zK\v\̂V|nC]G>o+t|x= ,Eb1$CU`<X4.+@ 'ͫly* )[~K.VA|kyĤub{"b|b؃\'O^}-[ڌ0ܞM[]Xwal*7~&`/ V}B=v~xFޕA."VLB7rK QWI-WS$ Z7nc5D ݻ## =*D&e,6iޭׂ^|aԅ=~k{RZS XBWae~=[ TbI +1.E 6l[! ]/:8 |R.@\KlEU6{݁>~{':& \5g5Ak\Be#m1m(Y>D +VGꚂDVlV]Xn~[^yBwaRw\uϪ4˿ /@a6PFʻ{M,+w;r3r+rksMy|Oq akQB" nȻqNo `x7<0| d 퍷*(?_(G?SbbbXB[N6,>wT`LVђy-s!e#&y(* 쁟 ::fsk7WnBn?>TyϠBT&WvAl]!WI{Pzm5u Y&*Vb~QlV -D9Z}3X/S SY^^`Ծ=[?={j ̛ԉ)ɉxđ֋O2oQo(_ׅU;-K *6]?-gq6 `kRYh\N1ц#3\ -K/}rQn +J?Ѐ|@fdr}C߷;=9$=5Qۿ_[n̻51HW"O_? o"C zFE k(WF=4І`rX_m)S>f`*NPLczJ\x4%F5I55< EE $'$xJ &^P^?6к%y7"`iܼ; Q_D|@T~U68WhqE_ EMZ$&i@JiQBD/a,bq\  :@ꮐC~qD-ԣjjj̜|( l(e*2> Hɻ<_[eA~ 7<Y[7T!ш/.ȫ2*A\aHQ(H5h\P0RexԿ O+05W+BīQ ROdfddĥ`rÂ>>؎ $5nJ[aP@{akȐ\ *D%5ax]?pOנLD--Q*D+=`3Jo$KoQ~45|p%7o}:%y b.';k7Յ5eeW[mmj *+=.?CL!;ԹyoPH#m8Ljb)h4gVVPBqb[?Òd}X؎@y"QU^frzZNo`:)yJMRYmфKG;~Ǽl_xAPi+C 3t6A{YږIwe6͐13.~r2ZZeC]Gn&KJJ 䔜̔,lyuMtV2 mokyw?c%4Oef$8 |!%,cb2l/*ۗ!7yW۲0_Şu#(bk,1r䮅d$땧4hW$xjkV\nsyxrF0:=>!!biBB/p$&!9?7=+/[Q58rBbAARRy5K0ȎʼHJs򪜎z(|藰kGfP| S}wc{ \*v 7uFA,Pr$Jk㽋%'뉓i$$wMyƝ,ݗţF먭計aYܸ4w:ƫg_W,nl|h-L HWkg (-CVy`# 0wDnP7huu*#ȿ))9<32?;ii|/c%O3'2OfdgeC&Y%}yyy%}J_9tP AI,72\O},8db#خn+~${{ s U8,GPh砾2Jq g[W- IrL&͚3 i32.Ŀ_9w{E8ӱ iy i¬tx8/o~lqNZFƙ N.WE'KrbSҲgx dggɬTh=Lʾ b" Y!S``K!qSjdw"B7GU= yFĢ[٫IC>0ic·`7to o5ZΏwI%5b ӎ.=s3]}p1!;!/5'd^zN~aI~AIaVBxjN61//=Htʈ~$K=UU^KӷqZo9` Jm!b8G `L>JAk7֧Mטc*$?1U>o2ʺۭ=/ & H|Vw1TVVuuڱc.}@_ɩ3's/&`gɫ'de2IMKRRJN:X^&67~BeʒT$[N-C cr]!MJm6&R0|`QSq'mTToa]#&r>zbV'NfK(,LKHϜ9Ϡ3;!!r? 1<4>u$mv`shM: uTK2XKnۡ^;C (s}*1`ҘX h35ID?&-0W"iwd"ۢrq\w2bB~a_zfFvvZBvVVN摄 ٧N,9Ȉ?y%99deK) iiyiNJ;c{-w0iS*RT MbV9MFBm%z/H,$-poۙ2P4-obv}8?WH˨5-w`` *%Pp~^8!x윸S 'O&f6&1ӓP,2s#@'yiyYy }@n }T6 !>i5N%FUR~5Wjݭ@ʎ8{,6tJNFj6/r?3WPOKɑpMN^z~^aftx4ƥi ;o'IEIŇ^/y6\Ub0ߩJE#AJ,brt>32")//YXҗ}$"I̸iSL$Y2wNφb;553laaz~ 髜ܔczrv|Zz aP gK h:ܻE[=xhSVMJNuh\m) *_Rб*ֵPV# ^ Q"zs“ }]e$ĥgŦ-=E4 8Ɉ174 ddp[iIIOOIӱģYp"NI j,a9rbw| iT,$b%W۶ad|!PII|A[ㄉ툽ہYyYyyĐyY9 q)%9qqiű1Ob8̖JndVT%NNFȻ)΄LQȘ45QtFH6mzv"jéZYe&29]ދ2QBa˒R#dZ*m^jISI10V)]}}'OTTI//IJ3S;I; ܱ17Nx11@u']r97&ŕ&dC1dt K0o`kC@ ZWtsvĆn(MaVBFl:,Nj}~v0iXcA bYNqq8d{.Hz킄XYz:41 qd#!،N1UP@{'ə1@ NJcO9r,7bO0y[_5=~W/*Q=ʴB+atBZi4}8Q-CZشJZ@^ pSw#((+,8O)?/4VTWZ\LLLZϟ*H=?'cpYxann.nf|lnf 7ގK|L8X](-[bNzTFY0(|yi}R-xkZO] D .kya{r鸌[ӑ)̉%fH (qqqќG+bc=~<1>{Y> ]_nEEN2{ EUC/ц %Q*>v6^Xz*yJQEoLK]EDBU-m s.Ӱ҉&WOb.> =ϔӫ cӲN>b܊Xh\,pW#olŘӧO?~4}>81u1P КW-`D'TVo}K/>O'ߨ! Ο&Zo~ࣟ霔@. Δ j ] DT@Yiоý~6 (=h8;H WW͍9z(zcqy'瘁|<\{< '\ . JUSпC(!?3'WGc*PO+jpoZXjDQxě"փ uܔPkX8K˝aP4 s}W7~ԗL ^]PO4'8-3oʊE*v昣"1ǁ29_,z9.=T`G+bmo W333(̍OPf~~r:0j[vZPjPt +d+U=8F2k|_7E* L/PQ6.T!7xݡzQsAw)LAWh2y3وHrRRccq)q΃ѣG#GA*O>S|E&4 Gcrrma۩<9Cq%E a5aҢS}Ck-6YWPϔ G|1z}1yhDR-@d"ӥJ4#?/"X%brQo1Gw?0<}<?g127hW͍8\1 ONfbzjjꩴՒO^/ !ȃ+x7!jѽXXP9EIT>SiI5Q_<ʹU"o$]XHH\Ɖ/:_`(aG^elYFT*뫨 ~ j2eC:\P\ǐ8דA9)*)?nب,j+Y*{v2djbD`94QzWbE#ra | b@VA QT?i9'0tיG=Ov`% -d\?^oI)C\|EpgJ S 9V՘xP+ Md[gC[[/l$.@&}'Sp2ODqg_ECbU6 mhe޼au\%9ˁ*?%h,’[B@%:Dz)wup0GJ!P! 9Q 'Z Kj-N ehUJ\h>KXGPd$~!(+9JH{4&'|iGn8FI\>Es4>NRdI` HRV9Dv5)Zlrb y‚Q)4HB5I]$ ڿDF_N[;`:sVFDr+ۗKaƘ,mb.%~`&K'/ƾ~|±IV="NC5A"Q2y=~;Ѐ1?AnJSa 盟,BY'L@,ɂЉj Nl` ;RuE*[H)8 nʺN!Sn0V1.5㡽Eٺs[|uHC蒓t7Lˤ~xld?rV$dQRY@7$Đ'L#.(MFq=lP7/|'RE8!C-"TimW fdXx>mb 2vp5$hAE*X8+I˩w&{i2:?ڑUQt`LşS=H;'"V*C*07k9w߿?68+*b9t|vq i04''&0VE0ZSZ3EuìB\4-ehzO|-d- +ԉPM=! a&,}j6L.>CNOyC 1b:fq1QъؘkǏ~fPgwu߽{w~{pYiBm?H Y>&%)Lj&%1wXL`>Y/sUNanv5I[#MuSJ8F9% JBĖj*?)$LGļcrϣRa;1xNܵ׮Uývk)k6@soſͽq|wddޑ 0ȿL +ŞNNI)ib55̯1PUPpJǾh <ǿxw߸qڵkiş[|9Zt$eڀ6L,:%'Y|TpDFXe;Ը- >;L8ڹiZ4*MTmbPh6eN͡"m(Dz%ŤʼvzFr|0Ó_xyʵWmoO]g-<__Ox盛.jGDZHb~s5Pi"G*?/5D|:CQaʔCpf>Q'\t B[CeεZ$g[A.e.RY8i@%F S.'Qs7viG87 O/#_|qs~ck7>H߸kiiuasXD4&f1h_UEIGXBj29.R* I)c l RxqwmPʴuIFjƪȳ&|P"lC߳Pyn,~wr-rصq݀텊}q3>p+w޾yuՑ?r|ql-ss]]Ck@>'(]rϒKL" q8Dn[󸭱8פmr_u}81y{dv{IƼggK6&%hUPV#ȧ(L#ibRe4a|`kU |A(|d®>a0 =T_Q5]/ %>6&?JZe)5ew$7n̷wONZz{[|-/ޚz0u狎3nWcx{zz ܘzvH\MxfvR)_姧&\OȎRr;+XzcX#@*%:/z:̐+j`5"C$ԭXZ2jĸ ZSxGb=o%84V E] MX) ID=5dAy(POѵAZK'm-FvTֺ󊳖UW`ggGֶζ+;mSuug}S yƈsn{1z1eyUFaiQ; މDT.Y~[.Y,|!o|0SRC*ImIkehC1I/VYE}%ȿI'rp/_k==r6UV^A8MnGU<[jW8:ކzT8Z39l;bPJrvY.xiY~xS+|_֠TAq&K"0ɞ=l߿ Jnb9ZQzre A⵻asmo*maPv:?ZؤVZZV[Qm]5wRcC q1o%jB*qM;1R$$cw'1;T^&% K7;DB҈湟 $whN Lݴ[R8ˠeݸEeAa#YB*)#l߿\RC4hbz+U[+:K޸KmkTdkT:4ގBkk,kYjoqW>jr;[Zl;C8pUOTSd(EZlbOOͯx<'o3 j 3r(`ԡȨ@L5[ T;9,+UP-[Q(#6D]H0c* E?|&=`LcDa?oNt ^DwJt۝Um+u*,öڶκκv>q?C 55=p`, ܕTYF|Cy''Yf U9*KQwCPRHR3O Zu¼!~MNb$)~|#vjRf KL\Zh[F.n"##"k"#]Gy&jAoG*rU+TP vz{]}mk]^ko+jkOnM>鬻 sֵڡ*{Q}miHkN}$0Ͷ:H2s>6?%zz!RcSIA5hb5ػ̇ՊjM_X_1Wy,5Т&1fnYrHl\ >IFT_!x2@WaW޽:raۍ6zjkh}RyC$G_W__Vu΢z.B}uilt̮u=^2$JOI=S&NtHi٧3Kb%lG"Tok#: x{fFI*^WгJ~51nk d+`jV){ 3ӋF#cd:pWh29JoW=8\宼ɯUQoo-' Um|Zyc캵9kBյ׺:!vgk~Ce ܘj߽/ٙ2}sM,X|^NLb_#kk!>dZc5+=~"+~;X2͕uC5)ʲyHe^ٷ?"216GrLV= U =7IV:KW0C݇E >8wx?E|8;`o>nO:ĕU~}?y* +Ev+_ w-}Yᇘu݇W ҄?:ܣNANWK5Dz!WE@yT񑴄O23iz?>=9> !)}9ȓAakͺCA8]1 D/LdFw60Grst Tsj"Ȥ͟R@[NJ;GiP%`2"J&kk6{m>P[_TWVWtC߇uΏEthq(~Md%cCkVyO.䑡:*dd lioNc'esW;}R>OF~Bt;d 3xZ[WePCa f}켌Jڿ'*\hHsIX=+RQ'U+V]j$G^ﴗ믴bu ._.갷bF |B(bސȢDbJz3)ed"-7lr({GF}Nbz|uu {!Q8t.[P}+iqA|^qUT5H+`i61\&X>Ī`{?OK^N;ĥ0T쮋:0.Jh MvtJQ BC }Z$G$%oRP@GZ~+ʞ.hfWK*2ɗȢ{ķ Ǿ ,$Ĭ3 r,'S"^[[ߢ.oٶe4EPO+̋lHHkjIIsM<,߷xxf@2)!QjVp=ɟ$F:uNgi}U[Q}}Ås4?tH\X2&mikh@Cy]ԒBGbQW^@ ]%9TٺYl:; ?IpRKˡhIJl;ݰ+L0jmu-Fm^@}s@$k&ї_!DsT )k%eEnkwvcvg][Z_ّ p@PxQ:9PxMX@6Y qݒ\^.3MԈYYsQ( tz @ GHDۮj6k~wTKZ4xqkDUP@ڶGͅ(ȭ޿Gi#4]sQ(V[jiq'RtcmJ/u^(*^F#KTa̿M618E[娄gR208D(퐘J8)UY^Չl4E%h*rخx]$Vw "(V9C@d"sgNTXN$n0+B訪Oۯv]ieB](e-d+ &s^okr#NЂ:+T̐ |e>ѳX*g12(EZ"OILKf/Q@/_fV,{2 UkM]͘mGNO"B~`d` .6w һ:Qԭbx=!h鰏C`5M]%sRK>6#'8cƸII}ko𞤼A~tqG ]-ELTVBH`\~^fleDŽMh>IIO.hkO!6 ƿW&NHǃJ( ;$v |,0DCD 6=CrbމCxV$V*R3{ Dm."JoXw46tb+-W%2SriS<&i1<YuŚZSH;CV[ڡQ|yss;x8ݸ ,ޫ}[6m,ۑɔM* 3eD켧 4!s3q.RdsW9kK]U%F'?%}CmD"偻+c:RjBcc4 UrveRm-Pg 1 SFw~St,ߘ |SP neFXA@^N :SK W:[?u8[^ =FkQ[zaIUפ{Bjlw=O|C QH?AnNэls~`Nv9$$}֊LeYe&>1Gũx_}31mvVG$N2SWP&P_y^b2נW'!F/2:isHpZe>+0iJ\Րj}갭I`a wW*ϡK7NZyKT+^B-G]^czsCCk}}4%AȔ8cYTS tN3||~"/_M}; ?,J_8,gG8uI5g+!'$oyZ\Bv\r^r"?Vv)iTۻ*mhr[䦜T͈r(_nkg#P[měRiTnabپǤōs} N3C`NfbbNby@*붒`Z;d!PUW~9QQH\K5T՞0X+QdD>m}h3=<' cG 7/bޘv6bmjnoudbmErCCE .!6-2izqgюQ ]Kl際umvqG2汾86$ u UduR2䝐bN [8xO.w'7;ș{SdahrI=ge!֝̔NrbNrAzr Ye|ӖsTQ{IcV&0!EQ(EOdJ7!jcae*Ci{r@R"#u?ǀ.H)Q(Bp8Y *gY _&orkq~ƅ_]u7oJ'mfz'DplN{ֻll&N8=y|RylH"9H|lq~z ;&pC&QAΊ2{ûÉ"L4-JC KR[yjƬ-VDOL2F jx^%!'_\W[\X6UJv|QMԷXv'J[&(7)ֻ:F\d{&'溚s90+rċk&RډC'Wg&kěUͽ¡Pl8X^lݲఔ?E:Y+9/L^q ^*Y6t&jk&A $/XKD(}|>!cp>|imW:FGG^VL07=5*grphIzZL*;3SΎ;GXnVվiLwM?{,/F4]fr(EI)L̯.L)ia5byd']E42@-^ 4K+WMMPY4N294D/ H#UDv_,jA^餕f: u;_}u@V囷;m7%XL]W|c]lNIl9dhǴ͐ӹX?w8'Ѩc_N,/߿0<o?@(J[  7,t cU O8/g½/х8PE)碽e;\M(-Թ쥝5|i]m?/)>}c%Ow:_K&52¾Gٲ1{l6)˻GQ8b08!8$-̜cdPXKJ~6f|BlnaġF͝g>ږykL[) M[j *N7WSiq:a 9+DJ-ivlcN'YQ_ZpNO?huWn~I^჆S>:JӰH;e ^!yX|e:r8!0|?1Ydy>A64ݧ?ik;OQڣn}mURZXP^_]?+4_BQ9 ֬Q?,?z3}mA8ش+[B￉Cwp k?BZ̃[yG}JDʲX4nV;rJlIˍDp}geO]' ~ \nW?VԽikOoϬz{'lG̓%2IWHٷBzaO>]F},//g 9E\c4m YRL6 0痒~tSTc;Trv0ǫ[4VM;+ ]hjqs⼘=UE,8__L(INIS*>>*y8L[ mn{e#)WAM_iw4ܜZlgu2Q%mST|vc%4үje"k=HKV-"5PC-V٬uډ wh?T+ǸSqC]u_,̄xf+iZK./mRi޹=FPÉB--yk=nP$p|PSh ?*$lWsJ-IOdrn*,w)s ]K򵅂mKlȗeQ0 ´<F8>OwOg֞~gi䉵ši">j6Y,`t6i8aO)=Teo3o/uU+v׉UE(|.9s^ZDؿ39 7CPNϥ-E#qwGs44tB7ew:tEr~c'"Z92ٳZMz<ʢ>3y=}:Kmbd`z%rNN1Ije]>f4b|hOAtOɶu73 $ꋴz:N'[ᖲ9Zl}8(U,snw Ll;m@jK@dpχ䀝&&}S2 4M-07Xmͷ?ob}ft,f,IǕah҈qXˁےiSvkEAS MЄ;j:;-ev<4Cߓfrx!pW̓Uc̣iݽ]rɕVF݃YCٜΨ,GVű&= /-L8$x~e55?2[?|{}qJ0?|)Ra̯:BR*ObE^y/tܥ&f'ʩ|J 9@CoQc l~4ɱY1wwPv{=8hc<[w^[S^^Ԏ*vѸ#GswO!~xW^V^^V?n.qaZ +8‘<s]̩IJ,O)e_]_(9aFf {s^Qa J?@#,[okRX o8RLg\!khq4 G-NFZct3-7ntaW/pWcݬIS]$9^QH/x!0_Kq.#h0/X (AIꆿu`_fuᝳ$s߽+T sͩغPr9-.gϞ^nl|t{ݛ 9&$ǫٝ^^]`}>@#CUyeENeDZ"VNk,K_; C,M jzL߻L#A| ]%3=tMREE+H[;!"˚s|{pE2Qw4z]~ֿk=F<Ǻ9R <Ӡ-⣀6W@]К^PjвXE_SS7WpH/~gOTy/w+Tg d^ fޥB8;qlUmxۼ1L#V1?^[gN[8+y/*5>7AmM}LynqnlZ`srONsdItN堲`#U#D^ּ`ҰFN1BQ@XGjAy{Wɛprݜ$@:nZ(Ή!`, {47huvʫZ(!a]_Ɲz(gi:tӱEߊ׷0wRjAxpHk3zF~gvV VtE$o%82bruz.iCKqxt;vHk)Po-;A7Ԇm@EXJ9)1L%d~ dE;߿/}Cӭ&)w{B߻;I_LjgYϟ|?iV <]buxe\wi=$]}B&ĩٜ-ےJJHvWonHaKނS4Jn[0yˆOg ,v>p>~\˺y2{fw.~樛z$r|_=ws;m|eCRrSО{ķm/(LgR_2+ s K nGaP9ɹ F; GGhO|K~VO7B<٧$1uy8MCZj^b^*kc6c^E=/E1Y/$y-VQ fBK W3{O0a(úPu"*hJGjs+SD:H*ړt|ŵ8;?*^*yO~P%a{x'OY֝=K=3nԝ~epCМ%,o|la}qox37"cL4(M`iyy,b+eqlx?Q  Eb;U2s:OA;(4C n-``1>N>1i~Ud~s݋t*8 q\]j4|pH,ly0=ۓ7$wfr  7ʢ'0/nh>e&s)VSLN'ByGmnjئ(=pI>*NJ(*Wᣊ/}L]ڼBuվtE߻ų`@)Vk BЩf㰽A1OQL>}lvnd 'n/>y/_Cv5+4 4ӯ*":{pjg}`fѩqڃ;#jFP_|=>W,,(G94T4c %/-$=9+=5RdETD$h; V#nKbmA %!Îŕ5[ۛ .'f-Oy|7>6G"nqqݻ)0dImkZj-kz]蔟r¸oܾ3~s&YQ7*9x7uPȇ?U$Eu2O:k8('2/0pB啨3)WE趞 (QBB$i0aE-A8[5Չib2SO^̬NɈ'=dmwpѰv6[Uv}rʠj?I\肻mxgiI9ugN'(JtMxW|c,^#iB$3:0ҲOY!I7-Ų@1PCY(3_e"5\)  zD,(20)Y4ElQʊ8A}6;ï?mV̒hs:zݬw;jr<^R-wz?ux|I:FYJ“C<ޝ>+ }Yznԓ4UhzzƖQ<si]1iXސJRRՏl2F9r[xcć6-4ڱ}L+5BUOg0-d=8<*5^Qg5ݭ,3ǩᩙ?N=gn$v֗[X_8Kw]Xs^Zj FRs)%GDЕ`K1ov8CO$~}ڔΫ fE4z e8S> 6nP//?X{' R='~b30;j{vwI?2Q腐9>[m+n}%l+nth럌LqFk](AOw{a.M~V@aԼB fH)RD-׵n(:\Q1y43ReaVZRUy |'3vDFENaM2#}U2gRkHaI& Hdq#&k~ --,={пsZ~;;ewScL\[\x\R,$Y|ҝː%R&KQjjZVVz^aB)%oz :QE@6Ʉ='x5. rMa^ ևY`ꌠT_~'sIS2ObM2# y'^_y 4jp~6G,M]̔O`Cov9B3M!r SL9I=TI偷dAJ$Iji.nݟ%n8B1Jf jLIx#mk D͸Ξė][ZOz7nvDc%$'%822z+3>􃏱]r" av׵v~I zsV _~uS峹'a8I2SciJ8qTV*+ ӳNfEm'GMUN*tĉu\O^)Ϙo؎$-AXC<CB>psE{+*Ĥcsi:q*- n:[O+^F[41߳麤F<yʽj HcYQ5%{gq5cD]M6 ʆ;஦Ϫ$//nN.e/ 67o~P$ S%PvbP=zY61Pn46-5al75{O,gafR`ssFAJMynl&t(@*ߟ~2KfCqcrϳhL&,fyK]阴qْ9.sh1)*9yi'R!SIeo ҇žߖe:Q(J ^ǿbA~yAP됝*+7f}5[5]'N9={w׊sew>/Tbޤmj{Wze?E_9M{aqYx_ +`#[y -#I#{rRIyYYMuHZra\maI~C[BX U ֎0M!ͅM𣵣J ԰/f0ysm7fy`YԟCT%QԺ +0# Gn߿ ehb#O]t1s%:ڑQmUBK#,tTax9?aꏟpz$\ԣOB)aߪфJwmT)sKa9gZs˙$GK1%5|:wMV~_~y p==q>o CYHB$$S 8sq^́PҎv>BV U,Ʈ)1"Hi+@ WjҒMVr!r_J?՟PV &&<13&>، 'LFdڿ rG[n~1Cs\)2CkÊB%QA[f a[xLJ}*MA* >}}R%|'흗Z]l0*2=5qԟp k*zGL qkO:UdxBP;t˲Liyy:GX3ØkH8Rettڃ+n̼oE{ٍ1VIͰ37jÖ4yXYβ ,̄Ljʓ;!D]}}nEr2B&Ƹd-h;!fgee!ꗖrJdI09ymC˗%$yw \B'f͓HIJ:\:A@@`n4;|: Y6]ւo>W)8`i~5ɫfG%p(xITnlDE3a(L;b4-4SKs&UM:0C0yeʘDCVD)J4lmY &"& '6lFNzj-tBͷ}2nd%5<:⒌`-t|Nᄒ35_;:fFו5Woe7_o#W aTЀ{BL $!6_"H>P5乃j ơ2ٿg֯3u?uX/_mt*'@^oY\8uo/L*H;&'22|yڕHkBsje1+9gKL}ɾ?^YY68坙Eu\0qfE`p%Nd50&SlIMYA :Pmu7˷vI[eVc li";h Z{d7;2b,.ԋ<ш6UOE{RUYgNTʎg_qN޽/ .Mt٪8u.@Vsii?O{~c~(c-I)P"Dom>0~n@OaIVYMRfYYtY]$ռO/Շ)Uw]_c+Ĵd"A(A7/IK"+dSwE]]6E$gNťӔyo}>Z N%ɿJ],Q$r˩_vLwthke~KL>]s9q5ΣLzN:PxvY I` 9ZKyGP̛+9o^$K.ŭ;@Su Š"͟'o`e%\;y,~ힷdڮ`ۤnݜB~ڝr۷G\w;oM=-. [}wx6]LLx<=X`ޅ}?dsہ$tls;[RSu/Kvq6RJE%mֆu^{cy}pFq,67:\Wi1'|cҶ&yI I/jjk6k[/k8Y{QjR[UV*:8T@{M=B)uQ޳Avt2:yTDk '!Xx_)JP%hIom%ՔmK_$k*6NSy/`~( @$MCe:rr~7%5_$ ayi@r`/aFrz"wubJl !!{֠b+d")[L݁js7/t}+ޑю;t]M-5XItKO4R-'%CIP%VQ-KFؽ:W67徥Gi)hOt䡲aRlTa8C0ZSLϲ[ { =hhTY29Ɖf[`-2Bik;zm3΀nvu|bwk6~mޜ؈.j0W_$͗IITV]IYblyUQ*CE~Po0rOa3yFwk{t@xHvh42wR\gu*/$ -vs+ -d7__Q[uKJ|[t\֏^oˑ 6q"Nu03\ -($tǦ2 ;+)p"ul TKpR _IB뒠 6)rDg I@݆مQQ~˶&'&Y|.*SgW"GGLqjh[T(&ə/o^͹i.Vyߘ$Y }e46Q6_n"` BI2 =eP-:;8wkC AK)H3 mJOeiDA#W4aH۵P;)r>=4h=cI#kjiUMTsO,ްюMv.>/_"aiad,/e5&ˎ9*2<Mۤ6^gRb#P&D"JO,#iz g ;mukWxKUF;hf2!GNfdqAjwtqG֡%j;/iDf}yY_O{ FrR6K<v^hca$_apR]~D {yNVJ+唑Չ.O$KEOVٷoʾA^l}ADN)D Rfo1mKvXZm*gswc(, سWņč61,JXFga}x" {˲)~Jwmk!{u2J9<\K?GJj4b3 ٨NbyhhBI`C]Շ__~K$ihBRK҃ q+7*4RKW㧒R!)X~Paf,;4{|JFMjé7bn:7r%:**)FygnD V?r;[[XQ PICjʕPdG=;&z?_$d٫FRyNrIzҾ~Ry 3v[R4U.Vm@V^F`{[ӌzP'̦ cNAhY=M$;o+~N~Jz-37 Gn z_i:(77ʦ8zI o6L6I{ S>z\דO|s&$6B鲍hHчw?zx- jtt a, pOZwAX&A#$)jkWԍ[j 2ID?S\bV}tol=COx̃ E]i~$ABd)&s/6(9%K 2qƇ|-brڬ2˺?GD4tƨaN iQrS?B0GX[ /#K,ijqTUU-Tꮯ^ضg;չ1ߤ_d^針U Y薮Wt}́邍[/_&^ȐarUA==CчFTYCn5{cLcG?n5zmfBVkXMTo6PQtRѯ S?iU7 Dhz1oZ稽:Mo7;F&tqt œm $UfBo7Jn!Q$2 [ʨՌ kT/aq,۲idWCm|m\~ i * Vt7`XjDCȔE/*!pGomA}`z|2@)o giCջ+n~|kJ^ kgi߁F|dd r+ $̭L𕯔`ݴhOr1%}"Ͼ}]~2Ģ[?UNP2Ptf *Fb-(&A0(n_I| 'pl,*qMLB~6NUf +jZji#Kh<( ~Pefjv;hZ;k>Nk#uv?r.FpS %3wn}4@l9f7hp>_ٷ4\S`m"ڊ~OXBo,6*0˴GpAEb}d9z iEW>% (FQëWA ̻j|SPbF4Hy4=dcWv<-h[Ԩ{rDv5a,#e!Gid>RKTΕ5ӲQFvy tkkbFUL1e^Zu2漑,iooʘ(ZGx K]~A-F{n(-N;iq7[hVGzdnݎ+C($ kKV "Q˿ 7ihfY͹IxKkao%LdZ-2QiY"˶/Y-Z3% aӀ`(ċ|$$ C_GI ڟZY%"W'}<5<ΉfMĕoV>TarJSǨQcdl c]M֖1͍ g?HbtC&E(D3~:4 efSUڒi7_QV2Zw774 T>EW8XGGr\aҳe9׆M{zڪ*bP$C#ͲQYyI5Ϙ'sfPCςD7Xsew3yӤooU(Kfn+ kjFtે=B[r0Rt/H=7I<G_ /ʄF'&f{p6F\ N`8va~{TV47q!X5Ǚ>|yq|O>]mԔV(:akgV$+`CO0KLXA;N^) ڵC h8M4!qWDpHʹET-l&KEh_gH5ljbc9 0o6yKO=}kdT|&v=Eo{Y;6V2K[/zǺ| *̻3np nm)̫D>z&^&:I 6T 7i°vZl`/a"!iТ|}("PE:I (_`ؑ{x<+0&v֞3yhqG4&Dr?=ppy :v#q(mn90c6-NLp^fvC1X-M|wCq(S;BM&_)y]R VO >٬*T*6~0֠ X CA٘8AZ'}`-({hq^٭Aյsk\akW9_qG0ZR6'56p. zb.XucsKc8M' Y! ܵK~{_bƦ;YhשW>zS,,ڡGZҪ؈ aykF#Zj$Օ-G~[Xdɺ8S=}){dGOfY5䪼D$;ޖ J\S)9LLJԝ/fZY:zݣö)50AA-g8#kWzB%*6D E:ѓ"VLMiX0﬿?R}&Fin]4gH[k0^̆Xܮtn庑 aJE"M=a esZ4x^Ϟ+eNl@@"Hd.kmbmķvƽ=l{K țkhLr]sr1xwqB,.&5AkT6 31`۵?40K j{`UFnC]jlQrΤOM@fGSpMCjJ%. vಡi5wC-JDY_jo:u:$lM=Ѯ0Jwp)O d~gix?>:Y4p%!;D҈ljs͉~#TR\V4a xPc-m-\s^ o5"Vpajϧ fs tJ|jf@5OIw/15ndU29o=rt՗5Z[_ZtU1sMx$1K-'4; (A48탲 ItPǝ. 5L?^< Ͻ8LFW!v=%-m(:1| |"uqB4jUPhn06xb㢫Bgx+[6 쎮y<+wthltfKR{{G]_ZyAi {}gq=H765~) r…?C/< ٭5 ;{?&vY^-˔Ri!5敜q>+ M66v[Dt K*!ݢ0hHenѸtL /&mݧ,{oķ?~Ĵ{/=s^j?Y;ԕrl Gs~[|(p{9Ẅ́1)+gD!+ E H@"EuDJkBf]c6[$АlKؐodWSC[[PM6GmI-{xHJ뀖ӹUmSjgZ TW\]mɋH>4-=l/xv٫W^dbҢEڴ?bf |qW85tb8-Q-ʶl\ssީ%H@hCn|IOg Ņ?-lG5gP f*WV[~:<1 ܢ.Rӳm P\RV %9(`?[&RontW˘ًWrU>W_Pz.8=k}anMy) 3nݟ <2G !8ini}h`֐4 n^bŶL3G%cR+q9|Al{vuy4RNa*CgO/Bƽstgv9D4RpP9qPs؄^;(.pxGaLeV(&Ck҃!fJ1#k? K6ӟV](JG˷id$xms/ZԕӫC?~ ⪃JUu0aHe:?\|,I+)"VbH\Z,nEKU _:լdžKv;m.¸MN.Ǩ|8vM=9ռ>#Ɯր SZXW#^Jauu *+Ki2R r9::+Mou(ܢ'Yerɐ5"L<lFR@Gʁ<طao>[zl)jQC|s =̢z|qfs^Do=v:cpV JlU ~;LE.Tt5p9z[P %@GsT$f}]r)FX Yxа}h2?|^({^ĖU=DFQeA]y@ a33qK1426{42"toOw]\rE&T UPإ1 Uȁ&ԹBqPwNc.4&J(Hk5C“K`EzgӉ[dWsSY$rL1ȽQ"KgDth":2 K9(&d%Yoj V3~c (Dv}IFuXj$gK2..2'^[$!G("oG*s%e `zu=S"dxHkZXyزt[t\EzZmK V%j?>3qE^Xk=+c46..PGQe1 ^]^[ol\'|*d0Fh L0ďFo$hZmLvU5S x]2|p"Jp:%a !}-RrCy"QqiZ%EdUQ{c'Go_RV,Y?V1G!E2UX"/"M]]~-*p*=cDooU[$1׭vd蕵t6Qu0/y+4brl"T[  MH҆+b=-MFףw&mJdn51r3Q6t`}3eE-%mTU,܊,Q@Ulv/vc(.VE6)Kc8nQƼ-#>bed&񁇺)I+A± >9PG`8O$D"1i$L,EN8z@OE.YmXścv6u1vkrf@=A ׽(ƶ8yqRw0Q|WpJJ &3Q~RĆ/31Zf"qꕳQӞ^d 9$2f#݌lhj ▍%4"Bǂ6h_[5m!migN{'c3>L7h qh mI^)APdX .ɨ F?*|1pY]eL%AidL6LQ!leLDueيQeWK, 7J]g+IA(,[h+w] P`.h4`->&`9fkvZBkOR*mna阬(^߄ =qtw^ UB`=~G 4^WQ'u\(S%PᒛeVJq-|Jxf!`U3RE})TOoKA]uU9sgԻԺF.|jJAe!;uZ/ qxLN:}&vhHiFTd1Y`͂su[[ 0ڵNq>ONW#ޒ#lmnű՘%UOL?>S"zW֡H]Ֆ)z7֍B3(8^ ovYJܖx%zg֖¶9SUY>iQ[$OZwf!tAHjq/,~7m#JIt,9=ĚBf0nE$&<]SK񉚃HEzl-6O->^[s@O[IRǛZ{Bkns,,ҩ!9Ax%g@+qvv slnxv$~du^\DJt{.&.9FrL"1(uTe4-<-|ʶk j{zS^dX X@ܙwlc#䨴J"{mRDC5p 2D>3}5zV=ĭGXbJn XJ~pA]\^&MQ͕|Ɖ>sLҳR[n' $FθZDq vN>G!T5)?W])Q[n[܅:oOz *gXюU]pJt\.&t >~ɏ?dH B\WN~_ ,tq(o=mjhlcJ'{CX'-Re y,n"מ)r,ڋj] +t ux'0h"sx>"@" vv*Z[-d:#OXV I*#P]nxv{p?.<_I;B;2%4wӦ[\g%! rTYQ%O~O0jQ*ow")g{}||J._~YTp^%PEWG&S tJӓ'd` "qI? R~K)l ea~m1ϖm1m},Mq%ǂy@Гݜ'OhN̈́D;q=/-aؼ /!C0F{J;ۓkHl6Ή1iVkbU*$Eo#vPEJ/%zӕ3rEmQi]݅ uuEEwn/PDÁLu:٭@^hF%9G9G:) E8*'s ~K :s=M īm*E…_.@F$L2ws+̛ےuOr-}3ďw:]\,kR!|nAP7#Qh9O+h5[.GTcksϢ h?0?Zx{e\.1,. 㰜kX/`iՏq?.UJMJ3"=^d]H)C|4=*oMF<8*?ª%rҠ| lٕҎ"z.󛺆_B-Qr N+d4Pĕ__7a1E]YK̿4^q~olZ`\)ȥAg`8:o!=LMt:z,!B Jc&#&XL'jkжuv6좶V>U_ݝ"Lo+*| WQնye-`[|*ǣgD@3_WV.745'~0]i]qN]nʿKXX&آ4asiy q:c\ 0{!DMO8ঞ;H"JGJcV4i!Ƹp}p/?8[C촳G{ft |~nCueeoN~+^? '7[u]qeAsD%FΞ}eVa'~?ʃSn[d"]_pD3 8l?1DzxWwrO Ǜ8qumv@*izv=j.'Җ@K3r>Z%ƆF/]_>?O9_O;|2h=}'|pjW` gN9qds35k~Fr3.{m=;$Y2n@2K7xW: $Pt^0OLY}kºGuJXT&\FEC!]-hku2фF送9>?5uF'}DZWFkurō#=_fϸlr|!d٧ԶZUu?tr׏)GG'Gnye=zWz|#%\<>xտ{=zw]`w;Jja)Y䶻"ϧ\:.)o971*JIJ:1*^67ljΞ /ꗗ_򗿔?կF~բ{Cgf;=/owpʤk|;iqOѽ68:nᨛ\uI‚[[lʓ}a g)0ۭm.كWy%?ßQ:{'F9嘒SWU3m|ћ6*uֻQ4?\DwZ~7*IkzOWDav،ʣ۬ ΁0//ۣקn>_ߦ'+\|s7&?_ܾFy8جρ~4} &WY u[:[N[^y(<6:2zˇ+닓7GmA|p ý{_?|y}2S1e [6tJ;5 {{lÌv{K$VH%pu[H~/ھt_s:ٝNO=S7U]qN{{:;x8DDho$X16nlHB89@&J۶em̤;NzqXZg՛=FwÞ(-;pNQW}Chѿ?|L*eYdXƀ+o3X>?qʤIlDg]6P؍OnS?v ax=}qL`$ɵX`%vvFO+3gg8r;G\`%=(Q$'Rwp0gm [|ஶ_0=H7uLY څfm48?C:C;v˵^DXh~Bt׵8 NY_IJ&}gSEH[ Ix(;>3@jSMi]zʛ"kyscNH<᭐ZَgWp2^DnF۹QwVfJSD H:$ݞX5Eo]ROţSxN ϏTƺhmTZרAq{ mb쭨mM'_W6wƮW߻}]}{RmׁUkliqo5{9O7|}lƹʍwphe%;5t,t˅< 3+qK&a"J`#_v,HniR;?> `CWOγ+O~H, Vr~c67l6\ -bJ,fE9S)~??M?^Oswq%I:~M/#p 3rp_9M~'?O5Hp\ۛa Ffrn_yUlp8ԹMM{Pqiquf֝_pKGt,Nf1p&ieV 1횊wJ3XMBdcnZ-OMZs'TXveQJF"IB0}pxee ϮWVt%NTzK|2xʆʏHf\Al mm0F`bm]#7m(ZSJ1uj?'x5Ru2wz~ۿ~W] )~Bg8EUmz^ 2xt&+ǢQ+gœI^+0\g4Fô{eM\2ӝ97^.eVJۅBZY xU~=5΄s3lOYс,IiʥIБ8\;r f3np3sɑ*xL{=:T}#i-v"K1nk4q;j׹_|INƏ %J<ݻW(ޅ]w.`E"Qw7]N>/~x34_\@jcG ?DScg>y7"sSDqn5T 47nύL;xtsl< ˓:?W\>Cy=]Ifl:^y0?(v7Gc"scn/1%Bjp6 ҋhS+$Ԙ/U2dƣ ${Ȑш9w5߻۲>L JE~ї5䛭'ﮱ$r7;p/ܛbM#]~@$ db*VI+o)̅g><9w>\29w;s7!907q 6I:OzR aD2'ON{r GX&晡lZLanW>vv; >mݏg&J oqoB c4! >wJe?Oe2boej^ZlaD)+S)X$K0ƊG8} S<j|IuT;H}j\ܓKW&>5 6V/.*Omm8=@%DDi5S?p$);_ gJI: c8~1ĭ)ҒAx\kEƩru |W Όgɨx')(xlr X:?\ 'ɕb9 GZ ixU(l\z&Z`4|:n *&f#<Ć}|=@  xԇgXmٗ5d*2Mi,hkA'dotw yCЪ}u. (wA @-,w(7Kt4Gzqhd,?Sʦc!G:gf%& )jR#[23ܺ%zR"x'LOE#tYg2P''iPE@8|,g= ZP I#^+}cܙT lJ<J84Cs_Npdd&|ěMzkJ#xf-|MՖ.amʜ쮸"Gߏ_ݻ`ڡbB&_64Βe o,IvE Gc1ʨsɇ+S l.'鴕v!G7|LT;nk0%G"`:ʗvFcpD{hi h\*FjRH(?Y@7 XJL,l ozC{7PV{whq)>O/퉵\%`xTe 0%& p4Y {)OB,YൠOaKU-{:C>AM6~ZђR+eR|ÅXPL >Znw" A{TE@]q.~? _;Y<(sbmLh;kF>Vhpbm1i ?#MeX)Oq1&w=#G )eHRD9ej\yJFppra18v 4`R"y6$f'?DA5WfaŊJȌ|B ,aTFDp\{V|!)8 0,QzF oGEZOb{uR}sP.a`7([ s~?nr=-%ڹ{nb;M=oXl6 8 3"&Lҥh d/bub NI{I(%iY⃄uz#IJ) 10(F&]rLY,Nnm;d++uh<u؃GPoaǡ᥀HH ˆ@[* g;վ%ma oI joVtW6l7ٲ9bٻ֯mDOˀU1P_D`LfzT% NLzˌXr!F%G T]x)g %^ WB).؄k:d<)S1Ejd! +DxƧaI! QF|!'_ sڊu"8~#z&43^5c0KX-%:h5Ġ}?{?Ƽ\:Ã@lG>l Q.a8#ެ Tұ㊘t1`B2jY ѤKgf;c$I+37p^"^q P%%TW2L蒁.d@BBDNŤ5f5 O*<8pql?jeC'QM)dlB[Zܜ(UD=F|)ʌR_FS;]k7Zs?p86BC4>+HKFSٙ<Ś.$s5]q/+܊.|Lv/IIBn;I0ebL&;#=E\Ƿ%,jV/H+"ŝ+Ƈv>uT_݁a'q'ʢ^&vf fw QmԕKcwk段аl5fnoljg8şu=CꚚ 1|`} Bn!TlS}(3w|Qo<؈(/briVIe)ؠλ$/-g(bwgbLu "bs5X;y"*,l)%K[ꉅAdfrܚ4eVVǢ*h'kXB4xn7}X^? 4 29>ŕ vr \ lm]<$lO x[CL|*!"|~ J!v7 ߢN[6 G=Y}"(A(J1˥t!zzQH>L˴/JOt-1wwN)Ji|~eBN"6󼪃㼘A f6^(e+|hP(R\JIjbF4JC].HOZ -np#X7 ia%Z\%핻6e"4- &W&b=^ƊU%UWOU>?qZ&8Zv&(јi%)`c@T4Y.1{mN Uza0stIy??󘛄wH0̯^@>]&q+|Y!Vi5l)Rm6MLֶ\7ιNJE5kC Aw/TDD51NGhd۩,)u&]}K,3]zewϖ@;Ԅj5K?~si!rcDɡ#\{_>c%Uu}0-ge4?Pp {j*`J2$*Nl9]xh7\_2]* %Bz9Ȥo/G^y;YJDBTY>\PBx$ 婩Lu+ y e/uhX8"J:Ư)z4l!6S .7B)M·DPV}Y (nxG ǃ"_e۹}y~doK< UnQ.`9bm]QcBtBH ۥt\._i\ @Ѿ s< wOplq3*4FJ+3, XqR8SAf ZLNTPMr33)H$Ls:0-r>(-ګ q,4x2$\K\E^7o|Jx@jof2/C^v[u` }JSD/++MuM\£s+dH+,1\N#;BnL3k[8&& ~2cNxuOg%7*$KNw W;3lV+͍lU(6Wr5k,Gt!:WVC:J@*t[?<Ӂ-5)TjǽCW!}]fvg=)*O!ݞ#\7Qkޗ蘽 w`fr9Gْmܾ@P" SZ&SXٚ)ŅՍZ:>^"G*(dcUvqR*x?S-˄ru<^٩Jɕ8q 1;-olĝ7^[Ilv;Z[!˃ iM%AᑏF@(8q{B޾ޙ簸we&[D9\Zcf'kW&/qCVg뜀jqȕ^>ȡ:Hkr;䴩V#[Dyh88i*yʏbqkssT(2(Bod$-҆!ZcAЀ-Y>Sؘ9:f+:4vTiTlkK,e [+x=;4M'BPЗ,Nmombb8lX,\ XNDݡ0]l_4҇x%ͳtEDbL~{ pN4 v:cAA$K|x?z gyqP<%]䎃⭜q4Qַ6v `n zJXjw(XD#mM|0VWrLӪD)3 #%a&67PS -ILJcl`DjVj-T9C`E]éi+1bcSap&ԕA#V6*QoaHB Ȅ \XגDizV,oAL&x\JUZ)oSN0)hhBlFCSةӑ%X՝=c:QܨlmV%ieh6kyKFݾSa2d NQ2XL vj~nA6xv·,c7w!'4\w{gf1w%&&͌//Q=<0ՙZ[E|8\n0 U@7 bh́vi/E"8DO,d穓 U ע={fH)Eڻ1"~jiGAZ,mW(o3Z_;~3G3wg趼ĥSQv1if%BwgOco䒖jv ׇEeyh ܦVu8Mtঋ8G{Ka5?tgͭdn4\\p%#b3 oT JI lm lW׋E AO(aΞ=p: *gI[f9:l @# lV@8 YwH LSkX3J_1"mRjBТ)ϟKǶNWGcr$\5yK k oJ{KQ{ş[>ܛzz ܭjRa E.{hXݍ`80 w&SFqYX/FgJ?]dr0]ͪC0G_\+*_n[[;V)T?QȞ+iVpJ'z<YXY, +b*43{ |V|@!t4r. g4UE.--.ݪy ?ncsUBmٓ7;u'>H ۴)(eQR 6C_s՟K$ShSͷs D1CM^ORdqm0Y 3L5Y( v)[RA OU}Ygqy'/t[qeSx@ݬP7`N&v(0TH,E?%M1vZ(Wg 8 ۬AQXՐ\/s_5{#-m/2##fO{?xhgwKZOo*vCq-ՁwO>Xddb0._܀ ̡K-~B~s.DPB)Ph(ER㽏WPD+o7v6 DfwߡMBiLiQÚe`(ϊCЫlD[CsRJ|ͅǍ.؈9ckW %s nocAqo^iсpsrɒFشsHY: (RAʈw J2 =Nrvn^"SAaCPѻ/vP'ΐ@cMV工 escsQTDxcc}MsSqRf8 J.c)Pӹ f Zp.vDs[לu7@h /jWbi9iϾrXQ&3`]ϞILkA߫1Ę{1~4iCzSO%CJbA dM6J ">R uܽh2ӛVm1qiyztdq /_͝Mo3*=xv0K> N7*m}3P\ h s#V.`Pe vFDq F A^/0@biuVK#ʕXbp=cϜ&O~}7:m:Z\-14eHXˡ&EAIA+F77;i 4<7ϗᜦ[fuNi:e{zp!g J^lndt8P$3L\dG p﨤)$Úى%xf)KiB="#%aLrs;hJ*2J8*6k`+t0gӉ/Ƣ)vCKms6t T6Iev%MMYkˇ3`"k>:ȥ,8 %$\$T sd\d8hmD3ZQL6ɖy4@Uc3bLXL1d:xs}9BX%Pδ[LNZ0= [#L~lj4l.y|fu@6p%N;0.:Qw*.ؐvE![g%aLA+yBr<=H I?:12w XU?AceX74;{66[[Z&fӂȌoTqQÖWxy)S~PL#u k0/Ue< :A'&,xyC2Dbuy7m &|P.,h35&%3g?{==\Qr-mK řj^^魇b9cפL&OqR"yWׁ9]\^ީBQTv֫tѨFy1`fq{ d {{QZwpm6ΥN>oåG RZNaDSӌct''WP3 eG}]%~ [m#Z uVƚ1 EZkZ2*ldI19GT*@77v`i< hR@LQ7`E+XlDy;[]٬WYl C_|b, Li+#ЪO#xWΰg/}0+j|K(,Qb FA0mJSIDP6Zھa(Q|aKphzyLȃe[Z*lQs[@ MCw6C%BKRi5 V!+$ Ve&E6^PN0??F4SQue5 fǐs]W]C8; MK1՛K4>5 ژXbYmR]Z7>JQuQSjơ0uyYabfXfRWw FIi"!=˔dg@DO}0:}b13C P)^WK3aY+:V^|u@gK#B7Q]e{Ru;;  "JMS%ht̮ I G8']CcqӦ%LA%꜑{wG6V~]V_GFY0Hggk=F`0/ccStد=̈́3b+9rVdC/ccBO@"B!3BTLv$ 'L^$@nKSN%/c{[DWP[rh&C9µQ2Sf!lwt0C3آL@ c_W'KK]Njt#3Q~ѸNk3w6%}go&`p==߽\ҪGijxhy"0 LC%G]\{d:,!fl)١I솝&M /v"IPH"L^ZaS*ܟ&!ج@Oms-dBpڊ, Vsq0f%RL̍5$}iLnrސjbjUe=p[ݻunwVQֶUj &SؒiVЬ /7iHN1M axZkOCڧR9(BBe:5U*,lAq#J mS}3i#;(ۛ4ie$;@J͝6vcXicflamkccRX@G"≪edd0>K˟ u"or/ ;\\r!!U%^S삟g*‡4gG.綋Vn%JK8_Deh6)rnQ)c r K| 44rki޾"1aA@l "uīB4\y\@xn+c@5׍T6;M5 vįTTlig@';4 * D7n.s ލDžuv::mʧ֭́eaٍkQz{3vWt5D%=96@%h8b v/9l^LlI3c*xbFE`%Wʄ@OL{w̦^0-3V`1U 9R`2mXޛ-$2 3!ts'rKuv&Mng(P`A`e۰LՒȿZ(  \ /(s)BlmÎd^k_)lrh(T$kIgk`I'~P>sM1D(kȍ,w}nYvL@EʎݻR]PQ7~ 4MMWt^4֫9ֻ?o3e񋕤ŵu@ʌ()S@71u( t vڿE)h 3f Xdݠ{u !@#<414CXr@ȳRR4!+JvZ/`$kk%S؊9y˜f:,d o{S-ݟX9',ejN(ss{LeK7;Zl`#'(kcSdc`AvFQ(K=B%G2N*Br F aцB$i:][Bs!dC?w[[u4%{ pD7.р.PFgPX'(>MfqKR|ɨv,·X{ kPA R8^hLQVrR}0T\5 UC&FMR?ݓ6݀FzN&S-ȓosslo ktL{L960]N]h ҷnZLPUءC.UǍ"J}`B*\Iv@Y9E8^BD'HMQSیZ3tIu2w!$QQ@%g sZV{Cez[GN6B??Gpkjk@fI?5,hL9ma `D KQtiGwVWYZz l Q-4lN!jHՍiC?gU"w(CUub/3I&$ـ_^͖;`2 7Cj3πЁ[;*kH-D{F}pqyp5d,t&^q %:]WA}Պpzxz 1LB $eNgĠRCNJLx=6H8bA%arUߺMJʜb4IV j'Gd+C\IntVk[.0$,#M sϞ=J4cg ^%z%_(V3J\nkq #n$cMg8G#]֖ %onb/Á)ܛWFSU^b:*V"k֓#MzB̝ApƴQO^~ Wo=7 u6lj:#9Ϙ߃{S.]s~kxk:WOx]"1fA_UXeӱ]sc9zi3XF.w3Y(DXfz+r]ϔ)Lc46rm'"7=b-@*XpgvOk<q Z&I'K<2F)˰ (8=]iKLTZRUlD"==.&?`$&Y2Pl~.vήs0BC)Xe;Kj 醆w,6(#hmhI%sNj@(D븣]>L]*x9g:DZ)w6 7 6$ta t_ɬӬ"4l-C]͹5IPbcёbjt 4ÛlوK= ŭlr{;mahUjr olKL 01!ATg4Pl8p,"$#kpE @WP-65K8ŕ/26G{tY;ցD{[DRJLTw{ν9}XuVa>D0G7Z&MPx'r 9dn--!3Fmdv􎖖.}RnoUȵɲ!ęRhܜz4He*=j2M $@8Rd̒GԆ _Z)•WT`!$7gm X+SjS@p ` |6\:afBٞIW륹m ]6{H5?f-EOk/]bL&86휚ovтfk*{$g}ģ͓J(o8>?5\{uk,f_Atu`U{s )]/wxnj71O>g37V)>+1$@<+:vf1>={6<`d YI7зkB-bq I6ݔ~/MC_n-~rΤXLI?$8˷YU5m{6g̱ jLdhPyL߿\I$z/49OYF'D״VIE@*ȂrKUJ4qwf c:}VPE;G1Ha z@M`EloН@67 O;#^ET+AdБ@!K= APu/c(h.󞔥aD?I* ,ֶǚfח*kkdaP:yŦzD2*20yUwZ2Au[4hF[-@ogJP%s=M4FN8#W 67Z]wze;;[h 2t# hu;ʒp6RW zuJKi<8@\TC"Lrm*Q@EyY/p;e1w߭,2yR08'ch"[KKĒE96LncK:[ɕ[*2eW]`hJ^a`7=EL2Vgn!0łW\PcP W1S,߯yhmoT`5]^^f%EWVՒؑR(#?Uhg :JY0^^VhfV榵ւnnqJ­(a/ہ!o:L| im7޽8ri¿#p{v[f4eXU?O0uzQz AgAw l|r4K2`P+ 깧EWX$;2ט  Doltܚ~Ny!^^7!#.=f$r[3P*QYX'1)e.-R@q80QsI2 $cf!JxF7+CV  ):X" $t WbZ|cZH}igrzӉWc$ߞL/$ ZXř/,$!י#ۙkfv' ѱ{`n.5&g#)ߣT=Sݾc3'U 1:ss3G /MG._ܻu]T΂,uPكVirZ+[^͌)^ ]dˮoyMdnJX0={ɳޅ޽U|l <#[Y]K`IzhQeS'0=aM `HDz0$}6rClc-5=Q+mS"dy ~@&Jxt(E( 3t)5|0%egݾ4l$kcbov*y,{4A&K}nA9ˮD;f4Eӟc/\CFmˌBtMmbЁ@ N?,UqPm/uk`\R " pm9ҧWQ)˯KƪwzӵR yTT@s%o釉B5 |Ʃ -6Z_0bI^R,Q-&V@PB]nAE ᛓQQFET0ץ RҥG#;UmOۓʛŋo~ MAM[IkZi)/Kˉ2f~zclU+ɗnT=H'bIth@Uc#Մ 7b6 fN2F DrX˯@.ZͳCk`7vzG7C~d')3|#61PՍ^Ȓ s۠ٚҶӎɋO.|ރ)(X0LpɍegD~l[~oQn&tMz[nnn5€S{^$<[nh~M)VJ ٍ-:jAUY<}n(/bc5#,bOgK{>뼵!JZ9{5TCNVvFjLJX(ݷ4{ii#UϠ=L0M7E!O z-z'Zxԙ6Aju݉n?U4E қ yugUBJZ$X)ɩe IC=y` h:[llsW2, >&@("NF@I,clO(Iqif> KaFH$K:[GM\bn';$`Fe Ug't`,$Vil;rzk"2) 0R)+d^m솎 ȇ4n'pS][~Ѩ%1&ŚR;[5fWu0G1;ϸ{Jn^x@;g $wX1+avkr4r}s8:: Z]s{9a@E!M{ۅw9V0Ѐ鹺 a@,[^3Svl]}޻ZмlpKaA+=9ڕZeME}8*zP_wukrsSD3Ow}`Og-9%1%|www߉KT.|)vq b?"UcYb$A7ЄmD wPM m8]SC >Z-,ڀFN9%=LVzMÚ9u9w Jf9iffTr9>Z.'"lc\փDJ.jڙ=,vM}1#a՜,{q3G `ߥ>ԣ=ލ&5`RxZ^l~uu &w{3̋JAcHaG~\MA߹Y,0ɲ X,I2~D{!4qK\vAޡ 14A" kKX`Rt@fK.OX6z-cp>gtrY8vr&kAJ6XqZgkȻ4wz=nvbod2lҵ,.i9w7Fg T6"߶ koO=FO `TОծüQΫȬ 178AwjB暇L ̊т&mؐ4s˯)U]g|zW*m1ܦ{,M}ۂYƢCV@I}Ϭ\BvN8K?aF"gXrqV"]'Z/ݽyAtw@8!hoD6ʢt'wf.4͕Ze,vTv_ip`~VZa9rof._'\H4 F> Ӓ"i.s' 0@L:ĥv!aj; JfYɴ5v=lž]K~4tp40G8PD ZN(c()=XNwMRvNp탑[ ׸V N #ڪJL'&Y{ Tɨ9| %[<=;y8}_7{po`J ek}t3mK /Łߤg'KK~#{ X}YAD brWb>:ҥX~Ԁ s9 $i LqX Iaf, + uzH ~־qR9<:PBbeV:]d^$=Z8wz 3 2z~e^ccMf6Yj $ fW~fk^]QXT$zuhZVKM(Ѽ_v?]ȝv=<7PBPʝ蝣Yks@]|+WIi1ԡR,Y؃΄Vzh\Gsg[PNFB 6N[5K2mܭ_(U"|;{ƙ(IV?w-'`nvÚ .L9.#ʑLSɵ\&l!}n{h\ƍ(KLuߚoߎzDYY$.k23w0%3ՙO&g܄:f6  ;uw4q d &nelDSEaM,ПIBJJ_b+wA<]XA.cϚ砳?5H418wa4٭wl&nXiU&s| N.\O4 NNMEkl= C$DYTho{wG FZߺrˋݢh&v8Cztlʎ_wn"ɢ8047iѰSj5pY+Dho]{g/at(6͓Hږ.4u'yrₚapQV$sd̍ cX &\ө917d:M.|Vf%̚sm -?(dF?ިaVY;p}]}3Y{[[>R jP: j"K:"˽BjZa5J3} b\TdԂiZ7I&0WVלF%5R99dCej/fq+(!bn*hNF+j:n]1I6S= O>c4jC]P@c LClxal!01 fY!6+ɀi?diaoCsz>pc56rb y"f4$Gh΃ RuF,0q(5Ø, KǸβX+Ԓej2^K@ 2YX_(78ڸgn A&Ʈ^WNBWlh? }Ymq-m2SAĜbgo yDUw(?wחP,c:9-*,/6;aA]usىas@[<E{jX벑{UK;4͆A[9"K!7puu: %N3$-w)rќh<5D̈'c8Rl8LWJFJGs ׃$Hc>511yC@ ukqxmwG&;G@& ޚZI05Su+kU]XbK4￱ eWHU4T - Zv짶&vbײ1zr򓻟}ա*([iN{Zjo*%T!e٨Kx:Dz1h4cB/ST &&>^ 6G~mxe/ԯNj|!A)>qo=6vs_ 74-!'qF;/ߟﳙnw} mfoϰ &Wc1xgWW߁O8>z.s\˰)o˜}sذT"~u ,3ԡfjz.N'68QY |_ٳ݅xV⬴A;ʶ*Tl./sO^j=wWuE95Mw&E3Q8Ed6j>ObIMM`OA<|27HG>Rx̉f%cnj8vCR@oEdsO?O?+>7@1܂hzK/űG iYC4ko6 !xw埗槦"K-s 9; E%{&lg7(Ǯ~z?|[  `ODYA߂ `&~~4 q}ZE]dcyߡ$@łDIt0j:$ax~-3˻۬KeDP(h WrûݙAe,Cg= V@}c$xWÿ~yF`ﯟś`ރYru[L`7૗¢VDcHPw> s߽ j ̳a[|tZ0 DV2+瞊ZSƠ\d9>Z1kƥPof7CÊ%zE@*/6nE}^[a# Gnb7xNI\?R$&X>_2uB`po}c5[Pp/`_|Qvh`0i@[䝆,D!TO!^jm ̓dGߙ J*9p2z 4W 9J㬋u}Ks.H&h/Gz,TNOƻ?[2t I\6yo_ P\R BKoNŹ @*@`gAɢ')_3c3{Q(&69"H+K(kI)up)݋eY-vENN`ct^^' F簖kti(-?;I<1i0h>Q'ހCšVX^JF@`O(4֙+#޺k<<YokoD8؍wz[Ҷ^U|MoL]2mMm 'C7CFjݒ7{z9So 'l FX Gw)j8H T}g'o}o^kAoM'+苠i5E(|-9}(7gC[D HouϾLjs~ө\"OYlY4Vk\ OۻsLֵGd4$/U(~s9kU=4]PThH vt0bij 7q@N57J'K(y=M#lbС"0ΘfўïvH081LJA5*i.q:Zaǁ2б K{ng޵2^gVTU^6~/ˆ=$&F6|ŒY ̻Y?wplyDr1WC5q<<$@m™\sK "7kJ NpH+;.?fhvq$b]ɎӢJ0"kEbmCx͉4h$5(ơ>NlmLa[IOtuML0|FI/f͚)rl9_}Q v@k6ަ`^6̒z>7:ne [4".ۻ>Y-ZPy}(@&Ҝ GA?a׿&-<VjomJ+kLw%`+>ޑS`pegCD0CѓajC[`"d5mb8y#N_[dI| zFb8Mxm{/yK'5 (snx]25K La|)=>Ns[/+0D@l1gm8a0oo{-[\wX!K/I mTеa(Y\u4p‰: ڑ7AQ.OASС'dL60%X?`c{GL'Bb>#u < ȳIĔ(CPƹ18$AR񇴔T)x?`n'ȕY螙[ٮb_x3`rBqmFGak ʔK(|̍ɽX͔I2Qf+l<\f#O)E,tKD  ]@~@ 5ekD4RL7X\A/eEG ڤJw9wk:ѫզDrsSTTѽLS B:u)fOH6{+|G_(25{^2y0xx">$k "~5¦ /25|[uHBlǗ1zIeKA ,™i,KV<'Hщ_emz_Fp㵠]7 s tK{bB&z%V%n(=ʛ|獆^5ҝ[2}f{<\j} <,YU9FpvJ=ޕÍ~q[|6wMT9/fdWg)sU!R#2: `8MҠ⃶"u+wLLA@h8H@1O$٧C Z<#n5[hVܮh[3ŕ͙k!*]0!&&h "ls9Q.4nmF(< y܌T*iZkuɗ0GBpI !9{U97|sʝc^}:AZ; @txi&is=oPĠD 8={qNLCX+Dx$J NCtfxZ1R7M͟[L~T v{Dw2j{Ռ`ȵ|O“ɦn5` 0&iIضo꭯_nՕw&F[G.1I?uDu 0s.eR756Kcmf=!A0c&=7ܱt>w-k)&vf@{;s/uͽw=;/%-hqNN&E{g$h7!@ 4A$ c:rL2=H9șæ&76{͛6HW@R2]@V<OLݺyeiI,.]ȪAFO=x v./31 . }i@=dKn;g]6]MY^d˳O'ƖeJʾ9uk @M񾸗CWi ƹYj"vˌ/^ޭ9?L}-MQҥ(³3;a T&I94/ps}_zҷ}knT.#GV*SDX؅j{Soe`}8mPT̞7$PAoE=L@w1Y:N+FMwVLn{1lD>;bޟOk/@NnZnZ!Rx9Cc@DD7v3uK9Dgs5{9N"֩i|ȱ:inA {d)V [O^o3fq։ Dk_|&v U`8ګC&' }u2,8iVOV](v~@Q]iè8?5 FAZ# [K'٥4yK}ǘnn'=3kk Fx=K9[E39=cŷ<}&/X4GfcqB} ?$S:=}܆ K)[;;"uM o8JL{)Cnv  ~%aau iO &  ͖'k mSX];w֪nnN"֕WPkz(jNAa˽AG2o{ƜA?o=WÁF)smͬXU-tou`DM^,?Кxȇ}_KT=YqBiF}m Չ xAFa:5@&[dK 2&C&h o > ;ⒹewSag DCÀk$/o+OK? ކF.ڌ4Պ}| Y`eK [Eҁ@Dj,q[ (Bp0ʟ-@͙c^fCm:e+7'Ϟ=Ƙy|37bwxm27ȚZMޔL QA3B\bD Ra`Q'O~v|ʥnSMaMq Ab4=!(!Nz߿Ed[-PZMadg(&l `jP2 $APm Fi*K]>CD7R< Зh&q[ZWL~1 K]흈*5n=rbO}jW]EB cZMj&db*:-9fC cv=|-,|ǿI,s$ei. 2:ւ f-~LI搗̍QCQ2i~x`N *|a*r$Nbl?O&r fЭ*1ΩPV+> )7(s'6oeq݊wC 1 @3Ъ4}hsɥ_krz/NZ$z)tr7Th-HV70vu6^}_K쏵mוgFGC6@U >r%93YG.X$z٦OcOv?"`CW[i'U6cq}n t4hQZkSWF. ?aYRNNg v`O:MhЙNo,5,%>2 s vV<0SIh?lB|"W"t"cԑf%fǃװo|"/=' րaj ~z.@fRA83 ڊ/9lфY{"lJiCHK x=zN|E @MAnHNԹZ薒 j ~7A*w,ÝZ[;27d֌.hٚ(vclI z]sk ^J-nTD{o5mSdٲ ]بAy4~b3^wP$ "X5ŦEq&R+hu-=Rh8x?x՝"sEvԍr/[;ۚy$EZǏo?I]s ELMKM[ ڴpFHEK}17:0>RE%s?DAv4K K<ޖ-"Z0OjW+~Jw+Wb7 SFmВ*cF%m#М;Wr9<t9Ou-ĕ:'O_n~~lJj ȍ|1linhnn̎5zߢoevpMp!H!'N?{$ ȱ6zBՠܣhgnidT]αK=E N\𡶵2I7, '!}3N'&4: 'ĞXF韦 PfS,c4!IV^8 =U还 ,_ck'戙{Dڬ6n!5^DA~o=`_)+/]B|@YWFDe󁦽`ґ{񗿀NwwÛ6pi)n`>o+ULgߕ?<mЎo4$:mp]ǍyZ9Pɶ XGjr[n%H931̵'fzn۸蕏,NGOo9ǎGW~cǎ8r{Ww%(4w_vmQ&W޿ivo9R<MG?r#ȑ#Goi:_׷H1ztk9ky郼S˱za˱-e`|p(zu GtZj<nWG&'Uvc7K;CP86_sb ?d#/Z͡`V6MO+h<IENDB`Ddrt  S PAfigure382-3Figure 382-3bS3)y"xq^ nS3)y"xPNG  IHDRn> JPLTEu03y|쑔сeo\e܄]).풜䔜kxz䋖䛤䤬G$)ymz܉줯嫴`GmmzL\E\>P~VixLdCXTlLdDdUv$3_JtElCdLl]L|TLt\T|DlLtLl;r5fC|DtTL|\T]D|TLDtTL|\eLL`0xDD|TL\DtjLCTLT\oDD|cԄ4佔Ȣ嶊켔ۤ{㬃伜䴔w쬄伤i䬌촔䤄쬌ӝ췜䴜켤IJܝ䬔Ȳ伬Ӎrܖ{䤌쬔ܥxZ܅j휀䜃줌v䴤켬o݌t{Ԕӝ䬜|jtfܜ䤔쬜gV܌|䔄Ԍ|윌ܔ䜌줔qa݄to]hXxi쏂ʆ{䬤촬䴭[Otӌܔ䜔줜Ԕ䤜쬤ŔPFXS܄|܌䔌윔뺶D>xqxt쏌|66][jh삂$IH܄䋊܌䔔윜*ܖ䜜줤䤤쬬䬬Ҡl>}bKGDH cmPPJCmp0712HsIDATx^t{'ڰ9/B"j=x(rPA"h/ku߽UE6I&Ebl0Tgdgfɂw9L:L|<׹@ooݶgK5cG@rm;zw ~ ؕHٷ}wuxK>'\cӦ?ؤsylcgc>S~7sGO=|C}>w շFw}vcƖ͛'i3<׍7߸~ݺV.]zj^˖u]qw{7ξN<iJ2Lv```+$O&{L>O6,Aro Ɂl2Y'|0 m'`뿎@>'{.ݻve2W} ew-{zҕ< 8͋س E}C( _C>=E]1WW.&? _uiCMlZ0x!^_о;wtǿUg節;ޞjH3=]]¥++ّOdԓ\:M z}- ɺ_H&YwnY ^&knw$2޽o;yV˖ɺ>Jh?yny㊝tڧ~=@ʪA @cGa &n*ryȦ`~Nvy?0i-M ll]]ۻ]$$&|*Çc$1Pk$fm; ;{jSL Ik2¾X!Ex? ޛ6m^,Ƕl <l1]@F.{@OS?%c:Rïs[xSx^p`[xf6=kߕ{t2= +2|㎹Ǭ;_ًu$:;]=T)0alw\ޅsylHoGb`@lyr,}k &λ-[|Nپc:HdWϛEew`?;XtDpGFUW({0â?)؄[h t0#ƶlۼlLr[I߿*ioկ2 遷Y0Nvt%!I<8rd0O~g۫2Ta D⏇=?;ػweEᓥvreI 7jp/}?D7-#w$î0fT_q0Z/=UXP_f񧞇La$xv/V;v !{Uv.ፘ}9cHW`x"MН؆##{7$6pRݷ\ m[iS} ⏞,/cK$f7̶ 2<,9a̛s\"_$Jeبc;_%yEnYCN\P~+'F>K ܝ@1Ah5{'JwRmx].p4NDy[-޻o]w27tt&Ɔ xw۰DJ$H@He9us)D60ƞW!`՝{vZXrmǟαm;+{˗O'iy:Avf#>,'K&J( 'HT!݃yCݯvrk{ b\JEwVMŋN0ݤ}-[{I11eXXQ(ԁѨܔ]oq$}Om'Li~ IB0>&uHھ# hUb)TZJTdX`cR`J\lu41mwD L! m=dAzEw.]pU'":!Dz{X-8ܼm2XD|:1֗gwLୈ}˱%'[Th.d+8;ƿ7[*2!ᳬbScpJ.\pDv ׃Y­sIN2-(/m/CgG6/axQ F`̈́$.eÌpۆ#ΦKj M$ 9M%VUID 2[fMw+Ie˓2 H!.Ɛ:P!eJ@Ddݭ m mg=V&$o.ɶ^۶koN^Yub;ZȻC3ܑBة'n$s`:n"nf _"{v|YX%ĵ e֯9*Ec^"3R|c=R};{1h'~b swLB;@*4"/]\HE|/8}yyw n(yK["Ж LT޻NWڄ9@ 8+@)M"C D>Y ^סʩ;q^ۣ?8=|J)Bd ߟ*.Α$wyנobǪ{mE^ϲI9xY!礚1+&|<L:"5B960B&CPɽs+dNoڐIZ6+1!G;X+e\^#ɒ]|BpKlp2 k &.Qj;B@'AV%&2G7TM|Q ONPdFsB|d!ThGҸ%+2mN-[^1nv Ex&,',Iع/ƍG+Ŵp]/ 'bn'AW;%Dž{|Fp+ "d!$u{u\mp2~.v@&;6 \"x C;Nh$}8mGu$'&!>;.ٽp=qI,CrΨnA\.B` 76rlaج{mUQ X.F):s.hnoi- <n^Uo91;3L{T#! E(Au=BZ~VWF WueOUr6`˗E%_mEHH(,1܂;UDDDoB*z%G+j1L(% oԎ`܃<SpӎWc\@SA+zS7d6̅1(mo p)__s۫\v4 >pZpG{IT|bXcP&=rвikчu/:"u%dΕFʄt og {ݓ P\|rޛ*T$r nG1K2Q&S6˷`lJ~{$"Pn@ B' Ic>Xopvt'Vf.28p|‚"8vh'Ry},qDfY?GQϬFלCj#02e.ڄ{dV jBF gx涐!+ݸK]̻'= X\ˢ%8zPpDVYbǭlw j?ztDjpYd>+ywJAɃM"=8c:􇜱?DKqhdR8>D$; yEG%<q}v T%>6q%T6u1؅]pW՝m' *q=!C$uNB&;IZCPz^c5ܨGE޵9!^ux7Rm~=|Er/::3|_>\$MRTT`*Q |T|Tps,紹7JpsRTI;ˬ ;JjJ'M$x73 >n8*)a3z}G~M9)iD'%C*vb.^X%}5l, Ӿ"=8*-,Q(PpD©Gy(cr[n)sRlҮ:P^* mʎm/a8Y)$ߒ|Ԧ.)LdH@1 F)C TGh | >-uDN)2-9Ѻce@y^"1Rv|2 o˿:ryzy{PȽ=7Y*YJsJBڐS TM6৵_K> ,X\Kr\ ||)͒/OO5](ⵓhVmE Пѩ6߳`BPN9}Z'Q{".3 !(>- X1[v$}V'͌`\ȟ$G-U^!""Qe7 ?˖-jEpJ4xz'v%0hBXG82Na/7[_NrLԒ-7A>!pſyT }0'Ba`XbgC ts2D\I(#V!YtU=H/J8\WUȿPm>)]"h)@eqvJxEtGރ;D'Xyh$6Ui'1@XGjpK_;bg`_\(]L+OGNP+}8}uЕaIJA"K`Xf\31z <5QVA9M4{$QyQiuE)e؆lB+5kr Ѻ m@{O/&K64ƽs۱׸l%b]@Y2ُqvne` q>aHOUc&95 wP3K|})hk2q_8vq8',6/!;B%]s^HA2)sQXVnRܬ8k\ PjG[m(}O*AI ({#Jp557礃8IK䰎{g޾Gێ!Iqlʼn$;*f,<"kgIaഇ_bO=SB]rp.}:pX&T.WB ,u'B\'S|b (`-}$`FާuJJW}bQ ǃ+j1*}CWuPA%D^YEIlO(MFraiI*UNʭ̹0ta JA.b&^bxs^P3 6\; 8;w$N"r_FGyG{FLH|1}+?O ip;ib.8Y>7z);Ry$!jJu@/N_V-ZZ[+JCsCkoMd'N8 7NQإ;9>(RB"8+ߒPkPGjJ5yU SJ)CQ r$"p7Gu$&J cj_2Ԕ<"Xk^Ck[hH:2EuonlB`fWߘ{ROBu#OZ+r̙3-{PREqJPr+m{[mNM '#gȑG\xnӀl=QD6vRp¿':%~^?Ry8%l:oo5S4+&31ʞI&8kZi1s7_RRWQ׎n]j!ǩ2:5 ͘0wGQkGyĐGu#y+HdR-Q}Gp= ʠLb H2(Xds9$#X[~6cQW06Ыd w Ǖ7GB_ZúveEO>Y*h#PTh[( ȡ[g.h$8TTC뇄#؀}S*#!6Z)&Š `U7G"$4 DՎ6+{yh[M![??? )#$/t=7*-|s]TH#h3r:BrRq=_QL"W wkKkssٷC+]5V!Zc5{7)Fŕ;}{K-{d!TY~etL&لXLF"Xbqz/ؒ&ɌZ-ۑ! au$n kWϯQa lO:Ir[bDtsE>#܉t i9xPE%VdI+B4$TjU)WJnq*x׵׊H(ǺNx yR LD)B~mt#U?:|J`e]^AiǡؘE6Rq:#qGNR) lY%_vwevW CCڎ:(ޛCú3 2F] nKZЀqͭձa͍5IzǪ`M^u7 ]4dh7IIy">y&.;[D_dG$0vriuŵ1lM)^!Epk,Xh{==:v13/߻BP^ǝwvcg9% G |13>jU\4r%|T:FPOJ T8iWF2(V  /т7ru\ {>ɤ[ U) ׃ZCD?A\cA⋼H(<܏.]+Mk+%q׎W߸+˰ k77RB*OBF6Y$Sy!QĜ[BhRLO(䱇n(k7pӉۅNRZL)3#wG疜ǘwpa|7I%V>DpCnQP LI嫅a\"J"P<%Jiԭ%2vڊQl߾O4_y7- 0tA$e{.= )!$m<^}a>q?ʔEy.Y}kVKMs+#p2YG5KbΕN1iEY6Ycr}}'*;>^]e %w譔ȱA:(^T8!T]W~eGTM/ _G34 x䐙8"2iq,M<$DKk~`lQYcxrXHNb#n⳼"e`AwhMAسiȤr?ג  Wf'}ުPe8-'v0TM" $[N3nlݺTuh.03 B:(X?𲔀Te1mb!\Sܬ ,*yr*~?xwG-9/kdCi+=GK΂J(YHvfQʎ^jtS];EOؠVY-5,vxBL2JMKdfn8p%K6clS(^K!#{Y+xC۷݆̔v(&''7ˊS8'8/i9 [[sJ|ՐSVHN$4ŗRN\@*p[Y(؄İӱVP&xǧO߫y{:/Ҫt00YSs\Z`Ce%!Ѝ][oԔGۿ4D^~sviofoh Fc(MU~]WTޱ9"L[' X!?C648* yZV҄lUubjT(MHȑe'.sX/ah}ģW'1p}Zb}Q#n$jedڪuxT87a8tk>p6vY!}3 &zΈ&D‛ JgkhЩl&ϕe.ws%$O>Qxs:-iLM'Bw A==.K4]9\Hkw:0_a >{=k#'.[;TPoU ʨUCąQV=V8]`aڥsG2bȳsۥHd[e&/baS ooT_3rʥZZەF3o[7 8iS_5֪ MCD@18\Ufle&s@uF p줫aNoMP,PjW~DٴXEso4sp?<,gU!UB-ҵfVxs[zl[##yo:|_˗J#2I*YwI 4\;w嚘I4rCݍ55(!͐+2d$||( 5tXւKr60:b%x;|6x&}8!@(*&C#牮[j!=}yq`s "ghhlo˶mn/VUJɪyQ!"8.^)l8>RiilA{7annaCZMUܚ_KZD%q<#?912wwfde-^e0Db^mPw\r7ϫ/8B =deщy{{"Ӿm{#4뭴؎>v9;+!RDA} yZs{d$iݷ,QTG*Wyo$ZomEf6]nfg<7ZrܯȽ}_wM}vF*ĕc]iLF=jÎ#y_Ar;ﮒum>>%]mmx8Dn.Ic+6lOgŞR~R P(KEkJGsF{|a(oLVЋtF9*_h{~&MJ4738xv\"MUMm 'f/ZFn(Jeڪ%F9=/1 on0"2֞I8&@T煶svD0hR(JB>8紤Xjr.<5KȮ9cޤ0ˈ@rbQIqN GR}2YCL]Pe(`L']!+O2mW_}a ]lT@*`5yg7I*Qq(*.V~2[7䎆B{. Jg؊aKt0ޏy'XEr^m2e [jEVɋUk- x Edub!fȉ9'M'W+*$9_$o)I ]ہ[}Eov8QGN!d(`1G OCJ|&b{׋p (A^)%̭;q+e6K펷)JQ^FQI2?X.75x'16|kimm(P9,1ѡwD2twHQl0i'B-,5-畽Z.fw}C{F}i[KhzmuI"_G !(k >%֮^@eo9&3 w_ &2&zcBєvt3b!ə ľ@$,en p}VU(N)30}ue⊓F<7 Re(SY" id/ğCS.=qu+k P^|]۷&]K@޺%tiKJ0qD4yH76}<Q y-aQIGXEۄ̀UʥJc4_/a Gdڭ`Wm퐷透5GD3Ew 6%Ku&WHVX,ᤌ[u>bÖo5)?2tQ75{=qD"婻 剟d֭w1oH髏ϽP@m2;(R0d Apx jR|5̭Fyٴs3^ FbF /K>zt,% DaWGC&Ha4F=?y--B9XۗY} nT7U]=.0V^ u*%Pͅe"P57-zID:Cen2_BR$!S`W Nf!5;*6=M?RT҅)P恁ټQJ*nakmRŊgo" -=6ٰS#I~Wl^1:_xmB78J0 ZفWǗY9nZʵ-l+"nDv6_hmb'4O4"w!ѰHS컪<:Qu ly9 N%DA͇p/Oo-9#Wm`dy!- 3ߺQDn h+ѯSyfўºKt{ `w<䠔19QPrك!$G`׫!&Ps$l[hsNJ:;D%] ) wK~h;(qUB8FY 0 bæDZwi+Խ(<hV5BԿ8enqvĂ7yTq\*DX]*#!u+21脺dh2jzrI`$K 5{(M+8+^3Rx˶AQDlSٌoZO4q+D)+=VuOz` ߔC +60Qaz5JXLo jڲDPe4%[U@"x~b(ۀ[>'9R@al;L#*v.mO2&Rr{M'ie@[poviKp:tє-xuI8j'-**{r[i-l@puC+6lN )^˙u+^r%2ҴՇ*lFTw Aqu$ ::S; x_h ڢPzH*'d$74+BnOT9HME`1y#*U#L"vvREAx42QnBʕε1l,4^`O*DԻۙUiX`O2DI4]ȶA8P8?jlI4A1Y +3s ™D-SQj6p?Hiʝ"dqCAHgRG|)QOWƂ#ㆿ(ֽ j}x't"2yn#x1MF4|P!Tg)ors#E:P)6UtQ=F((*?kT]0"<5:H0YhavH^HVDk&ò Nz|B'BD=ix1vhwuVpGX Qrٴd_b]=*f [{Urt=*I2;#>4x{9duqSH]O!$ s\ܖ|`Cm+NTp֎<흪Q h1cQW6_$Gx7˙Qɉ#C]2.)$[+(r;_F \A]LRQ<*K9F|;:9)w%߯B3r洯9}HyZ]eHe3~}`nCv!2C`xS:&p#?9& oR\"V-8ZS';YFb+xq0>_ ȁ>q2ƭW`=kVa5 إN7۪'T2+ve͎E?!ߣ$lS)4*B{$зgq\v_ ?( Џ!w4ɱє6U?ۺӰiM]O40jrĒ7(ȝV9*P_V8n&ˌ"2+'S#o~OHGtTg N-qohNgߣg섟Nн }JӇ57v HG dq@5ۋk_K6_PE 9Rela *u9C$OyZa9 lk;`>%E8%erd4u%zR!6J%mu?'xZzO5GAttUhv.W9"ݍJB;n"VP;T1էnN(Ө}n}BKy_9pkWppQ s͋a̮ٜ*0! h7Ӡ"d;s2M/YrUPJA0 x_֍PL]PpeG*+ .w,hY#7oIzk.Jμk#З*tMK;/j`=7 71oGKEigؑ٩BN$〢v7]~]]wa=g' ͮ>zVw%'Daơ9AJO %d.2t/Wq :)2yyTD"!xSdw; ۱+kVH O_wZh2LP&C2ЉH^ Hn,;7=M]EWlgW{[Y*q}8N M}ճ%3ϱyO 7Zh ْP7/-W.+kQG0Wtyx9UCjΗ \Ų8NqSBqJ,D$|xP F;׭kXx\ЭR JFJINUTnLBV'֫GIc-v!럤AەMup#Wl|V8ԞeDXqχjHM0Ȱ8up}C'e{ pk圚W1m= U=[ħZ۸=0xܣ>+& b*?RVLjiZ%dQr+`^ո/`7=܏/Xwen> ^j#5l.病'aCLZ;ZI=-9JMA'tgWgwJ%>,?#5Hn{瑑p )ko>RI15}su&#F}(C7i\Es)Kb~ Yu@aa'V+s{$H`+YDIBk% 4e{ox Nd g| D>R>}x; Gf C=ФTc" KY=3$I]_|qX`r P ІzWBCt;!3S/ɳr)@UL1K&yH pUR&knw*WN`qp#_)kEۡn9NTsÑclV5uI' Op#}[rƸ+ X,ۑx;\O$"wrL;yT;dfo^JEsߩHMRbq=iU;}`tj)ý[aўFn[}K,jWDK;LhUhvp9pDK`ʴLo5+ ޝY=AGu(D&GUo:R _;YIL .6 :%wIK(=P(=d&vaML9dzI)ՙ}7]w!.};W/qy9i*Trx?iL#[!SD c;gB\Eg֎ljzwI6D&Yk \# -[.Xzs \$ ppLvיvNXmn袐0eC M9l]liO/u29 L,CdXl=|pG0rՄ5&W]T.gp)\u9IMdq@ADGnz>ډ–JiX%b 4 [J3Cp di$dknk3 [1! BԽ9"\]B)9Bych c[F8/glL!~! SŦlЅ}[GA+'eJ( ?\,e~u,Rۙ~I)7'KS qnW0ѺpHZn0f1 >((ԞmPdꀖ1oƯݵ16S oJ-6\}oKefӋhXAXny!nPӓ,[&!Uqc&nǦGK@<ȟA}iNGϞ<e< D 3` 3iǴx]3φ X&i_}2>Fȶ Mx~ƫ렅N=SgbݭožheV!-υ:Be8C,YLjzm%2:f247Q%X֭ayB@e]TJB`!TΑBOaP_R'e`іfiQX Bj 7ET 63ц mNOe:6xg\qVfkƖ.˖${.{/]JkkqtOrqooQ.'\(e>a0>\?: R=P)IWߤQQF^PG؄Φhޝ^F GxɎR(R`|Ѷ%:BLoB݃_ʄflq_$?@PGcg&vś郁23>CR,S<`tZ67_Wކ\_I)_{hٰmCk}ewKB'bfPů ';^+(ȿtO69MX *w'Ǿ$YdkH6PIK9׭SjKL([[E7,6R#L.Q͉(;P&XcNI)ĴL9 5ɲBKgM+Ćlaײ w .]{X DCC6zBQ8S>r|v!q!pC鯶[$k574qE RkUJ0 Ir I FGA /'@lb'ݕvܖ=ݝ6R[UR2#trdӧn{Ҿ[f WKh!nL\l*9R ZwnBkmɔIZfJl$H>j$Ow;:" ٍn~NKQ&.4p=a!Vl:QEr)z`^f.ɜy1vgC$"CN@6֡\'V7oQMx nF0bС,L8.pǜ"<5}п6ő.CC&/J` ޺/Qni yԭ9Q9э.kQkaGg4Va!9$m/ܨ!PeG[ Â6{kPoEųhu]wQѩI|ZHl.ɤ(?8[|%].R3.Sꛚ[obC={#wK߿zM2$siɿΡP QnT@Rc{O qT!{U"墍#8:N!8M'42O8Xڸ7(^Uj ܌T`!ͮE"vٿeP&5?x WjTg/vNȕHhD^rR6[j?!ӷ sf aVˎҚʸ-^~4?닣:ƿQXRDXY yugܑf/S|'*6Nfٹ >}trdm.FlGqYF[ynxo|஌nLh ]ps̎&Z{{E=J8.A\fo"tUd9@5#| ȼK{lZrՋLo~\a Ě|(`\7*5cnE^qamW1XÓ*MF*bUt¸j .vT.hsbX,2 YzYjށ>$q8Uf2#n@xI [+V uZi }cKCk#x9mP`[ԞHhHԥcAN?֓Z wpg\$I020ˎX+F?Uc fz7V+kg~yoL>4cko¬[\f!ǁ^5Cs='G&$"+1@{4rє=Kb ]NU鐁@ѽ7UD!Z-JRJZZ[r1!vJHG(nR@2Tp=(_'ITI/],VW!S>Ly^#$͌ayM _icSr[̣X&A9ttTwihLMne߷_إVfvK, [n7]@a&HƫO$@NCȷn`:d#mB3v-tGz[pS} )ۓQ߀W, -^@apaԩ):3\+`45;;'/e%ȩs-]zƈ4k^*R:܆Js=bl{FJQ.  }˨_#S/\Sᕳ+Ri0Mvװ֭.w#@Ձ'TbvU%n"&Է=G"a6ePa")lr.-Lohm.*!Nj7.?";,~'@koT IWnNdj-DgMTh5S=wW JyŠB0} V_ /Ifƣ5i97j`aէm]PچFr(,5y髵~+LCuh)lBl=B}]=_B6g2j#O|;:z &7][&$$Pe-\r|yYkm]Ia]/OxX !?E pmۦ}~y@,)nz*=2ȅ1W7$6˴!Fd}gؓfqGH;{ ` zT2ѽ (xUl)i"y_"oL;shPplŮNO`;KiU΃W]=o9@?$XhQ$UZdNK{b;XJEs&`:>x8Kr< sr~w5OМ#>zW)7ہ!Ij-H+%P_^QWv/f+6 5UkX=RwzV2Zcgks=ɕ4 EtboD` #lp]=}=Vv4Eq^օifwWH2Dd4]>\hyp`pH8X# ~b! c/ʿ䈻%adnNJs9c2J/ |Sk y* &EgCt,:dx ChVޏ|lg*qrabPmyٽ7IJ˵Ӄ n@J wd$vm˹\*䙵$PM;htV̎((0҈"U/զRcY3E&ٍPXy(WGUU1IgtB!,kcю]QְMqGRnON{I+v̩Z]( U`bpWU ~jinUCt'c:AHi~JppKvuq< 戭{hw/<ꑝOZ8:\MZ Z6"1:P]"zM[؟Kڈsi2;#dpIg~DT~D$a5q@UGRځ' Sڧ 'v@_dXU+7Ǎ Bн.w)NIX7p(!*J Gw͔JGO-mGiH(-G=a)ȯFPA bY @!S_#3tO iaDegxR$uTBѠ2+2:~jvR9N?]!a$2< +=O$I4#Uu~%)v{o瓵_6*Z,<&7ljTp֓ΉLNh @zq*T^^V+WwVHBH{F ׎ֿqn|@EkXVp(Б*`aqPЂ9nҗܚ#!0ƄBUu x4IWi1nVo;BQ@7Q|ERMs|RU鳮g;Gc~pl"hE?<[ =oİ,2 .k饦cjDpW#ߣ̢#`NvaR*(Tye3[ {){FG>Q_[wT%Q$i\ă4A:p輴  kaR݂mP ([Z+l梓G:8f/t=C?e4Em;ADHEdbRa%Y 7ܭvUd`?!u)C+AUSY*d 0r,oRnBVVRVXi y4Al8G}@0aA$tU"& ;ޯ}\),%n> |K~$(gCRrbia"(f!J˫AuKApA^KveO[˲B*|ؤ Í?^iZV~-C "+jqd;g{)` aQ0⛁tXnǪ,!IBOW>MYoա$-Qhf4 |ܲpXb_~l1H#!4ݨ^0" ɰH g#wc9jO:9<>U KݸrI88xEiB8>)CGCu[㤛⾏X2Wa_&7o1|RʣqZ%[ZR j2w.7zp-J0)>')S3<G#B&Xl-:—BY3'z" N|aH-hʺ}@ ߋ!!*CDE83TXV?pdxcD6<q՚xz[M @+̩UFjxBeP!B(c߸U.Γ6V1%ӽЊ/i,74LDžpM6,pdoN>jld ; ֑*IjcWik' 2Sx NB;m%h$\T* &2OUTHF+A ˕&&|Pcu&ݚI*e-͍w^-xh[(i_qTLl Tq*1 [i/Igf$]5ӒDp&Zi^DI4Bpo@*n7|SMwr#[[lr_}7-m$YcLy noO㨵e4b9iQntl*O67s%@MdL PA2BUh_D,)Oȭ$&xO½X,K tS*}nʉ~ B)ҟ2tMg5K&I%o:6"|䫺X!b^V> qj վ)e`ZKo nqwc'H6677GSӖ)8gV$iIae6tŧ9d\D`uT:LEUUrD=t82܇HgHZLLF&[lb}n(ӹ8⁂;IA&S@[΋Jy8R`: -a2kx-Zu=^)ai&WeL=06zݭrZ*Ҙ0 ɹa%6EomPCZٽ(hhi ?kX d|$gip2;cڦCDei 74'ح$,*43@+IL%ם; ع4%($o_Eh"YRDXx jK o׵/7GuGe;muT(5VqsUE$pgr6N.,]ͩjioe%).i;*,I4RSPiJrOh;&Q;ƯpEer yp]԰ה` .y2QRBtc޲n{9uS.+Q3{8 ubZ4r2 0)T0kR:([Zx,#驎0t~:LCČ toZ~EQJC1M9ܴ s@iDFU|;zJd SI,W5ƄH@g G+?*>P,1Zim̢7?=$M(ORR}/㭃빀)}Bn̙=k~BlV S7hsLPChgO|PA (:<ܤpJBq*!ՒXfp7*7Y3E1踹y|;J}ԩVk3F$wi^onȁKphU&^J7M68Dsz,֟m/Rr LjAԏÒlgϝ#6C|.&C6⯁6_S]_"?b:%m|Y2>^Vln-Y"' P$/e4CԹlźR4ҀJ JFM]OyFƱVxJ dıi -CEvpMLGrS^[pp42Qmi-j*Cd4t:E#(tqM"J+>1+Q|ub.Um)DhSm@{s4(g2UszΓ欇(Z|#V.Py/^@')GhTDQ=؏ɕp8^ʞkկ_g嗛>mBm 4(U(x}AI9pkA "Oigȵ,rW},OV1q IZUg?%.vJi"Ui)Vg<*ŵ9>L{7oLJƉKS]jmfL#~Rԗ2 Uj|YUUFf<$[/&<5A(4rX+#Huv[.扏9pK"a>2Xi5_9\KBCK(T& d6)oL =s]A.* rj4!1v<"LT~O1L I65˫4k+i&& )!pSoh&@䣱:ǩӦNJ^CqJ`N_"\!؍󵹩ŠQ寁244PQ2cYSyjEQO?4ԭsU t_5(EaH)J}-iX>58&:0Uf+0i'M[*GW?A0m'ԗv@ `ZD GTUFYy+hd\KIpMk'S s`a\?FXzP+FŇ\ ,nm$SZ2[qAu ~Yԡ4k4F:B(qK> Wd.(UJv#)S̚uO^'B(HJQc,uV`Ɗܘe^ĥ܂Uj]+?8y#N18'd *w:32+psn$1EMtlFk4+ҏj4F!z"4:bcB!Vs MrrEn]{ŲZhE LzjP&+p_Ꮍ/RHj=(>M{S).^Wзf}=Y' *K:sS1OcH@zKU^~s-"dp&L̓WHvUMA_u 3VFOu rVO(0‘8ε2WGDpgI=牫ٰjT :XvSHn9:b>B:(T>[1o& ~VXSN%pϹПRURF`Hd8 ť#:Մ2Q)nS}&4G4ZEǨQ"CXITqS0h[AL{<~pbI7]CØWr/'KP2mj=9'PҊ+%:KJ剘%>rP~Z}`M5ݬ'5 ":5M{C U2\ R)i4Ql6?!25Lir>l,IIO|;_JAi sfYP*1z67zy5_h"^ln|(ݓڒ6Y/1߄GnRNӄT^vM[ 4/Mx#ۄ@ol9Z= 8τZpF@in/z){))`\+48l/]J@Hc<ņ"vLROCa gs5G5;CLއm ͸.T@M&9Fi(X)ɝf$͹3TCIr8Z#J~zFH 4Ae|$WR+ ܧ**ǜ)F Q6EQ̨ZH~B2&'>={8Xqh8Tjƃ. Y* OdDHckuUnǸ [yk 0UMDtTO?*'e-6ߖ[[\7&mG{*>l^8Sy "6B8JV*4 u|*j?arpN@WGa5$A a%}Q]?̛k P҅v* ~~lo_ nc$Ϟ%tK%}=foF+$#Hld73 C)PV%5Dÿ5+v֕eFNjOB\ӥ }%}"a4?W/+6p[="`e CL{=ٳ_s+hOF(Swx쇣(IqϚ79LDjD8y隑эU%? #MVOLVfzUqzƣņ1D"$ɿE&^xO"LĪe-7,( {5X}h]#|;e]%iH͹799xt.Hpu鉋-#'nn'6_-~8[?gL//J&nTP\'2D5ܩJ5&,i"L)| =}Ss Wg6ќpvPOfSE,`5ZB껿dٜa ;5.2K~C?G{b`GɢW)5mV2Ė%eUŅ埩Dbd!I+#sg?@l"&[/HR.O`7B%[=ݫT堸RvtgG&USBELU.3B_s5 dV-G,,uGW_&F%]H:)hJxr<> 7Lѽ kVʼnӤw*jhTOȹ% P_śRMNg$iy<;0mUzożo߾ĹӥQe@?VƵO\s_7"Z|[O~`N# n*4dW !:) C\cBxNx;lDȒSD{` Kg~XpSKoVA2B'RQY^A*EzRԿMP(42IIUMqāBem_&c ٔslބYQF4tm7o>IN0H]qw}խRnq2g1ē.!* ZXf=3tORPۖ&*3h&Z|DZi[%"*eAMYA$hmnyPG~_O<{u˸KUjȴIeI&5g-B$0 hpɹ #SJ\kN Kp}atHJQ\v%Kf?_wZ89izn;;jմ2Lc`x Af]{k8B%AI&D{ ]j=glHYTconnRyW[ɟjTJN*as?TΓ2WREH>VIz})Lbl%DV$4FI1ʹ s_ļthk"B9;f2ZWlٶ[o-HPpD%}LTfv=iw N4ϓ,|D],$pk giL*nU\,fjJ#ʵom@r@N".) wOBRF6SP7wn,LN{r:.'J(&%V2o(m7)! 'H}C\xQM< Fڸ*Mg?=~%77 oy en&)L[A"' фwicڢ/aI zf .qHCUj˶e [ ÎjB 3|gq癊z6/T0/d{n{*C/ ~8:rt[׭Rq|E,.@lГt%/VGӹI1Z5$usA&g-~JNi'Mspɜ秔Pyǩ7ig7‹7+ SkCvQ_ᡥޒ 4)>mi.ʟwNasLW'&EZQ#J6Tr5SL>Эø)2 2S:K%Nm"BG e$+bGrƊdAZUĨsF nIC3;Hǿr[bbFs__ y2R4#0P7ӿ@0Al5HP϶k xO@yfjtHsATVJL$S!k#5[ ȣ N{A{n|,T%:R"| iYAz5]Rǔ욣Pu򂢡p37߷MTaA2ST̻x$C oFgfi稔 D o[g}@ޠKȏޭ3Uc*VI Ld#ͧz/\3 *!D f{ 6w -0}!t[р\MMTٮ^1*GL %/RՊc%#;t|yo@s\Vs&&!@f` UߡBuJ +;X7HdbguX1vu|>I& f}0H0WsI$̙3]&\9Rjˣwy ["?\Fd@)y{{/ H~,Ƕ`P$+'i<1vYv ]"89a:E4-tU*MMG:9|SҠ"9ݰ T9CWjjIVcqr{7<]p33&%!^ޭ81V=,H&my}T ƹ%θNT@5~ݹ&bjh/]a1׽5VyQH&k4⻽ҕ+o8zם9$1quuYE%R:qWpVT* C4 в4l}pP;4Ep @9ktR$>|i%OХaBJ7ml܉9[gCQMΡ]ސ2M 4-GN u+f"fp?ސ3 vr ?rkO9us ӪbC>SvZVrFMsMd흇v =ͤ/qC2U^GnѺJ(cPa|Wn$mC(fn3fd14b'D*˔W1q!߾_.gʃQiBT R>+1EgKTg9>Q wi{" aGL6#8ȦQ8}UjĄv2ܶZ==aN%[ІJoOQWUqι=w u3 bĒpu A/nLmƉS5X~DpMD͏ϿVb@nr`0oz8PL'F\FE4$Ύ&HhuOYo}35t G ֨<"y ; !eHlÈ/Km>t܃ %Pݱ Ԫ]gQJ$+ܦ=KP8S(u;%F;#x>ʡw~.Sw19{9+y^ 5I„$8֯"ALzXuԬmzu&[Vp-.л_F7$[ jjo+7}UA5@1pv;ug:7VN[QDDudF b_'n;_-=W}{SӽɜӞ5ܑqO/}682Nm;v/p%uн6bJ譶ExNZ(l>uKӬ2Ŕ=XqOv ]wj7n(D $+$?[flwSHtT(uxO#Bâ[319-P:~`K:ҕQib̚A=m?U]]?MI!QOZcmq*(v%n3˖^ . ?Du̔/@&S4;W*W%S.AOJrw~Pw'$4UiXfx@Eف=H?MR.$yJ|6_>Mx3O>#wWlZt \ iMf);./(}@]c!dgS ͔QȺ,JW;ȿJGB* RiRJƟ;<%'5&(>pf IP!WǼ"-ȅ>>e_T%prk;f\:&*뛯%jCKkuI C^0k߁#I's,^tWM󣽣HȁH?%hEɕ3:uS^F8qcf7MM,Ow۵IN8_&$hW~-5b}/QB7Lu/6›LR7 Ta3gvM~L&d(ƚ;{n0L)]BiYXSLzA)5ل0z*-Y}},L 9O$∺M97a1ضZv0Hɮ V4}ǿּ_eiuNJ;4?Ӯ?_^" x@9df0SkVY+}opDN2Ek.eX-VDn:t p7MadJ@*HJa -2TZgfP(o%5IxRثIT6 ykge=LZ&u~"R- Obn!7 iUλ4Q)' e"Ƌ@Å?f+c\y Y>5OZCӃc t?58ϊסAh###) U&X |jdnP^}$>u\-崸$Nd *_>u#\5=-YqS/6 <7R]\^/sQQꎓjS" *|Gn[Y` ׭W[nI<4i3P0ԜYyO͑B3_`\ [&jw|ʔ=WڹL"#MA;|wt¸m:Ч N CSrzC*vxn򠏺x62|isU+̙w!'v)K +R'XȀOsNԥSm*B 9/l3NS"JzMs tyYǼ9SN )3E(L -q-7?ǔ 5`c[nf~SFnW:#]{c%`z 촶ąv:M3T1ah' ܳ&NwhB8@h,}( &.x6Y㗻5)=K% ӏDgWsM/~ڤzMVU,RTŗ\SM(ɸo*|Ll"u`ʬ}?AcTԚ~׿ֱ`0r?td آ5\)ʝf\SV1UfMK5A5W5e/RYerwF]%OR.n-wRMY8Y~3}NAwX˓,C}3 ~T> _ ^0,BDw7au$̻3P' ]NKz秚{lIk~zpHYm$R~Kܳ oSN V>$+afeF*F{/7x nPY}9W>Tw]_o B^Bxt,IjW}Vxn:ZA1wtTL@IeY$;r^`v`ߖĕ~34+Q+8"h4)QVZR9yfy^?q7 0K ~۰/תtqR W BP$5fҼSSlW̜0Qx5yiJI , S,oO%2]M^NLvV27jq77Ԙ}AFƤO>lnwߓ R%ҋ2uǻo(`*Qݔ0b>0wzfv~dNM{#M"[7tnNĺo]PGOEPˌ+0([pp O*#ȘTƭy'~Ҧ'I-KBj|Pd+iz #W_>{3G'&Z{ =La&f\rg,+$ȣBLW[˕?i.CD5:G[J R7NPtj@b[okx_-`BhvC"}|8^>?E)輣?w5Y|Fx DqXu|6gp5)G[tN~0e?Uc @gc' ёWP$9kk~ a+eߊw?Qs1!iʦ"aBSL]s'0; ~]ΫEhTp%WTY. el~+˼r@ Vy>0D@a^Jt>(,!88ah8lM aG; %sAR"!؞CMT65yj|Jw-i2ѸKJ4L8lPuSb/"Q6Y/ඦr9==(o:&1lhE |ME",{c\Kܔ9~Ї7i us>Ds l}鿿HX)>$*.FHN12Wrq#aS;[;){࡭]τrUr]믿-͛NgpPS{B8ygm+/:ٸw3̈́5]e q }ԓnFc)P|n wuVVV(?K"(蛤)s%00,ݬy;d1p*ݤ}fʩO{u_ww5ݺ^a-Su@II:m?bͮb*1 I238M1dD%fǺSY*& oh+!"'V@|2m h6 U Cd᧣ h kRf)rP@4_gfYS|sb(sKnr 9*~ЪDc,i+ާNā{7 `Uwá/mTBЇEƪ.λ{."Gɂz^Opɼ?e.5%&oyVu cܪJiډ*<8LECݮZ}l|.ī\%eT;N6_h )3(ԧD$Jw ObAN'Cއ w pcwVw?0oC\V%#AJaCX8}Uďy~lIwfhRN9 9:>T |Es]x7C3]'&FNJ K7 7HPQ]hu9WeRrՑ>ZLx݋DoSWrȤj g0&pnp!.2eߋ/Qо{׷ YK#PQz //RLbJYuk6<mg 7:5@3'j>Wq8,9],#2'47 ;ezrrt j0K'ghtp$bs{KJ=Ǖg"֢u"a;jJ859a Fp) (Տ1ܓB?Rl2{֔WvضCgU j"9׽?^ZEV{nN=Son#PjCW^P +GkU4,Rl=p6!ӎD *mI4-…^s杯n愋Ge2j1f jT`!Q@OJoFSVbL7 =XdB@U3)-#ٸ }TEHXI$<.c2`3K.o'ȩڶ; ush0f8L6Ay!MvSױK7$+&tnDz{^n3&mNɭ[^072)onj c4<9-t)@hsum?A{D1_Z[5W^|ppt~Ę y _/nzH_O֯jm,\olVF |_~8D I/e^A"uv=Tn1Ep[kn,XFGJʐ09^ϥk}7(2X [Ze!}WX9ﶱQF1hT,n>*hqQ֎fCQǶfּuwUq{`DZC1?^-`IX%oƧ؞Q(K 5Bq7EYvJ# 1 !maBJCK3=pOpuZsѤ,O۰n7ozB;&'d΂m &50L7qs~YpᗂzځCtt?2'N̽ J梉D#uw3ή>RMmބ_]:ea+ݴz7j)wK G4Mu:MQNL0Sps 6fJ2im%Y_jy;ySU q1A' 5"ޣC_jlV_Qmb?+t0bZ5Ec0 Tc&JbOMq$tn0<>΀TEn*zt}|o1)s]pa2*TfP[`nkll7 0&qCT d QB*{RUF"IRE{W~ud=z"ji K. >35/i;p/ ^uaQg- $X1k:1> šn/qx'_exMe~ӘtB.S7 joN%hߢezso~5wfUP >gu3agxA{J9$V#c3 ǦU> 9PV}䝟ץA;a2V:h`?}jM<9Sen-_ӧ7e]~h˳.¸*4&AK{/O#5=fw--u-BFcJkԏvpq"$+bWzr;jGk#ĨxMLӏonv C`!7p(I/$9AB;a2e#s*eJU ϛhVZfr'85꺻SpKxLty=LxG`wڛY&vIN&taU{uD,%_Hc1_ 8uL!5#,[Xn V4A<`tǥ1޴ʻUgܽa–R0mi,X302a2Hs@E2>1UJ/.UJ&ҿ q5V-͘@q#O;6/z7,_}z`ٲ_N<ƺӧieT予#5Wg(5һ)wZ-&xU-~@Qf1GhK@0PIF?B ʟooO` %ofltF`  Cgьc32A1aY`LRd"D\c܁QR4,A* EFdIJұ)Z IS[h$2C5Sv/İUM@2Ğ *-e+idl Ek,uu8)2{łk2Z߼§ Q KmP'"0FOw)ʌ3/i(oI^B#MSLS+$nӹlߑu=ۚKu %emJE8*Ң3m03uݴS4ȘfXڒBZδSaKTk?J4Pr!w;h=fN[:#իe|J==E0-e|fvDNTm3C@M-"LK b΂2ReaQԓSUIҊN ^1gǀl-j:^`͸$uQ /[t[Zvm33B^K Ts7*N :ݯ$oISpxS w,N=MUhzcNB_L2ys.Qk h؉ LTjL6nT5,dᑅd ~9=t{Z !o2gFJoƦo1$bWJ7J4)PRy`iJk%YWP$8=ANɀvl@Sr5d-Wi3kU;RڕV} ϫcNO-~a6$NpJ K H' (bA o5h(HŀN$j֋3rân'u ~ꆱ {϶}BK0"-%^&͵|cHݟ+ͣ'E/pCCo M&D+uCc+02{jxӉFn8wl[|.!URBǢYr{aa LnnB*\p}?>s6;Cٻb!'̫Ec4V%ZInܭrzcUݢfIUFQXZjS$dP~{I Bz'ETu~Wp(Eit-9`-6 ωOiTmPlaqҥ!oAm#O>rwlTKW/]{uh>tKw= h=ϛEIz 59iS#'Id/Aw$ק .~)ᓠ%"[Z"OI=x 0G|˩S=%.>t! 9k&&ݶSԮ!uy :LJ'qq?'zAG$e\ӏ%et(eƠ݈3WQ˶m2d zҵH;PvUU_{"R4uu%XPEH],ˍpi*3p^pe79 瞧eݚpc݊Fg%kCwNmBЄr(MZc49-%GJ-:d9jl3kCnR:}r% Z%:P%ou}y7&s -,/VeZ4=(U4 M m$"<|R}LN1tV]GEaEST*MRZCʷcx Xُ|~lފ;첼d򽤺}N:&9l sUIHIi*Gi !跿%1׬bGi!p 5ʔ3f\񁯽'?-M֝:-0R\_}&Nvظsǖw$W/[zki)°FkLS"Hh%))ȉ-@~jҾ1TE:%|/lkKAe—4C0P÷?=T*-. $D*g^2`nO SiU.9*_J7ꪠ ?<6)>yU5H%j_7p#M~>S$m d4XV̌ꯅ`8+as KW (eRτS3Au%c>.s olp{L#ӹK)彜֜D8A6-֚J2Xעʇ\қ f_'qB**A!qI(-T,5V+1 CB?o jSz 7 SjB ꊼQ%jւ>hK ꬼ8%-#|Bxsrs\ [h]nVru^3ێM%Hax% |_^EmjM@9({Wu&[E:=$O]JږoQr5f)yնUD} j_7*!͡S`_*:Ntj\%wĹS Ϟ]?bSnwN&(*-e!r|D Phĸ\dhq `:Ew| E Ŋ%39_u {a2ýF'S5pQr ԟ ݄*mM&gʷoc5X F;(pVN  A9^e asi oJV%nR,uV개L12u@օ]cxk3L q~UYof$$82[(td_)̗ʷܟ.qqgqqi8`%M݅2 ]H޽n167^|Y2wId|JVܥN*Vtw,ѕ-^-Wf4]D%`bvy\ă'yp_z}oHh01c}M9IRA9V*ڽ ϰU`6% 'M^Lm3_(tW0z#mi +L[=#owhg|c[Qbt#SO4{C=1 ˀnNĕ6mD-W>k5 ًAŸKardѼ~ѓUBܟ|ͲcׯvAWCэו?e/6+'FmKB7>I& 27?Kji ZnBT\u -}3u D/:Oy7٦˃/Tv,g(̤$%Ɛ2|%COĩPК# O+$̙|J?n5DLg#C-/KBDBmi$UF8n3`%8txI#pߌ n,_c"w8kWݰ?v͏gغ73p 0|Q T&61h ^=yRѴk9DX$5hZz-'"Ac#!h#@KEhiA4='U[Ĝ*.Xg ~5s̀^rs LC4dL \jVxC#QJvxɖ7=\NV&M0.q<p!PJ2||35ZBd&Y nʓ ?''$EMξ&Iy > +},> @3iiO߲6p:w/\»+1q^t9*46_c)wi 1NҴ8v%xnXx5 [ (zēn՛~/j9(&I;%R0<_pIa[/?:{RwÒ/\ܽ 5d-s匍L #Sx[7% Vhؠs)!܀My^!';nIA0qnzEh"ibA$JxǓZNMV.Y(S8gA*2J 6h":\O~OiuuάNMR{ȗs|K<^''F.]u?Y&wڙ3~F {dR>JWNP *8!x] 'Dl(REJ0$h4N  SUaIs1CZǩqIDI [/mKWzrR}{c~ew쵃Q9̶Q|^7/(] ~_R69JsXz .&6>RyAa7<'!I&'ORY72,$ܜR {hq LSF-)xR}('#vG|NaVIJ1釄r}ko?q;1m=ĉ)|Āe`i t$Sc!.QGATImwsq$ *Q,+V-NL4lU ]֊ܨ"g:/}Ǔ'iR稼osRqN#+×sfƔxQ{ϫMHlD?>zW1=IA%4TcO>Ho;0[.*rSyM|)_j8R$mZY(<"c/ pzp>MnDwCe(%0|ܥs3<³xn p3PSg;LkjE~Y7'/}|:9$!ge߯3 J;e4xuț^5 G35=59T'5tpb?)JŁ[fNi5@yӱP @^B/3BaBAI-rbTb-T2 SlηNDpX?pFi Pm#?'8(wL+1pYQNu'iňxmզٓExT[lZ^H;En"/Pl ](ah-6q7GpCQ1d58f4#<%LpA[|+LSa(oy=~DnԁlʗX$+#9gЖHä)UzM}`8 0㒬*3 ; n|/u ua84 恻[z~.2P&b2] "! Q7-Ue!D򅀠;4c}}o yL_g}.Hpźm?v2U}:{92nl[B/U}zFyxupf$ܨn#s8ccy;bQnWa!^Ca SDb?QAČL4 bᎃ&AuKQnEuґu/5_MVZ4?i'?pOz?NVfće PYȤ9NwcX|=%|m٫'KVrR5?M#UߤQ8!cCV5bmɮ)~%D(W)BETYNG :eAzU'\@ǖʉ, nm*)lޥKȉhvU~~[o\r}3bql .Mk"le! SE7D(qBKZFa[CGCaF&N?upRnAv?W⩅͟;?xR|jkVݷdɣ-).T^LJ[0jM? }W2T!:K#8-ROm"2wk}go1pT^ dYT|{ҹm`|~Tf$ "LS +NSrw?SԳ;,tu8c`,k1Bjq؏Z wuOUYvFH ƈ=C51~_ElVTZb˒NݢB8U][[SLeK WbT`e"ԢsG蕢b_9ޛ7}>o9T*/@x% 9u~p{4aOU:{u?~W`R\pa(˳SE)&oc/yF6ك{C,z-䫎L @*k4e~ (H߫d1c3Lz Mʽp>؁Mv.j&gȆV`=1nݴHHkͱw[L$g'bk<r:c댦dB{Zɚ'6 }xٶ.'u(`y5ċSS$;59$olMsaqIEEU*R'sZ$JJxI7(JDȎ;2eL,C3M;_#QhЎ2''JM9D؇#8YJDut5M=oF om\MG&s9KA MVLHTx6 dyp D96>>MO?&SҢKH6f rHiDqJζ B{4P4|Iˉm*U B$Z0BMQ  ~Z Y\*!M~K=G1`݁t+֭Kmͨ K^ɳck,E@O9poTe_;;Iqo>R3G6yH9ԎJFɒ L~N1SwN{VlzųklKnrFj&S6L =R~"\ýg!*@(]V B-VaޥU$Ied+:9@ap,KU;n/[ZGf06 (e҃ʣ0@a[INkYUoBn=nqȫ"'$R1_IM"xhE'%U蛉JLø3:RRQUYܐI}qێkkNv8^I*' MXRof.*kx*HJٶ{/>(2}譍k^A,ޟChAF1WPG06|Lrwg۟ob46927j! i"A[}Ը3{͒%hkΖj},xt9K{ׁWtt7%Tz&=27Ҷ4c K>9>Z^Ԇi% :AWorBmY6hJI&6ikAQQq hNUB&q-RՐEڛO~+aum pw%wkIR_j"55?D[,sU[TN_w|Tʵj*&Ug7=g3u8 ƪvy1 gW>.C@7bQ7f&蝚Z6=ZL7F{ktO-#1hL w.|b%[C#!nbx{~1Wh+{3HNZ)5-Ҍ0 aR 7pO뼕Kv2M0ĩLh|?**.W6]^TX3E?U@K?5)sȯ &V$;:2>2EYUÖ|TDٰX%/?6'Xv<^_6կh@\.m$f' +?^6/ MȭO]$5-t -᮱ >0ˮJV-r5#q7bС{8LV%Di%vp LpW̏7emxbiusYherRd*!@Vtj5QzUdV߼!I1%*/ic L++Cj Ý_gN"͘t#p׷'ZW#7]:_E5_UCN77;0YD) lJ N攠$V+WuqrU"YHEMI%ymҩa-m+0a(@\}M֊D5 tCḻ_M 1\*ܷ?[{@ݜA~=^3 TG%B0MyJI褑O@$!0 ߑ_4uf= n^(]vj[';Q`-r CE-$cnkE׷?B~%HR/Q@5KIw׭avArLF%_)㎨q75ʋ MO͙M8|xK񩮾[ /&7t|:V ۷Ycp<ua|`ldm Q7rOΔfURƱވQhm'uЇ ? YSѼKB'plD&{K$f;(F֬!5,)n lp`p1Z :Mj@{Z?~]\knHuڛndu@%7)&NMѶnNڵwVM?d%hعlh&YÈ 6ӈý`zoEOXCʒnV$}Iq&&'u_ݜC8N+7/ݹ}ht~u{a%QG w~6f6fgI::wZyAU{WK5;:UJ3K[R`xWT r?J\/[[ʵN4M-t$?b䳾U9<NII;Dye-uGɥ$MYd` }?-nN ˵4O6SsK8n nx,j9hz ~L fXZtGùLx@@u#w#$90 T"L*j7e.ttO$Hkl"Y7 5UxlSE< _mĮO"ܓIIjxNZmMrj!M)ѤP=mDH_O5ַįN$@-|xއ0%X7ppoKChfo-fa~ѹdmjfqP6 r"&Itc'>iƆ{ Y;R4ᥱ Mrq C5gtS5%҅D{=}oLIHG7/ёΌ望@A~tg|; LF%F=+3au W ?3I{ȶ/h]1SScXKg'~8}GZK1T,;t'7wzhN0fHgqma>[pm6RL8GSEl:Jc\Y}k,0]^s ♫|^J{1:ȼ_?I:d!ii{bbf_S`GղvG,$,џG&D+~ ډ6iMbZ!LM/寻 ޡR~#G,|NUc0nȺ976ph&dOnE o+dțD6TL7|/yg~W᱉tT1!ސDԦ1m+@;҆hճق!eyԥ4yZ9VRLB9\3[7)-Ǘ7 `+H☆D-nU^n|!&$k?;"0-\}z(U̻{f+M?b[LyZ@zK [d_xg75\@&kZ tk 5]ܟ-QܥISVܻ ;Ru~R)I6%Me}Ȣ}HDzz0gǞ?'U8HhNn>``TkިK($%Vd&aEnN&hnD N.ue]Iǩy_OKRnڅhq6:JN,>q"nX&LbKd*X]E[h4ǜ{.{%@рJbɟЄ=X~v3-[gXSKFѾV.pV>$m}O$:J 4WD`RI5Xq,YuܺAzt(R!бc3k/]o'1fKh\܃;hX"7p'Y9:Ya2JdJ@֢oKعưIv*ͱt&Jy۶GFߞn-<%z 7V%JY9mK6{>nk*eU%QSVy_<&5RϽqDl^WnFe8擽dz#c57Qr䈓}m}~39KK%SʺA-dfԖZ;[Bm|$px@8M4͛H @VsfO Y)Hـ::Շ7oh4Kn WѮCK|TfwqtGn_cG >|Ǫ|y&m,{#B]`WD*:KsY1x=[g+w& wȖz;qoΚl VWXBx;3[X$BG'9a|$%eLE 2#A6z[xWC%f{̺j /o0>> [$77r]rYq7o^kK:Ex.;p ad,;AEJ?MyS]NUx${&4Q̈́'n6ۧ:spof _Y (GL0 P'Fw7Kt|󞸛ǵ;v .URW>]Z(p-1Vw`:6ف7?zBkyA3,@ўL2R(?X2ͱ=Z HʏU0PddDFo$q i3{&PfUjnwjtYɛ "єL+1\f}{nqBOg<[IM_J"ܸւd/&CD/ 2U5 GY=FmYf4L&bKj`l|Oy &gmE)VAӍ-AnzBuShhvKeV W`NZ3_'\7[U_;9yj2ړInݳ3۸{GQ&fT;qMn^@(y-.f{h.:]m8m#WKq,Ym2t͚ᮥҠD|Kuh%eoۯؿ.sN߸#-' ho"c{KYV&^5+Q{ҤoVuywckفf"nC":gW &I,\ nrUjmȹKntcZTFN!ﮒY7$(LXwRE)XufT:9֖}>&*AQxyf:ޓ ղ<8ozZ;r6Eā}~@}Z8~eJඑ&s\}J _6:Nb, )X<\Z-_BII0R vժTRpGoTRUyʚCzUߌ\Ijտ>iޱde{A!h{=}L޿?W.XD3q"ϟF1pNoM*Uo䷸ ۝cǫlds٤ZJ핚)/ϷC%[R<=r*Wٶe[՟@(s瘺EptD?⓸J8w&e&bvUMjӖo>EeM vk(B pة{\==@R=hlNW6o㯆ݿYփDv^Sr֙;CbE4/We]v}xl>6.$gzۮk2`Z(%f$f ؁](󊊸Wx_8x^Uo?1\FH걲l}L-Yz&^9wvnr?8z(WE ?S/vgְfXo; [=)1t+ m)g5 Qϝ ]LT1ҠRkBlu 5 1-Rf#K4rpeNs?DIQ/w!5^{sv9OTqsfиQob[~ L~i]IN=[ fXZW6Y 6e94tJ&m7o]o,J)5Hk犝?z=>6M`#Uǫ;{U fXAs֩;D٦bٔWus֭+eX'\X?q{-R|ʮٻ}]VO*xFx]E q $MPiq ʶ-&uA'5 R-mN]QҤGRss6WqamI*T,-/HhP峌`u|Rao5' gL2/1JO J27Hq4Y3!qDoʕ+dSE}nIDAT"zLU&# P 񉗨П'W-阁zbӣx(2p+8JZ5U}݄t\4eQhlChbJ(2p0 tml*<KF~Kfۭk {l{0Bj!C 5Ӊ AyCH_UTlB\eӢ&\HAm;T( -O5iyS>9m%ص3P9~BԽeɌt?c2N8qe}~GnK-2QI<SRlg@{Y%;4Nzs{4iF3 q ܆5Je,8Lm2X>6.LDRFak}c/XYHxҝTKJϞ=WǸOpp ja_i%Sm]br[xQ-{ y%u5,;z.͸K}Q: sW+BYUDw?yZgv nX 0n1GeN5U"q)~գ=qӐfԫA 0Oi{2޶sxM 1NzIGh[ୂ'sjf$v'Thi ڜ~2=uR~3twlq+cKTr5RXH /Bx^ Oz7uA֓<+fo0'{:J.< „ aЌke1+a_v7K/SV wdkia'Tk2qQ q(N_TLLl@n\ߒ\}{* F77?\ʞymۄVy?/ "AB10,ޮʰbk!X`P(4" 6ņ0#Tqj+TeJfʯGG0]I;7k!,%W/a ]bjKs>wmRLrlv2P۶u'd<%+3u$O+@5zXL4rIuL-S:uº+V׺9"jN@-MB(j-u_!oBW{YpSl!+ ^MjZEŻc~*3hik77PO'e.X&[;_?82ȉT4I CX9]M?Zl8,sD\F${Ĕ!Ve DkR ٜTykU_| إP*I_^kb1+2.Օw^u gSЊNo==eb5BsVAܾ蝘1C8,fܖR~-+Ji\nR4.)h: !mF0&z.ɀoZV %H<CU5DkϩHjX< .R.3ZljB%6tz,{tL>dO{,>Jf](}+mBثUL)8ggɜ28Ȅ,n}r/-L Q"7,b*zIU1s3=l>K@ /RJ{QUpj$df72n%X@bm-Bw+i~%ܠ!@Ѐ4sm=6g-? >]u1|hmYq:h Vbb3m{5&yO)Ly\?_W efB'&ѭYHR^V'P9ЗMȌݩ1SV&eE )Mu&ӸPxc"ޤUQKͤV)Yuc-en]1s,1ݖn pEt6ߢ{F\x#AO2-EӲW·=,RhuUJ4 se!aOnDrfDO>ߪa MTgp[5o-"T QX̫^2,5%&~!ǔY7o-Xtq&8p"'cIM'_j+?0#OdX>15g)IALWe 5ۛp<5=_2PX>gz, v(.'@&$ 5}oI} IENDB`@@@ NormalCJ_HaJmH sH tH B@B Heading 1$@&5CJ\aJDA@D Default Paragraph FontVi@V  Table Normal :V 44 la (k@(No List R"@R Captiondd[$\$B* CJOJQJaJphfJOJ head2dd[$\$5CJOJQJ\aJJOJ head3dd[$\$5CJOJQJ\aJRO"R headbreakdd[$\$5CJOJQJ\aJ6U@16 Hyperlink >*B*phw`B^@BB Normal (Web)dd[$\$>+,f5[7   x()*!#!%'d(*W+|-./013468v:<>ACE-GHGGfHHrLN{NKQLQMQNQ`QkQlQwQxQyQQ$S>SU^^^^eii.ilj k]km+noppUppppppppqqqqqqqqqqq0r1r2r3rHrKrNrarbrrrrrrrrrrgshsisjstttguhuuuuuw ww;w;0<;0>;0'<'NO[Xhx{@`0jmnpqstw~'Mmxyy2zzzi{};^ՂmdҌI-XVkoruvxyz{|}l=R=#3UW( \ ^   /  MYl#% w}B M !!""$%%&''t'''p)))a,,,-_.b.*///000p111:333%444566647=79i:r:5<<<{>>>?@@:@@@!CCCE~EEE$F'FFG)G8IIIJJJKkLnLMNN2PPPOSSSSTT TeTiTMWWWWXXXvXzX^]]]^^^^I_K_P____T`W`fZf^fij jjfjijltlxlUpppqqqq,r.rbrrrrcsesjsssttttcueuhuuuuovqvvvw *urn:schemas-microsoft-com:office:smarttags PostalCode9 *urn:schemas-microsoft-com:office:smarttagsState8 *urn:schemas-microsoft-com:office:smarttagsCity;*urn:schemas-microsoft-com:office:smarttagsaddress9 *urn:schemas-microsoft-com:office:smarttagsplace     &,-3 (\d+"+11 222(23399 ;%;>>H>iBtB$D+D HHJJ>QAQb\j\\\ffggghii_ilikkHmWmn)nnnttteuvwyzi{{||}#}d}l} ~~~~,in9A?ςP >@P[\߇!|ZeȗޗĘҘӘȚ͚PUŜڜ ǟlwxݤͥեѧԨߨ*tԪܪުv$&/Zf',3"QVW] 156: ;K(OR  7  z}D J !!%%'"'00445,577=7U7h788l:r:::= =&A+AII2N5NeRoR||io|15DNĿ333333333333333333333333333333333333333!+KQNQW]pqqfisher67fisher67 Tony Jabbour fO1[ -jz.߮Kc0}HF ^]8aAd.9<=h 3akjﮐ<(:{N^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`.^`.pp^p`.@ @ ^@ `.^`.^`.^`.^`.PP^P`.^`CJOJQJo(^`CJOJQJo(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo( <(:{HF<=hz.[ -fOc0aAd^]akj اBݾ~zbW'  `DlH2@'ń4t\&:L6"Ơpx:3ZLvɲ6LLm fvi6b0xvtXGgpf pȬ} ~`&P1N(hƜ/ڥvWJG| ^.np7̪oD<:^[O4urtԨ0l8 ^٨ʇ&?r͚^D\rҨP"l9X 0TxfGxa~.nK)~0skUppppppppqqqqqqqqqqq0r1r2r3rHrKrNrarbrrrrrrrrrrgshsisjstttguhuuuuuw ww;whhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch101/ch101_p01.htmlNG;hhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch383/ch383_p01.html;8&javascript:popup('ch382_acronyms.htmlPM','contents',350,250,'yes')NG5hhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch383/ch383_p01.htmlNG2hhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch365/ch365_p01.html;/&javascript:popup('ch382_acronyms.htmlPM','contents',350,250,'yes') ;,&javascript:popup('ch382_acronyms.htmlDM','contents',350,250,'yes')zG#Zhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/noted,gzGZhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/noted,fzGZhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/noted,ekZhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/noteck Zhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/noteaGZhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/notea,bkZhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/noteakZhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/notedkZhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/noteckZhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/notebkZhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/noteakZhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch382/notea:N&javascript:popup('ch382_acronyms.htmlIBM','contents',350,250,'yes') ;&javascript:popup('ch382_acronyms.htmlDM','contents',350,250,'yes');&javascript:popup('ch382_acronyms.htmlPM','contents',350,250,'yes'):N&javascript:popup('ch382_acronyms.htmlIBM','contents',350,250,'yes');&javascript:popup('ch382_acronyms.htmlPM','contents',350,250,'yes'):N&javascript:popup('ch382_acronyms.htmlIBM','contents',350,250,'yes')NGhhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch365/ch365_p01.htmlNGhhttp://harrisons.accessmedicine.com/server-java/Arknoid/amed/harrisons/co_chapters/ch383/ch383_p01.html:N&javascript:popup('ch382_acronyms.htmlIBM','contents',350,250,'yes') ;&javascript:popup('ch382_acronyms.htmlDM','contents',350,250,'yes');&javascript:popup('ch382_acronyms.htmlPM','contents',350,250,'yes'):N&javascript:popup('ch382_acronyms.htmlIBM','contents',350,250,'yes') ;&javascript:popup('ch382_acronyms.htmlDM','contents',350,250,'yes');&javascript:popup('ch382_acronyms.htmlPM','contents',350,250,'yes')QJhttp://www.utdol.com/application/topic.asp?file=drug_l_z/162031&drug=true?yThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=35&title=35?{Thttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=37&title=37?yThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=35&title=35Zhttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=35~36&title=35,36Fhttp://www.utdol.com/application/image.asp?file=rheumpix/diagno46.gif?x~Thttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=34&title=34?{Thttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=33&title=33?~xThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=32&title=32>{uThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=26&title=26?}rThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=31&title=31?|oThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=30&title=30$!l?http://www.utdol.com/application/topic.asp?file=rheumati/46057k)i`http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=28~29~41&title=28,29,41k*f`http://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=26~27~42&title=26,27,42>xcThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=25&title=25>y`Thttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=24&title=24>~]Thttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=23&title=23MNZFhttp://www.utdol.com/application/image.asp?file=rheumpix/vascular.gifWZhttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=21~22&title=21,22={TThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=15&title=15>}QThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=20&title=20=wNThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=19&title=19=vKThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=18&title=18=yHThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=17&title=17=~EThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=10&title=10BZhttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=10~16&title=10,16=~?Thttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=10&title=10<Zhttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=10~15&title=10,15n59ghttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=5~10~13~14~15&title=5,10,13-156Zhttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=10~12&title=10,123Zhttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=10~11&title=10,11N0Rhttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=9&title=9T-Zhttp://www.utdol.com/application/image.asp?file=rheumpix/behcets.gif~rheumpix/retina3.gif%-*?http://www.utdol.com/application/topic.asp?file=rheumati/16947O'Rhttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=8&title=8@$Rhttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=7&title=78{!Thttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=40&title=40?uThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=39&title=39ARhttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=6&title=6KFFhttp://www.utdol.com/application/image.asp?file=rheumpix/vasculit.gif?tThttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=38&title=38BRhttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=5&title=5F~Fhttp://www.utdol.com/application/image.asp?file=rheumpix/oral_aph.gifC Rhttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=4&title=4c9 http://www.behcets.com/ +?http://www.utdol.com/application/topic.asp?file=rheumati/35329%,?http://www.utdol.com/application/topic.asp?file=rheumati/43913v)Xhttp://www.utdol.com/application/abstract.asp?TR=rheumati/21584&viewAbs=1~2~3&title=1-3  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwyz{|}~Root Entry Fp"KvData 1TablexhWordDocument.>SummaryInformation(DocumentSummaryInformation8XCompObjj  FMicrosoft Word Document MSWordDocWord.Document.89q